gilead sciences inc annual report file period end address lakeside foster city california telephone cik industry biotechnology drug sector healthcare fiscal year quicklink click rapidly navigate document security exchange commission washington mark cid annual report pursuant section security exchange act fiscal year end december cid transition report pursuant section security exchange act transition period commission file gilead sciences inc exact registrant specify charter delaware state jurisdiction incorporation organization irs employer identification lakeside drive foster city california address principal executive office zip code registrant telephone number include area code security register pursuant section act security register pursuant section act common stock par value title class indicate check mark registrant file report require file section security exchange act precede month short period registrant require file report subject filing requirement past day yes cid cid indicate check mark disclosure delinquent filer pursuant item regulation section chapter contain contain good registrant knowledge definitive proxy information statement incorporate reference iii amendment cid indicate check mark registrant accelerate filer define rule act yes cid cidthe aggregate market value vote stock hold nonaffiliate registrant base closing price common stock nasdaq stock market june number share outstanding registrant common stock february document incorporate reference specify portion registrant definitive proxy statement file commission pursuant regulation connection annual meeting incorporate reference iii report base closing price share exclude share registrant common stock hold executive officer director stockholder ownership exceed common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registrant gilead sciences inc annual report table content item business item property item legal proceeding item submission matter vote security holder item market registrant common stock relate stockholder matter item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure iii item director executive officer registrant item executive compensation item security ownership certain beneficial owner management item certain relationship relate transaction item control procedure item exhibit financial statement schedule report form signature certification right trademark copyright trade name business include follow gilead gilead sciences hepsera leaf shield design leaf shield design liver design tablet design tablet design color viread vistide daunoxome ambisome tamiflu register trademark belong hoffmannla roche report include trademark service mark trade name company iitem business forwardlooke statement risk factor report include forwardlooke statement particular statement expectation belief plan objective assumption future event performance contain incorporate reference report base forwardlooke statement current expectation future event believe expectation reasonable forwardlooke statement inherently subject risk uncertainty control actual result differ materially suggest forwardlooke statement reason include discuss report head risk factor affect gilead give risk uncertainty caution place undue reliance forwardlooke statement forward look statement include report date hereof undertake specifically decline obligation update statement publicly announce result revision statement reflect future event development report indicate refer gilead subsidiary overview gilead sciences inc biopharmaceutical company discover develop commercialize therapeutic advance care patient suffer lifethreatening disease worldwide product currently market market country worldwide research clinical program focus antiinfective include antiviral antifungal endeavor grow exist portfolio product proprietary clinical development program internal discovery program active product acquisition inlicense strategy worldwide headquarters foster city california european headquarters paris france incorporate delaware june january complete acquisition outstanding stock triangle pharmaceuticals inc triangle whollyowne subsidiary gilead aggregate preliminary purchase price million include cash pay outstanding stock fair value option assume estimate direct transaction cost employee termination cost triangle develop drug candidate antiviral area particular focus potential therapy hiv include aids hepatitis virus triangle portfolio consist drug candidate clinical trial include emtricitabine treatment hiv infection emtricitabine treatment hepatitis amdoxovir treatment hiv infection clevudine treatment hepatitis triangle file marketing application emtricitabine treatment hiv united states european union product viread approve sale sell commercial team use combination antiretroviral agent treatment hiv infection european union european commercial team use combination antiretroviral agent treatment hiv infection patient experience early virological failure ambisome approve sale sell country treatment lifethreatening fungal infection country prevention infection market ambisome major country europe copromote ambisome fujisawa healthcare inc fujisawa hepsera approve sale sell commercial team treatment chronic hepatitis hepsera receive marketing approval european union march tamiflu approve sale sell corporate partner hoffmannla roche roche country include european union prevention treatment influenza vistide approve sale sell commercial team gilead exus partner pharmacia corporation pharmacia country treatment cytomegalovirus cmv retinitis patient aid daunoxome approve sale sell country treatment aidsrelate kaposi sarcoma sell commercial team independent distributor abroad earn revenue million sale royalty product sale viread generate aggregate product sale royalty revenue million total revenue sale ambisome generate aggregate product sale royalty revenue million total revenue earn revenue sale royalty ourproduct million million million outside earn revenue sale royalty product million million million viread tenofovir disoproxil fumarate viread oral formulation nucleotide analogue reverse transcriptase inhibitor tenofovir dose day combination therapy treat hiv infection adult drug work block reverse transcriptase enzyme involve replication hiv sell viread commercial team major european country european commercial team commercial operation food drug administration fda approve viread market october european agency evaluation medicinal product emea grant similar approval european union february viread approve use combination antiretroviral agent treatment hiv infection indication base analyse plasma hiv rna level cell count control study viread week duration study control dose range study viread week duration study study conduct treatmentexperienced adult evidence hiv viral replication despite ongoing antiretroviral therapy study patient previously receive antiretroviral therapy antiretroviralnave patient ongoing february report week datum ongoing threeyear randomize doubleblind clinical trial study design compare efficacy safety combination treatment regimen viread lamivudine efavirenz combination treatment regimen stavudine lamivudine efavirenz antiretroviralnave patient hiv infection datum study demonstrate treatmentnave patient receive viread experience substantially lipodystrophy low elevation fast cholesterol triglyceride level improved level limb fat weight gain achieve similar reduction hiv viral load increase cell count compare receive stavudine adverse event report percent patient include rash bacterial infection depression fever pneumonia low discontinuation rate approximately percent arm study week datum supplement week result study submit fda support use viread patient prior hiv therapy intend submit week datum potential inclusion european label predict fda emea accept interpretation datum approve label indicate viread use patient prior hiv therapy base datum approval week datum study recommend committee proprietary medicinal product cpmp february major challenge treat hivinfecte patient drug resistance exist therapy treat hiv infection aid rely similarlydesigne drug process patient develop resistance drug develop resistance drug class believe viread approve regulatory authority offer advantage approve hiv treatment available datum show patient develop resistance viread viread effective treat patient develop resistance therapy certain resistance datum obtain completion phase clinical trial similar resistance characteristic week datum study datum obtain limited phase clinical trial major concern hiv treatment convenience dose combination therapie positive impact require hiv infect patient numerous drug drug require multiple dose day time dietary restriction result inconvenience patient contribute patient miss dose adhere therapy viread approve administer oncedaily oral pill schedule appeal hivinfecte patient physicians hiv competitive landscape crowd complicated treatment trend continue evolve branded anti hiv drug currently sell advance stage clinical development competition exclusive worldwide license patent right relate technology viread institute organic chemistry biochemistry academy sciences czech republic rega stichting vzw iocbrega obligate pay percentage net revenue sale viread european union country product approve patent protection iocbrega academic consulting relationshipsiocbrega ambisome amphotericin liposome injection ambisome proprietary liposomal formulation amphotericin amphotericin powerful antifungal agent know ability treat invasive fungal infection cause fungal specie infection generally life threaten particularly patient depressed immune system aggressive chemotherapy regimen stem cell organ transplant hiv infection ambisome treatment effect include kidney toxicity study deliver amphotericin ourproprietary liposomal formulation ambisome reduce rate severity kidney toxicity injectionrelate reaction allow patient receive high dose amphotericin ambisome approve sale country include european union rest europe australia canada country middle east latin america asia countries ambisome approve include authorize promote ambisome empirical treatment fungal infection treatment patient strong suspicion definite confirmation exist potentially lifethreatene invasive fungal infection remain country ambisome approve sale approve use firstline treatment invasive fungal infection secondline treatment conventional amphotericin therapy fail conventional amphotericin tolerate finally ambisome approve number country indication example cryptococcal meningitis aids patient prophylaxis liver transplant patient visceral leishmaniasis copromote ambisome fujisawa commercial team agreement fujisawa entitle percentage revenue generate sale provide fujisawa purchase ambisome manufacturing cost collaborative relationshipsfujisawa major european country australia sell ambisome international commercial team certain country sell ambisome independent distributor revenue ambisome europe expect case foreseeable future license commercial right ambisome japan sumitomo pharmaceuticals ltd sumitomo exchange royalty generate activity ambisome approve sale japan ambisome face strong competition current competitor expect competitor treatment late stage clinical trial competition competition current expect competitor likely erode revenue receive sale ambisome hepsera adefovir dipivoxil hepsera oral formulation nucleotide analogue hbv dna polymerase inhibitor adefovir dipivoxil dosed day treat chronic hepatitis hepatitis cause highly contagious hepatitis hbv virus cause acute liver failure patient develop chronic hepatitis infection year lead complication cirrhosis liver cancer liver failure approximately patient result death accord recent estimate world health organization center disease control million people worldwide million people chronic hepatitis million death attributable chronic hepatitis worldwide year lead cause death worldwide hepsera disable hbv interfere activity enzyme know hbv polymerase necessary virus replicate application european union marketing authorization include datum separate phase clinical trial design evaluate safety effectiveness hepsera dosage treat patient hepatitis virus phase trial design randomize doubleblind placebocontrolle study clinical site canada europe australia southeast asia study evaluate hepsera treat patient test positive hbv antigen common type hepatitis trial study evaluate hepsera treat patient type hepatitis know precore mutant hepatitis common southeast asian mediterranean country week adefovirassociate resistance mutation identify hepatitis patient treat clinical trial suggest development resistance hepsera hepatitis patient delay infrequent consequently believe hepsera resistance profile important drug treat chronic hepatitis certain resistance datum obtain continue phase clinical trial hepsera continue resistance characteristic hepsera approve sale treatment chronic hepatitis adult evidence active viral replication evidence persistent elevation serum aminotransferase alt ast histologically active liver disease commercial team sell hepsera march apply approval emea hepsera treatment chronic hepatitis european union approval emea recommend cpmp november receive march plan sell hepsera major european union country european commercial team vaccine available prevent transmission hbv effective people chronicallyinfecte hbv expect vaccine widely available incidence new hepatitis infection decrease advance prevention hepatitis individual suffer chronic hepatitis represent patient pool significant risk morbidity mortality underlie chronic viral infection chronic hepatitis common china southeast asia december receive clinical trial permit initiate phase clinical trial china commence clinical trial june license rights commercialize hepsera solely treatment hepatitis china korea japan taiwan rest asia latin america certain territory glaxosmithkline gsk approval commence phase clinical trial china hepsera grant class designation hepsera ultimately approve sale china gsk year market exclusivity hepsera respect competitor able begin clinical development adefovir dipivoxil follow approval receive chinese government approval phase study give approval forward phase program begin patient enrollment december exist therapy treat patient infect hbv compete hepsera treatment represent significant competition hepsera competition exclusive worldwide license patent right relate technology adefovir dipivoxil iocbrega pay percentage net revenue sale hepsera iocbrega country product patent protection include member states european union addition pay small variable percentage net revenue sales hepsera anderson cancer center academic consulting relationship tamiflu oseltamivir phosphate tamiflu oral pill treatment prevention influenza tamiflu class prescription drug call neuraminidase inhibitor act disable common strain flu virus prevent virus spread patient approve treatment influenza tamiflu show reduce duration flu adult average reduce severity flu symptom incidence secondary infection take approve prevention influenza study show tamiflu effective prevent development flu tamiflu approve country treatment influenza include japan european union treatment influenza child adult tamiflu approve european union prevention influenza adolescent adult develop tamiflu roche roche exclusive right manufacture sell tamiflu subject obligation pay percentage net revenue roche generate tamiflu sale date roche sale tamiflu significantly expectation roche experience problem manufacture distribution tamiflu reduce net sale royalty base material effect revenue collaborative relationshipsroche product available treat flu time show effective safe neuraminidase inhibitor competition tamiflu market alternative influenza vaccination believe influenza vaccination remain effective method prevent flu vistide cidofovir injection vistide antiviral medication treatment cmv retinitis patient aid cmv retinitis condition characterize lesion form patient retina affect person weaken immune system common patient aid leave untreated cmv retinitis lead blindness vistide approve sale european union country demand vistide low product revenue immaterial commercial team sell vistide outside pharmacia exclusive right sell vistide pharmacia pay percentage revenue generate sale vistide collaborative relationshipspharmacia active agent vistide cidofovir consider government strategy deal potential bioterrorism attack involve smallpox lifethreatene highly communicable infectious disease laboratory test cidofovir demonstrate activity strain virus cause smallpox current clinical trial diluted smallpox vaccine conduct national institute allergy infectious disease cidofovir consider potential treatment vaccinia infection adverse reaction cause smallpox vaccine additionally national institutes health hold ind allow emergency use cidofovir smallpox outbreak marketing approval fda know efficacy cidofovir emergency use effect appear use cidofovir smallpox predict country government stockpile vistide treatment smallpoxdaunoxome daunorubicin citrate liposome injection daunoxome liposomal formulation anticancer agent daunorubicin firstline therapy treat patient suffer certain type hivassociate kaposi sarcoma disease characterize widely disseminate lesion skin mucous membrane lymph node viscera life threaten patient suffer aid daunoxome approve sale country sell daunoxome sell abroad independent distributor demand daunoxome low product revenue immaterial product clinical trial emtricitabine hiv acquire emtricitabine result acquisition triangle complete january nucleoside analogue emtricitabine show inhibitor hiv hbv replication laboratory study emtricitabine antiviral agent hiv strain obtain geographically diverse set hivinfecte patient laboratory study show emtricitabine share crossresistance pattern lamivudine common resistance mutation agent reverse resistance hiv azt case phase clinical study emtricitabine complete collaboration agence nationale recherche sur sida anrs france study study ftc compare emtricitabine onceaday stavudine twiceaday combination didanosine onceaday efavirenz onceaday patient previous antiretroviral therapy july study unblinde recommendation independent datum safety monitoring board dsmb establish provide oversight study interim result evaluate study dsmb show emtricitabine arm statistically superior stavudine arm primary secondary endpoint safety efficacy eightyseven percent patient onceaday emtricitabine arm persistent virologic response month compare twicedaily stavudine arm patient emtricitabine arm significant improvement immunologic function view compelling difference favor emtricitabine arm dsmb recommend study unblinde patient offer regiman contain emtricitabine application marketing approval emtricitabine submit treatment hiv september european union december application accept review fda advise date review july emtricitabine hepatitis emtricitabine show inhibitor hepatitis virus replication patient chronically infect hbv currently phase clinical development emtricitabine treatment chronic hepatitis development activity undertake emtricitabine treatment hiv assessment emtricitabine treatment hepatitis amdoxovir acquire amdoxovir result acquisition triangle complete january amdoxovir purine dioxolane nucleoside offer advantage nucleoside currently market activity drug resistant virus exhibit laboratory study early triangle initiate phase clinical trial amdoxovir august fda place clinical development program amdoxovir partial clinical hold result concern lenticular opacity possible effect characterize clouding lens eye extent amdoxovir increase occurrence lenticular opacity patient receive amdoxovir unknown patient clinical study benefit amdoxovir new study involve patient fail treatment contain drug currently approve class antihiv medication require amdoxovir regimen continue treatment discussion fda partial clinical hold plan clevudine acquire clevudine result acquisition triangle complete january clevudine pyrimidine nucleoside analogue show potent inhibitor hepatitis virus replication laboratory study november triangle initiate phase study currently conduct phase clinical trial clevudine treatment chronic hepatitis chronic toxicology study complete reproductive toxicology study progress novel nucleotide analogue reverse transcriptase inhibitor process body yield tenofovir activechemical yield viread cell chemical composition allow cross cell membrane easily viread lead great potency viread quarter begin phase clinical trial treatment hiv infection research development research scientist foster city san dimas california durham north carolina engage discovery development new molecule technology hope lead new medicine novel formulation exist drug therapeutic focus area life threaten infectious disease total research development expense million compare million million nucleotide analogues scientist work proprietary nucleotide analogue develop treatment viral infection compounds treat viral infection interfere activity certain enzyme necessary virus grow believe small molecule nucleotide analogue offer advantage therapeutic molecule demonstrate ability work infect uninfected cell enable develop drug treat patient infected virus prevent healthy person infect place second drug develop molecule show treatment activity patient long period time available drug enable develop drug require frequent dose convenient patient hiv protease inhibitor evaluate number small molecule compound know protease inhibitor potential treatment hiv infection protease inhibitor act interfere activity protease enzyme like reverse transcriptase necessary replication hiv conduct number preclinical experiment compound demonstrate potent antiviral activity lead candidate currently undergo extensive preclinical evaluation antiviral research undertake additional research area treatment viral disease effort focus potential target hiv therapeutic drug liposome scientist focus apply proprietary liposomal drug delivery technology develop safe effective convenient drug liposome submicroscopic hollow sphere drug pack believe research support belief influence way compound release distribute body place liposome turn improve safety treatment benefit compound commercial operation international commercial sale operation marketing subsidiary united kingdom germany italy spain france portugal greece australia commercial team promote sell viread hepsera ambisome viread ambisome europe australia ambisome sell fujisawa sell vistide daunoxome commercial partner pharmacia sell vistide outside sell daunoxome outside independent distributor commercial partner roche promote sell tamiflu sell commercial team promote viread hepsera direct field contact physician hospital clinic healthcare provider involve treatment patient hiv viread chronic hepatitis hepsera promote ambisome infectious disease specialist hospital home health care provider cancer specialist international commercial operation europe australia european commercial team support medical operational financial regulatory manufacturing human resource personnel locate primarily european headquarters paris france australian commercial team support worldwide headquarters foster city california country outside agreement thirdparty distributor include distributor certain country market operation promote sell distribute viread ambisome daunoxome international distribution agreement generally provide distributor exclusive right sell viread ambisome daunoxome particular country country specify period time january announce program pursuant sell viread cost country africa country designate develop country united nations take step ensure viread product sell program serve patient develop world divert market international distribution support expand commercialization viread hepsera significantly increase sale force devote additional marketing resource improve coverage healthcare professional treat hivinfecte hbv infect patient significantly increase size commercial operation europe manage commercialization viread anticipate commercialization hepsera european union current intention retain commercial right hepsera market directly distributor canada europe australia new zealand turkey april enter licensing agreement gsk gsk receive right commercialize hepsera asia latin america africa certain territory agreement retain right hepsera canada eastern western europe australia new zealand turkey gsk receive exclusive right develop hepsera solely treatment hepatitis country significant include china korea japan taiwan gsk responsibility development commercialization hepsera territorie viread hepsera vistide returnable original unopened container year expiration date damage receive customer customer return ambisome daunoxome shelf life expire product damage defective customer receive ambisome approve shelf life month month european country daunoxome shelf life week european country viread shelf life month european union hepsera shelf life month additionally certain governmental agency customer state aids drug assistance program entitle receive discount require provide rebate state medicaid programs date return rebate discount material financial result fujisawa establish return policy ambisome north america roche establish return policy tamiflu end flu season significant return tamiflu roche reduce net sale royalty roche base collaborative relationship business strategy establish collaboration company assist clinical development andor commercialization certain product product candidate provide support research program evaluate opportunity acquire company product right product technology complementary business accounting relationship find note consolidated financial statement include report exist collaborative relationship follow anadys pharmaceuticals inc june enter collaboration anadys pharmaceuticals inc discover novel antiviral compound addition access fee milestone payment subject limitation gilead pay anadys royalty product develop research collaboration archemix corporation october enter agreement archemix corporation archemix agreement grant archemix exclusive sublicense selex technology identify aptamer subject exclusion development area right grant forfeited right selex technology derive license university license equity holdings inc ulehi successor university technology corporation predecessor university research corporation financial term agreement archemix provide lump sum payment total million archemix payment receive warrant purchase archemix stock agreement require agreement ulehi share portion cash payment warrant ulehi academic consulting relationshipsuniversity license equity holding incbukwang pharm ind ltd february triangle enter acquire acquisition triangle license agreement bukwang pharm ind ltd bukwang pursuant receive exclusive license bukwang right clevudine use hepatitis field human antiviral application license include country world korea license obligate milestone royalty payment bukwang include annual minimum royalty begin year fda registration grant fdaapprove product incorporate clevudine technology glaxosmithkline april enter licensing agreement gsk give exclusive right commercialize hepsera solely treatment hepatitis asia latin america certain territory addition fee milestone payment contract revenue gsk require pay percentage revenue generate sale hepsera license territory agreement gsk require enter clinical commercial supply agreement gsk require arrange supply clinical commercial requirement fully burden cost subject reasonable forecasting order procedure agreement gsk expire individual country basis later patent expiration year commercial sale particular country addition gsk right electively terminate agreement month notice gilead subject fee elective termination circumstance early term agreement eyetech pharmaceutical march enter agreement eyetech pharmaceuticals inc eyetech relate product name macugen develop treatment agerelate macular degeneration amd diabetic macular edema dme gilead invent compound macugen base selex technology license gilead ulehi academic consulting relationshipsuniversity license equity holdings inc gilead license eyetech develop macugen license gilead eyetech require pay fee milestone payment percentage revenue generate worldwide sale macugen agreement eyetech expire later year commercial sale product develop date patent expire agreement eyetech grant pfizer sublicense relate macugen december december connection sublicense gilead agree enter license pfizer term contain agreement eyetech roche enter collaboration agreement roche grant roche exclusive worldwide right tamiflu proprietary influenza neuraminidase inhibitor december receive license fee milestone payment roche total million relate execution agreement regulatory filing approval tamiflu roche fund research development cost tamiflu include reimbursement million period january december agreement roche responsible pricing manufacturing promote sell tamiflu worldwide basis pay percentage net revenue sale tamiflu subject reduction certain define manufacturing cost agreement roche terminate individual country basis later patent expiration year commercial sale particular country addition roche right terminate agreement entirety individual country basis prior expiration time month notice fujisawa enter agreement grant fujisawa exclusive right promote sell ambisome canada primary responsibility promote sell ambisome gilead copromoter fujisawa pay approximately fujisawa net revenue sale ambisome reserve right promote sell ambisome rest world pay fujisawa net revenue ambisome sale significant asian market include japan korea taiwan china india manufacture ambisome sell worldwide sell ambisome fujisawa sale price equal cost manufacture product sale canada price equal cost manufacture product plus specify percentage agreement fujisawa terminate patent cover ambisome japan expire osi pharmaceutical december sell osi pharmaceutical osi pipeline clinical stage oncology product relate intellectual property boulder colorado operation consideration asset receive osi million cash share osi common stock additionally osi pay additional million cash combination cash osi common stock achievement osi certain milestone relate development advanced oncology product candidate separately manufacture agreement osi agree produce osi liposomalformulation product include manufacturing facility san dimas california pharmacia enter agreement pharmacia relate vistide agreement pharmacia exclusive right market sell vistide country outside subject payment percentage net revenue require sell pharmacia bulk vistide maintain vistide patent agreement pharmacia expire individual country basis patent expiration year commercial sale country product cover patent addition pharmacia terminate agreement month notice notice individual country basis month apply marketing approval competitive product sumitomo enter agreement sumitomo give sumitomo exclusive right develop market ambisome japan addition milestone payment sumitomo require pay percentage revenue generate japanese sale ambisome ambisome approve sale japan manufacture ambisome sale sumitomo japan price charge sumitomo supply ambisome percentage revenue required pay determined price ambisome japan agreement sumitomo terminate later patent expiration japan year commercial sale japan termination agreement cubist pharmaceutical cidecin september jointly announce cubist pharmaceutical inc termination licensing agreement commercialization cidecin daptomycin injection oral formulation daptomycin terminate license agreement execute january grant exclusive commercialization right product european country follow regulatory approval term termination agreement owe future payment cubist cubist reacquire european right product academic consulting relationship supplement research development effort regular business enter arrangement university medical research institution arrangement provide right patent patent application technology own institution return payment fee relate use right emory university university georgia research foundation inc emtricitabine april triangle obtain acquire acquisition triangle exclusive worldwide license emory university right purify form emtricitabine use hiv hepatitis field obligate certain milestone royalty payment emory include annual minimum royalty begin year fda registration grant antihiv product incorporate emtricitabine technology year registration grant antihepatitis product incorporate emtricitabine technology certain major market country hiv hepatitis indication respectively triangle begin pay license maintenance fee development milestone achieve emory gsk settle litigation pende united states district court relate emtricitabine exclusive licensee foreign patent patent application file burrough wellcome use emtricitabine treat hepatitis license settlement agreement emory give access development clinical datum drug substance hold gsk relate emtricitabine emory gsk shire pharmaceuticals group plc shire settle worldwide patent dispute involve lamivudine emtricitabine term settlement emory receive exclusive license shire shire patent relate emtricitabine method use manufacture shire gsk receive exclusive license emory patent relate lamivudine term license agreement emory automatically acquire exclusive sublicense shire patent relate emtricitabine grant term settlement resolve previously pende patent dispute emtricitabineamdoxovir march triangle enter acquire acquisition triangle license agreement emory university georgia research foundation inc ugrf pursuant receive exclusive worldwide license emory ugrf right series nucleoside analogue include amdoxovir dxg active antihiv agent use hiv hepatitis field obligate milestone royalty payment emory ugrf march triangle begin pay license maintenance fee development milestone achieve begin year fda registration grant fdaapprove product incorporate amdoxovir technology require pay emory ugrf minimum annual royalty august triangle resolve outstanding patent dispute involve amdoxovir shire term settlement emory ugrf receive exclusive license shire patent right cover amdoxovir method use manufacture term license agreement acquire exclusive sublicense right exchange obligation pay shire incremental royalty future amdoxovir sale settlement agreement emory ugrf gilead grant shire exclusive license patent right bch method use manufacture license agreement emory terminate late patent expiration expiration obligation pay royalty addition right terminate agreement entirety respect indication hiv hbv country prior expiration time day notice anderson cancer center enter agreement anderson cancer center relate hepsera agreement currently pay anderson cancer center percentage net revenue base sale hepsera agreement anderson cancer center terminate later patent expiration year commercial sale iocbrega enter agreement iocbrega relate viread hepsera vistide agreement receive iocbrega exclusive right manufacture use sell nucleotide compound cover agreement currently pay net revenue base sale viread hepsera vistide iocbrega agreement iocbrega terminate individual country basis later patent expiration year commercial sale addition iocbrega terminate license particular product key market absence commercial sale product month regulatory approval university license equity holdings inc ongoing collaborative arrangement university license equity holdings inc ulehi technology hold company university colorado boulder relate selex technology identify aptamer arrangement ulehi grant present future right invention cover patent patent application selex technology improvement selex technology make discover oligonucleotide molecule make selex technology computer software relate selex technology require pay ulehi certain variable royalty base revenue generate sale product derive selex technology develop world collaboration bill melinda gates foundation family health international october enter agreement bill melinda gates foundation family health international fhi provide viread fhi multinational clinical trial evaluate viread effectiveness method reduce risk hiv infection sexually active adult regularly expose hiv clinical trial conduct fhi fund million threeyear grant gates foundation dart study november enter collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection fiveyear clinical study conduct mrc antiretroviral hiv therapy africa trial call dart trial development antiretroviral therapy africa aim study clinical versus laboratory monitoring practice structure treatment interruption versus continuous antiretroviral therapy adult hiv infection subsaharan africa provide viread cost dart studythe institute world health january enter agreement institute world health pursuant provide ambisome cost phase clinical trial evaluate ambisome treatment visceral leishmaniasis paromomycin india great global burden visceral leishmaniasis clinical trial conduct institute world health partnership world health organization international distribution agreement distributor europe asia latin america middle east africa grant distributor exclusive right sell ambisome case daunoxome particular country country specify period time agreement provide collaborative effort distributor obtain regulatory approval product particular country marketing product country agreement establish price distributor pay product require deliver quantity product order distributor enter similar distribution agreement viread country promote sell directly january announce program pursuant supply viread cost country africa country designate develop country united nations humanitarian effort recognition extreme impact hiv disease resourcepoor country world case hiv locate country take step ensure viread product sell program serve patient develop world divert market manufacture ambisome daunoxome manufacture ambisome daunoxome commercial quantity separate adjacent facility san dimas california medicines control agency united kingdom fda approve commercial production ambisome daunoxome facility produce import ambisome daunoxome european union manufacturing facility dublin ireland perform quality control testing final labeling packaging distribution european union use commercially available material equipment manufacture product currently obtain amphotericin use manufacture ambisome daunorubicin hcl distearoylphosphatidylcholine use manufacture daunoxome cholesterol use manufacture ambisome daunoxome single approve supplier ambisome sell freezedrie product currently freezedry ambisome san dimas manufacturing facility use party freezedry additional product give current projection growth ambisome demand sufficient capacity meet future demand option instal additional freezedrying capacity san dimas additional supply necessary prove unable install additional freezedrying capacity san dimas locate appropriate party meet need ability meet increase ambisome demand diminish manufacture liposomal product particularly complex process new liposomal product develop require unique complex variation manufacturing process antiviral product contract party manufacture antiviral drug clinical commercial purpose include viread hepsera vistide emtricitabine amdoxovir clevudine manufacture viread tablet single contract manufacturer european union sale distribution territory addition second contract manufacturer europe european union distribute product approve respective agency obtain qualification seek qualification european union contract manufacturer active ingredient hepsera contract manufacturer final hepsera drug product commercial supply seek qualify second supplier january roche announce production problem liquid suspension form tamiflu approve treatment child young yearold available liquid suspension form tamiflu return market time flu season production issue affect availability tablet form tamiflu adult adolescent year old japan flu season particularly severe roche sublicensee chugai corporation unable meet heighten demand satisfactorily january chugai issue press release attribute failure manufacturing problem problem japan reduce net sale royalty roche base date production commercialization issue material effect earning expect material effect earning future enter agreement abbott manufacture emtricitabine bulk drug substance final drug product currently seek qualification abbott european union contract manufacturer seek qualification european union second contract manufacturer emtricitabine bulk drug substance abbott recent history violation current good manufacturing practice regulation cite fda work correction fda consent decree fda conduct preapproval inspection abbott new drug application emtricitabine issue form observation abbott december january abbott submit response form observation fda deem abbott response form observation inadequate abbott unable supply initial launch quantity emtricitabine timely manner emtricitabine launch delay supplier approve fda european union manufacture cidofovir vistide single fda emea approve supplier final vistide drug product commercialscale manufacturing facility antiviral product current plan establish facility future antiviral product need develop additional manufacturing capability establish additional party supplier order manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale unable develop manufacturing capability internally contract large scale manufacturing party acceptable term future antiviral product ability conduct largescale clinical trial meet customer demand commercial product adversely affect believe technology use manufacture product compound proprietary antiviral product disclose necessary aspect technology contract manufacturer enable manufacture product compound agreement manufacturer intend restrict reveal technology certain manufacturer comply restriction addition manufacturer develop technology relate work perform need manufacture product compound require enter agreement manufacturer want use technology allow manufacturer use technology manufacturer refuse allow use technology demand term use technology acceptable believe compliance material environmental regulation relate manufacture product patent proprietary right patent proprietary right important business properly design enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection internationally file additional patent application appropriate cover improvement compound product technology rely trade secret internal knowhow technological innovation agreement party develop maintain protect competitive position ability competitive depend success strategy number patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent follow table show actual estimate expiration date europe primary patent patent issue pende application cover compound market product product candidate patent expiration european patent expiration product viread hepsera ambisome tamiflu vistide daunoxome product candidate emtricitabine amdoxovir clevudine application patent pende patent application issue patent protection date indicate instead rely patent expire early example european patent viread issue patent expire provide protection patent cover viread hepsera vistide emtricitabine clevudine amdoxovir hold party acquire exclusive right patent agreement party collaborative relationship academic consulting relationship patent cover active ingredient ambisome daunoxome instead hold patent liposomal formulation compound protect formulation trade secret patent filing cover form hepsera china certain asian country application pende asian country include china relate specific form formulation hepsera asia major market hbv therapy obtain patent compound year obtain marketing approval limit time prevent company develop compound reduce value product apply patent term extension example extension patent vistide grant number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain important infringe patent proprietary right violate agreement grant proprietary right infringe patent violate agreement prevent develop selling product process cover patent agreement require obtain license party allow use technology certain require obtain license thirdparty technology obtain reasonable cost able obtain require license adversely affect patent application confidential period time include patent issue pende patent application patent eventually issue prevent develop sell certain product obtain license use patent technology patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation reexamination proceeding enforcement validity exist patent future patent invalidate patent substantially reduce protection addition pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product develop rely unpatented trade secret improvement unpatente internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor research development agreement invention discover certain case jointly own corporate partner case exclusive property difficult determine own particular invention dispute arise invention competitionour product development program target number disease condition include viral fungal bacterial infection commercially available product disease large number company institution spend considerable amount money resource develop additional product treat disease current product compete available product base primarily efficacy safety tolerability acceptance doctor patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing adaptability mode dose product market future compete product offer competitor competitor introduce datum show improved characteristic product improve increase marketing effort simply low price product sale product decrease certain product develop future compare favorably product offer competitor exist future product compare favorably new product develop competitor ability competitive depend ability attract retain qualified personnel obtain patent protection develop proprietary product process secure sufficient capital resource substantial period take develop product viread hiv competitive landscape crowd complicated treatment trend continue evolve grow number antihiv drug currently sell advance stage clinical development brand drug available zerit stavudine sell bristolmyer squibb bms fix combination product combivir azt trizivir azt abc sell gsk represent direct competition viread company process launch formulation exist drug indicate fda oncedaily oral dosing include gsk dose epivir bms new extend release formulation zerit antiretroviral product candidate expect enter market year include atazanivir protease inhibitor bms fuzeon injectable integrase inhibitor rochetrimeris gsk pursue oncedaily dose ziagen abacavir new fix dose combination ziagen epivir company compete hiv therapeutic category pfizer merck boehringeringelheim abbott laboratories ambisome ambisome face strong competition current expect competitor current competitor include conventional amphotericin bms numerous generic manufacturer caspofungin product develop merck market cancida caspofungin voriconazole develop pfizer market vfend lipidbase amphotericin product approve europe include abelcet sell enzon corp canada japan elan corporation marketing distribution partner country amphotec sell intermune pharmaceutical inc presently unapproved expect competitor include class treatment call echinocandin include fujisawa micafunginwhich receive marketing approval japan october submission regulatory approval canada anidulafungin versicor inc product candidate evaluate multiple latestage clinical trial finally schere plough develop noxafil posaconazole currently phase trial competition current expect competitor erode likely continue erode revenue receive sale ambisome hepsera hepsera face significant competition exist therapy treat patient infect hbv significantly epivirhbv lamivudine develop collaboration shire pharmaceutical sell gsk major country north south america europe asia orally administer nucleoside analogue inhibit hbv dna polymerase introna interferon alfab sell schere plough major country north south america europe asia introna injectable drug immunomodulatory effect hepsera face competition clinicalstage candidate include bristolmyer squibb entecavir idenix ldt oral nucleoside analogue currently phase trial competition include roche pegasys pegylate interferon alfaa currently study chronic hepatitis tamiflu tamiflu competes relenza antiflu drug sell gsk relenza neuraminidase inhibitor deliver orallyinhale dry powder addition biocryst pharmaceutical develop neuraminidase inhibitor antiflu drug peramivir represent significant competition fda approve drug administer oncedaily pill oppose tamiflu take twice daily treatment certain tamiflu compare favorably drug base performance price length dose effect criterion vistide vistide compete number drug treat cmv retinitis include ganciclovir sell intravenous oral formulation roche ocular implant bausch lomb incorporate valganciclovir market roche foscarnet intravenous drug sell astrazeneca formivirsen drug inject directly eye sell cibavision daunoxome daunoxome compete expect compete number drug approve await approval treatment kaposi sarcoma europe include doxil product ortho biotech like daunoxome sell liposomal formulation number company pursue development technology competitive research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently biopharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program anticipate face increase competition future competitor introduce new product market new technology available determine exist product new product competitor develop effective effectively market sell develop competitive product render technology product obsolete noncompetitive recover money resource develop product government regulation operation activity subject extensive regulation numerous government authority countrie drug subject rigorous fda regulation federal food drug cosmetic act federal state statute regulation govern testing manufacture safety effectiveness labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume fda approve drug sell general process approval follow preclinical testing test drug candidate human study drug laboratory experiment animal generate datum tosupport drug potential safety benefit submit datum fda investigational new drug application ind seek approval test compound human clinical trial fda accept investigational new drug application study drug human clinical trial determine drug safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug give small number healthy human subject patient test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug give limited patient population determine effect drug treating disease well dose drug possible effect safety risk drug phase compound appear effective safe phase clinical trial phase clinical trial commence confirm result phase clinical trial longterm involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug uncommon drug appear promise phase clinical trial fail rigorous reliable phase clinical trial fda approval process believe datum phase clinical trial adequate level safety effectiveness file new drug application nda fda seek approval sell drug particular use fda review nda hold public hear independent advisory committee expert advisor ask additional question drug committee make recommendation fda bind fda generally follow fda fda agree compound require level safety effectiveness particular use allow sell drug use unusual fda reject application believe drug safe effective believe datum submit reliable conclusive point process development drug stop number reason include safety concern lack treatment benefit certain clinical trial conduct include viread emtricitabine hiv infection hepsera chronic hepatitis conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit fda require complete additional testing provide additional data information improve manufacturing process procedure facility require extensive postmarketing test surveillance monitor safety benefit product candidate determine new drug application contain adequate evidence safety benefit drug addition fda approve drug limit use drug approval withdraw fda believe comply regulatory standard problem uncover occur approval addition obtain fda approval drug manufacturing facility drug sell include company manufacture drug approve fda subject periodic inspection fda foreign establishment manufacture product sell approve fda subject periodic regulatory inspection manufacturing facility locate california include san dimas facility foster city facility license state california compliance local regulatory requirement drug treat lifethreatening disease condition adequately address exist drug designate fast track product fda eligible priority month review accelerate approval case viread drug receive accelerated approval monitor postmarkete clinical trial order confirm safety benefit drug subject federal state local regulation workplace safety protection environment use hazardous material chemical viruse radioactive compound research development activity eliminate risk accidental contamination injury material misuse accident involve material lead significant litigation fine penaltiesdrug subject extensive regulation outside european union centralize approval procedure authorize marketing product country european union include major country europe procedure decentralized system approval country european union obtain approval country european union simplify application process approval centralized procedure pricing reimbursement approval require country vistide viread approve european union centralize procedure viread hiv drug review accelerate approval european union hepsera receive traditional review emtricitabine pricing reimbursement insurance company health maintenance organization hmos thirdparty payor government seek limit charge drug example certain foreign market pricing negotiation require obtain approval product expect continue number federal state proposal implement drug price control addition manage care organization common continue seek low drug price announcement proposal effort cause stock price low proposal adopt revenue decrease ability sell drug depend availability reimbursement government private insurance company government insurance company demand rebate predetermine discount list price expect product develop particularly aid indication subject reimbursement issue certain product obtain regulatory approval reimburse government insurance company regulatory approval price generally require foreign country particular certain country condition approval product agreement seller sell product certain price country past require price reduction connection product approval certain regulatory authority future establish low price regulatory action reduce price product country practical effect require reduce price country european government notably germany italy implement consider legislation require pharmaceutical company sell product subject reimbursement mandatory discount mandatory discount reduce revenue receive drug sale certain develop country significantly affect hiv aids parallel import generic competition occur adversely affect revenue sale market share viread management change march announce john milligan phd promote senior vice president chief financial officer report directly ceo restructure combine responsibility corporate function support strategic financial communication technological planning broaden senior management role corporate development finance corporate communication information technology group centralize leadership milligan addition announce time completion organization change include alignment manufacturing group san dimas operational area report mark perry executive vice president operation establish paris france headquarters european operation employee february approximately fulltime employee believe good relation employee website website address wwwgileadcom available free charge website annual report quarterly report form current report form amendment report soon reasonably practicable filing provide hyperlink edgar website directly report risk factor affect gilead evaluate business carefully consider follow risk addition information report follow risk materially adversely affect business operating result financial condition viread maintain increase market acceptance result operation suffer rely sale viread significant portion operating income viread face extremely competitive marketplace anumber drug treat hiv infection aid currently sell advanced stage clinical development include product currently sell company significant competitor hivaid market gsk bristolmyer squibb roche pfizer merck boehringeringelheim abbott laboratories competitor potential competitor substantially great resource resource include great experience promote market hiv drug superior product development capabilitie financial scientific manufacturing marketing managerial human resource order viread continue success maintain expand position marketplace competitor drug viread market penetration limit particularly use treatmentnave patient give data datum support marketing approval reflect use viread treatmentexperience patient population obtain datum safety efficacy viread treatmentnave patient regulatory authority allow include datum label viread marketing effort unsuccessful include information viread use treatmentnave patient viread labeling datum unsuccessful convincing physician prescribe viread treatmentnave patient government reimburser private insurance company pay viread prescribe patient prior hiv therapy viread maintain increase market acceptance result operation suffer significant reduction viread ambisome hepsera sale significantly reduce operating income require scale manufacturing operation reduce sale force viread product sale year end december million million total revenue respectively expect product sale viread constitute substantial total revenue foreseeable future ambisome sale year end december million million million total revenue expect revenue sale ambisome continue provide material portion total product revenue hepsera product sale begin september year end december approximately million total revenue expect product sale hepsera constitute substantial total revenue foreseeable future accordingly foreseeable future expect continue rely heavily sale viread ambisome hepsera support exist manufacturing sale infrastructure provide operating income fund significant portion administrative research development expenditure significant reduction sale viread ambisome hepsera result introduction competitive product hurt business scale manufacturing operation reduce sale force safety issue arise market product significantly reduce limit sale adversely affect result operation datum support marketing approval product include viread ambisome hepsera form basis safety warning product label obtain control clinical trial limit duration case viread limited post approval use follow approval product long period time patient take numerous medicine underlie health problem monitor dose compliance new safety issue report postmarkete use rule contributory role product required provide additional warning label narrow approve indication reduce market acceptance product example observe kidney toxicity clinical trial viread kidney toxicity report postapproval use viread viread label update include warn safety issue market product arise face potential product liability claim sale product halted regulatory authority similarly discontinue development adefovir dipivoxil treatment hiv infection safety benefit concern arise study doubleblind placebo control study adefovir dipivoxil demonstrate safety efficacy treatment patient chronic hepatitis study show adefovir dipivoxil significantly effective hbv hiv allow use low dose adefovir dipivoxil hepsera treatment hiv infection dose adefovir dipivoxil hepsera hasnot associate significant kidney toxicity clinical trial date patient preexist kidney problem take drug know cause kidney toxicity fda grant marketing approval hepsera certain result phase clinical study hepsera demonstrate satisfaction regulatory agency include european union hepsera safe effective treatment chronic hepatitis hepsera new drug gain significant market acceptance hepsera new drug face competitive marketplace currently drug sell treatment chronic hepatitis potential drug late stage clinical development competitor potential competitor substantially great resource resource include great experience promote marketing pharmaceutical include hbv drug superior product development capabilitie great financial scientific manufacturing marketing managerial human resource order hepsera successful establish marketplace competitor drug early determine hepsera achieve significant market acceptance welldevelope market generally accept treatment strategy hepatitis market sell drug treatment chronic hepatitis successful able develop therapeutic market effectively long term use hepsera reveal safety issue development resistance hepsera patient marketing effort unsuccessful hepsera turn safety resistance issue unsuccessful convincing physician prescribe hepsera patient government reimburser private insurance company pay hepsera hepsera gain significant market acceptance expect future result operation suffer fiscal year year operating profitability able maintain profitability sustainable basis profitable operating basis year continue profitable future expect merger triangle reduce earning effect earning increase earning certain estimate correct december accumulate deficit approximately million loss result principally expense associate research development program less extent sale general administrative expense operating result adversely affect reduce sale product increase marketing development expense acquisition product company triangle unprofitable time acquisition result risk describe report develop drug treat hiv infection aid relate condition change regulatory commercial environment hiv infection aid therapy harm business product product development address hiv infection aid relate condition product include viread emtricitabine hiv infection aid vistide cmv retinitis daunoxome hivassociate kaposi sarcoma develop product base current policy current marketplace hiv infection aid therapie prediction future policy future marketplace therapie business subject substantial risk policy market change quickly unpredictably way impair ability maintain regulatory approval commercial acceptance product operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis achieve continued compliance delay commercialization product product develop approve marketing sale regulatory authority subject extensive regulation fda comparable regulatory agency country continue clinical trial ambisome viread hepsera currently approve additional use anticipate conduct variety clinical trial file marketing approval additional product year product fail receive marketing approval timely basis certain hepsera approve european union regulatory authority countrie hepsera receive marketing approval country significant limitation place use certain emtricitabine approve european union marketing approval significant limitation use certain able obtain regulatory approval necessary expand commercial effort new market failure delay limitation regulatory change action recall delay commercialization product adversely affect result operation addition product market product manufacturer subject continual review later discovery previously unknown problem product manufacture production thirdparty manufacturer result restriction product manufacture product include withdrawal product market fail comply withapplicable regulatory requirement subject penalty include fine suspension regulatory approval product recall seizure product criminal prosecution result clinical trial uncertain support regulatory approval product require demonstrate safety effectiveness product develop intend use extensive preclinical study clinical trial order obtain regulatory approval product result preclinical early clinical study accurately predict result later largescale clinical trial reason include preliminary result indicative effectiveness clinical trial achieve desire result clinical trial reveal unduly harmful effect drug effective drug delivery system desire indication successfully complete largescale clinical trial result marketable product reason include potential product show safe effective regulatory authority disagree result design study trial potential product difficult develop commercially viable product number company industry suffer setback advance clinical trial despite promise result early trial end unable develop additional marketable product delay enrol patient develop suitable protocol clinical trial increase cost delay regulatory approval rate completion clinical trial depend rate patient enrollment substantial competition enroll patient clinical trial drug development competition delay clinical trial past addition recent improvement exist drug therapy particularly hiv hepatitis difficult enroll patient clinical trial patient population choose enroll clinical trial sponsor company choose alternative therapy delay plan patient enrollment result increase development cost delay regulatory approval clinical trial carry protocol acceptable regulatory authority committee responsible clinical study site study conduct delay prepare protocol receive approval delay start finish clinical trial addition feedback regulatory authority result early stage clinical study require modification delay later stage clinical trial type delay result increase development cost delay regulatory approval approximately half product sale occur outside currency fluctuation impair financial result significant percentage product sale denominate foreign currency increase value dollar foreign currency past reduce future reduce dollar equivalent sale negatively impact financial condition result operation effective january begin use foreign currency forward contract hedge percentage forecast international sale primarily denominate euro currency hedge portion account receivable balance denominate foreign currency reduce eliminate exposure currency fluctuation date sale record date cash collected additionally mitigate impact currency rate fluctuation cash outflow certain foreign currencydenominate raw material purchase enter foreign exchange forward contract hedge foreign currency denominate account payable use forward contract reduce impact foreign currency fluctuation future result certain effort successful fluctuation adversely affect result operation face credit risk international account receivable subject credit risk account receivable relate european product sale european product sale government own support customer greece spain portugal italy subject significant payment delay government funding reimbursement practice significant change occur reimbursement practice european government government funding unavailable financial position result operation adversely affectedproduct development expense cause operating expense fluctuate quarter quarter clinical trial require regulatory approval product extremely expensive difficult accurately predict control timing expense quarter quarter uneven unexpected activity program cause operating result fluctuate quarter quarter depend relationship company sale marketing performance revenue failure maintain relationship negatively impact business rely number significant collaborative relationship major pharmaceutical company sale marketing performance include collaboration fujisawa sumitomo ambisome gsk hepsera roche tamiflu pharmacia vistide certain country rely international distributor sale ambisome viread european country intend rely international distributor sale hepsera relationship involve clinical development product partner reliance collaborative relationship pose number risk include able control corporate partner devote sufficient resource program product dispute arise future respect ownership right technology develop corporate partner disagreement corporate partner lead delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor corporate partner marketing right choose devote few resource marketing product product development distributor corporate partner unable pay give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue exist product include viread hepsera ambisome tamiflu decline january roche announce production problem liquid suspension form tamiflu approve treatment child young year old available liquid suspension form tamiflu return market time flu season production issue affect availability tablet form tamiflu adult adolescent year old japan flu season particularly severe roche sublicensee chugai corporation unable meet heighten demand satisfactorily january chugai issue press release attribute failure manufacturing problem problem japan reduce net sale royalty roche base april licensing agreement gsk give gsk right control clinical regulatory development commercialization hepsera territory include asia africa latin america include major market hepsera china japan taiwan korea success hepsera territory depend entirely effort gsk receive royalty gsk equal percentage net sale gsk gsk fail devote sufficient resource succeed develop commercialize hepsera territory potential revenue sale hepsera substantially reduce exist product product development accept physician insurer patient ability product achieve sustain market acceptance country approve marketing depend scope regulatory approval government authority manage care organization adequately reimburse patient use product addition need convince medical patient advocacy community effectiveness product treat disease safety product administer patient advantage product competitive product physician patient patient advocate payor medical community general accept use product develop product accept result operation suffer company target disease condition competitive product company significantly reduce market acceptance product product development program target number disease condition include viral infection fungal infection commercially available product disease certain product wellestablishe therapy generate substantial sale addition large number company institution conduct wellfunde research development activity direct develop treatment disease product currently market development competitor technology product obsolete noncompetitive expect competition treatment disease increase future new product enter market advanced technology available compete license acquire technology company plan supply viread cost certain develop country reduce viread gross profit margin rise unforeseen liability launch distribution program pursuant supply viread cost country africa country designate develop country united nations receive profit viread supply program reduce viread product gross profit margin reduction depend volume viread flow program predict certainty additionally supply distribution drug resourcepoor environment complicated undertaking program develop face unforeseen challenge risk rise unforeseen liability exist product subject reimbursement government agency party pharmaceutical pricing reimbursement pressure reduce profitability successful commercialization product depend availability governmental party payor reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement government authority thirdparty payor increasingly challenge price medical product service particularly innovative new product therapy result low average sale price example majority sale ambisome vistide daunoxome significant percentage sale viread hepsera subject reimbursement government agency result significant discount list price rebate obligation business adversely affect increase international pricing pressure pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general recent year new legislation propose federal state level effect major change health care system nationally state level proposal include prescription drug benefit proposal medicare beneficiary introduce congress federal reform legislation state enact health care reform legislation federal state development possible predict exact nature legislative health care reform result operation adversely affect reform europe success hepsera approve sale tamiflu viread depend largely obtain maintain government reimbursement europe european country include united kingdom france patient reluctant pay prescription drug pocket expect success product development particularly europe depend ability obtain reimbursement reimbursement available reimbursement policy adversely affect ability sell product profitable basis addition international market government control price prescription pharmaceutical market regulatory marketing approval receive pricing negotiation governmental authority month long sale compete product attempt gain market share introductory pricing program competitor require low price country adversely affect result operation foreign government passed consider legislation require sell product subject reimbursement mandatory discount product revenue reduce import country product available low pricesour sale country relatively high price reduce product import country low price market case pharmaceutical product sell steeply discount price develop world export european country resold high price happen product particularly viread agree provide cost country africa country designate develop country united nations revenue adversely affect addition european union required permit cross border sale allow buyer country government approve price product relatively high purchase product legally country sell low price crossborder sale adversely affect revenue able obtain effective patent protect technology use competitor patent company require stop pay use require technology success depend significant degree ability obtain patent license patent right preserve trade secret operate infringe proprietary right right foreign issue patent file continue file patent application abroad relate technology risk patent issue application patent sufficient protect technology patent application confidential period time patent issue result know competitor file patent application technology cover pende application certain invent technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete patent patent filing china certain asian country cover form adefovir dipivoxil active ingredient hepsera application pende asian country relate form formulation adefovir dipivoxil asia major market therapy hepatitis indication hepsera develop obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale commercial value product limit addition patent provide adequate protection certain country africa asia include china competitor file patent application cover technology participate interference proceeding litigation determine right patent litigation interference proceeding expensive successful success depend large ability operate infringe patent proprietary right party infringe patent prevent commercialize product require obtain license party certain able obtain alternative technology require license obtain technology license certain term reasonable fail obtain license alternative technology unable develop commercialize product addition use significant proprietary technology rely unpatented trade secret proprietary knowhow protect certain aspect production technology trade secret know independently discover competitor country require grant compulsory license hiv product face generic competition hiv product number develop country government official group suggest pharmaceutical company drug hiv infection available low cost case governmental authority indicate pharmaceutical company patent enforceable prevent generic competition major pharmaceutical company greatly reduce price hiv drug certain develop country certain country permit enforcement patent sale viread country reduce generic competition alternatively government country require grant compulsory license allow competitor manufacture sell version viread country reduce viread sale respond governmental concern reduce price viread situation result operation adversely affect manufacturing problem delay product shipment regulatory approvalswe depend party perform manufacture obligation effectively timely basis party fail perform require impair ability deliver product timely basis cause delay clinical trial application regulatory approval event harm competitive position viread hepsera vistide rely party manufacture bulk drug substance final drug product clinical commercial purpose example roche responsible manufacturing tamiflu january roche announce production problem liquid suspension form tamiflu approve treatment child young year old available liquid suspension form tamiflu return market time flu season production issue affect availability tablet form tamiflu adult adolescent year old japan flu season particularly severe roche sublicensee chugai corporation unable meet heighten demand satisfactorily january chugai issue press release attribute failure manufacturing problem problem japan reduce net sale royalty roche base additionally emtricitabine seek qualification abbott european union contract manufacturer bulk drug substance final drug product seek qualification european union second contract manufacturer emtricitabine bulk drug substance abbott recent history violation current good manufacturing practice regulation cite fda work correction fda consent decree fda conduct preapproval inspection abbott new drug application emtricitabine issue form observation abbott december january abbott submit response form observation fda deem abbott response form observation inadequate abbott unable supply initial launch quantity emtricitabine timely manner emtricitabine launch delay manufacture ambisome daunoxome facility san dimas california formulation manufacturing facility san dimas california manufacturing facility ireland perform certain quality control testing labeling packaging use party alternate contract supplier fill freeze dry certain batch product event natural disaster include earthquake equipment failure strike difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome daunoxome meet market need able obtain material necessary manufacture product material utilize operation facility example depend single supplier high quality amphotericin daunorubicin hcl distearoylphosphatidylcholine high quality cholesterol manufacture liposomal product supplier key component material name new drug application file fda product significant delay occur qualification new supplier require supply supplier interrupt reason unable ship viread ambisome hepsera vistide daunoxome supply product development clinical trial limited experience manufacture exist product need develop additional manufacturing capacity product potential future product potential product development need develop production technology use large scale order conduct clinical trial produce product commercial sale acceptable cost certain able implement development successfully manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation fda current good manufacturing practice extensive regulation govern manufacturing process stability testing recordkeeping quality standard addition manufacturing operation subject routine inspection regulatory agency similar regulation effect country business rise product liability claim cover insurance indemnity agreement testing manufacturing marketing use viread ambisome hepsera tamiflu vistide daunoxome product development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company successful product liability claim require pay substantial amount impair financial condition ability clinically test market productsadditionally require governmental regulation test product sell patient result test require determine recall product market subsequent testing product recall increase potential exposure product liability claim internal research program effort obtain right new product party yield potential product clinical development long term success depend ability identify internal research program potential product candidate develop new pharmaceutical product obtain new product product candidate license party significant portion research conduct involve new unproven technology research program identify product candidate require substantial technical financial human resource candidate identify research program appear promise route identify potential product candidate fail yield product candidate clinical development number reason include research methodology successful identify potential product candidate potential product candidate study show unduly harmful effect characteristic indicate unlikely effective drug unable develop large scale manufacturing method efficient costeffective capable meeting stringent regulatory standard hold intellectual property right prevent develop make sell certain product unable obtain suitable product candidate product party number reason include unable purchase license compound term allow appropriate return product competitor unwilling assign license product right unable identify suitable product product candidate area expertise product candidate acquire approve regulatory authority problem safety effectiveness unable develop suitable potential product candidate internal research program obtain right new product party future revenue growth suffer use hazardous material chemical viruse radioactive compound expose potential liability research development involve control use hazardous material chemical viruse radioactive compound believe safety procedure handle dispose material comply standard prescribe state federal regulation completely eliminate risk accidental contamination injury material event accident hold liable significant damage fine risk relate triangle acquisition january emtricitabine receive marketing approval single agent prevent delay commercial sale formulation viread emtricitabine submit application marketing approval emtricitabine treatment hiv infection european union ability obtain marketing approval coformulation viread emtricitabine depend emtricitabine receive marketing approval single agent treatment hiv infection regulatory authority european union country grant marketing approval emtricitabine conclude safe efficacious intended use addition regulatory authority european union require new product sufficient efficacy safety advantage currently market product extensive preclinical toxicity datum authority conclude emtricitabine approvable single agent emtricitabine similar chemical level epivir gsk lamivudine product market treatment hiv infection andavailable datum indicate product comparable safety efficacy profile emtricitabine receive marketing approval single agent unable obtain marketing approval coformulation viread emtricitabine conduct lengthy expensive clinical trial coformulation order obtain approval propose coformulation viread emtricitabine technically possible effective safe approve regulatory authority intend develop commercialize coformulation viread emtricitabine achieve anticipate synergy potential benefit coformulation significant motivation merger triangle depend successfully create obtain marketing approval coformulation viread emtricitabine expect emtricitabine receive marketing approval major requirement obtain marketing approval coformulation viread emtricitabine clinical study show coformulation emtricitabine viread biologically equivalent emtricitabine viread administer separate formulation need chemistry manufacture bioequivalence package show coformulated tablet give exposure viread emtricitabine drug give individually uncertain possible bring formulation market emtricitabine approve marketing regulatory authority approve require additional clinical trial order obtain regulatory approval addition physical combination emtricitabine viread technically feasible costeffective drug coformulate regulatory authority approve coformulation require additional clinical trial grant marketing approval requirement clinical trial delay failure develop commercialize coformulation emtricitabine viread material adverse effect business financial condition result operation successfully integrate triangle operation business adversely affect integrate gilead triangle complex timeconsuming process prior merger gilead triangle operate independently business corporate culture location employee system gilead triangle operate combine organization begin utilize common information communication system operating procedure financial control human resource practice include benefit train professional development program substantial difficulty cost delay involve integration gilead triangle include distract management business combine company potential incompatibility corporate culture potential inability coordinate research development effort successfully cost delay implement common system procedure operate combine company site international site factor increase operating cost lower anticipate financial performance addition combine company lose corporate partner distributor supplier manufacturer employee factor outside control company achieve anticipate synergy potential benefit underlie company reason merger depend successful integration company failure integrate gilead triangle successfully material adverse effect business financial condition result operation unable manufacture emtricitabine successfully reasonable cost potential future result suffer manufactured emtricitabine familiar manufacturing process emtricitabine completion merger triangle responsible making arrangement obtain supply emtricitabine party anticipate commercial launch follow receipt marketing approval european union triangle adequate arrangement supply supply problem party manufacturer emtricitabine sufficient supply emtricitabine meet commercial demand case future result suffer triangle enter agreement abbott abbott agree manufacture emtricitabine bulk drug substance final drug product transfer manufacturing technology emtricitabine party manufacturer rely abbott party manufacture emtricitabine period time seek qualification abbott european union contract manufacturer abbott recent history violation current good manufacturing practice regulation cite fda work correction fda consent decree fda conduct preapproval inspection abbott new drug application emtricitabine issue form observation abbott december january abbott submit response form observation depend abbott perform obligation effectively timely basis fda deem abbott response form observation inadequate abbott unable supply initial launch quantitie ofemtricitabine timely manner time emtricitabine launch impact event harm competitive position new manufacturer emtricitabine approve regulatory authority delay approval rely abbott emtricitabine supply long period currently anticipate cost supply emtricitabine party manufacturer unacceptably high result operation suffer able arrange manufacture emtricitabine low cost manufacture emtricitabine sure emtricitabine manufacturing cost reduce acceptable level profitability depend triangle operation incur loss triangle inception triangle incur loss inception december accumulate deficit approximately million triangle loss result primarily expense associate acquisition development drug candidate general administrative cost triangle generate revenue sale product candidate date expect triangle operation generate significant revenue achieve profitability trading price security subject significant fluctuation trade price common stock volatile volatile future factor announcement fluctuation competitor operating result change prospect market condition biotechnology stock general significant impact future trading price common stock particular trading price common stock biotechnology company include experience extreme price volume fluctuation times unrelated operating performance company stock affect factor cause volatility price security include clinical trial result regulatory development quarterly variation result business product market cycle fluctuation customer requirement availability utilization manufacturing capacity time new product introduction ability develop implement new technology price security affect estimate projection investment community general economic market condition cost operation product market predict individual effect factor price security factor individually aggregate result significant variation price give period time assurance factor adverse effect trading price common stock item property corporate headquarters include principal executive office research facility locate foster city california location lease approximately square foot space proximately locate building lease cover approximately square foot space group building expire december renewal option remain lease expire march september option renew lease additional fiveyear period occupy facility san dimas california location lease approximately square foot space house research development activity manufacture certain administrative function lease expire november fiveyear renewal option addition lease adjacent warehouse facility square foot space use product distribution administrative function lease expire april additional fiveyear extension durham north carolina lease approximately square foot administrative office laboratory space sublease approximately square foot party lease expire september currently negotiation lessor lease term addition lease approximately square foot space sale market regulatory finance information technology human resource operation europe australia include prepaid year lease square foot manufacturing distribution facility ireland lease expiration date believe facility adequate suitable current nearterm future need item legal proceeding reach settlement elan corporation plc successor company liposome company company agree dismiss legal proceeding involve ambisome term initial settlement agreement initial payment elan million agree additional royalty payment base ambisome sale record million accounting charge accrue litigation settlement expense represent net present value future minimum payment require june enter agreement elan terminate remain ambisome payment obligation initial settlement agreement exchange payment elan million november ulehi notify ulehi believe gilead materially breach licensing agreement ulehi concern selex technology identify aptamer thing assign right agreement ulehi consent contest ulehi allegation meet ulehi allegation actively engage negotiation settle disagreement negotiation prove unsuccessful ulehi choose terminate ulehigilead agreement arbitration concern termination likely result unfavorable outcome arbitration rise award monetary damage adverse remedy possibly include conveyance ulehi gilead right obligation ulehi licensing agreement sublicense party legal action arise ordinary course business believe legal action significant impact business item submission matter vote security holder matter submit vote security holder quarter end december item market registrant common stock relate stockholder matter common stock trade nasdaq stock market symbol gild follow table set forth period indicate high low intraday sale price share common stock nasdaq stock market price represent quotation dealer adjustment retail markup markdown commission represent price actual transaction high low quarter second quarter quarter fourth quarter quarter second quarter quarter fourth quarter february share common stock outstanding hold approximately stockholder record pay cash dividend common stock inception anticipate pay foreseeable future december issue million convertible senior note december private offer goldman sachs resold note qualified institutional investor net proceed approximately million follow table provide certain information respect equity compensation plan effect end fiscal year end december share thousand equity compensation plan information number common share number common remain available share weightedaverage issuance equity issue exercise price compensation plan exercise outstanding exclude security outstanding option option warrant reflect warrant right right column plan category equity compensation plan approve security holder equity compensation plan approve security holder total include approximately million share issuable gilead employee stock purchase plan note consolidated financial statement item select financial datum gilead sciences inc select consolidated financial datum thousand share datum year end december consolidated statement operation datum total revenue total cost expense income loss operation gain sale oncology asset income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amount common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharebasic share share calculationbasic amount common sharedilute income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharedilute share share calculationdilute december consolidated balance sheet datum cash cash equivalent marketable security work capital total asset longterm obligation convertible debt accumulate deficit total stockholder equity complete sale oncology asset relate technology osi pharmaceuticals inc record non operate gain million record nonoperate gain million sale percent interest proligo gilead sell share osi common stock recognize loss sale marketable security million share partial consideration sale oncology asset gilead sciences inc select consolidated financial datum continue thousand share datum prior period restate reflect merger nexstar pharmaceuticals inc july account pool interest gilead adopt statement financial accounting standard nos collectively refer sfas accounting derivative instrument hedge activity quarter change account change accounting principle effective quarter gilead adopt sec staff accounting bulletin sab revenue recognition financial statement change account change accounting principle cash dividend declare pay common stock item management discussion analysis financial condition result operation overviewgilead incorporate delaware june biopharmaceutical company focus discovery development commercialization antiviral antibacterial antifungal treat lifethreatene infectious disease multinational company revenue approve product marketing operation country currently market viread tenofovir disoproxil fumarate treatment hiv infection hepsera adefovir dipivoxil treatment chronic hepatitis infection ambisome amphotericin liposome injection antifungal agent daunoxome daunorubicin citrate liposome injection drug approve treatment kaposi sarcoma vistide cidofovir injection treatment cmv retinitis roche market tamiflu oseltamivir phosphate treatment influenza collaborative agreement seek add exist portfolio product clinical development program internal discovery program active product acquisition inlicense strategy acquisition triangle complete january internal discovery activity include identification new molecular target target screen medicinal chemistry addition currently develop product treat hiv hbv infection expertise liposomal drug delivery technology use develop drug safe easy patient tolerate effective december complete sale oncology asset osi pharmaceuticals inc transaction value million cash osi stock transaction allow focus continue strengthen core expertise infectious disease note consolidated financial statement information year end december gilead adopt statement financial accounting standard nos collectively refer sfas accounting derivative instrument hedging activity result cumulative effect change accounting principle year end december gilead adopt securities exchange commission staff accounting bulletin revenue recognition financial statement result cumulative effect change accounting principle certain prior period amount reclassify conform current presentation forwardlooke statement risk factor follow discussion contain forwardlooke statement involve risk uncertainty gilead actual result differ materially discuss forwardlooke statement factor cause contribute difference include limited discuss section caption business include risk factor affect gilead forwardlooke statement include document base information currently available gilead include effect acquisition triangle guidance specifically note evaluate detailed financial impact triangle operation consolidate financial statement assume obligation update forwardlooke statement follow discussion read conjunction consolidated financial statement note include report viread sale rely sale viread significant portion operate income number drug treat hiv infection aid currently sell advanced stage clinical development include product currently sell company significant competitor hivaid market gsk bms roche pfizer merck boehringeringelheim abbott laboratories give broad range competitor depth resource viread market penetration limit particularly use treatmentnave patient give datum support viread approval treatmentexperience patient population ambisome sale rely sale ambisome significant portion operating income lower price product compete ambisome product compete ambisome recently approve european union product develop compete ambisome future antifungal product achieve market acceptance antifungal product development commercially available revenue sale ambisome likely decrease result reduction operating income acquisition integration january complete acquisition triangle acquisition carry inherent risk able successfully integrate triangle operation obtain anticipate synergy cost saving unsuccessful obtain marketing approval emtricitabine develop coformulated product failure successfully integrate triangle operation business obtain marketing approval emtricitabine adversely affect financial position result operation market acceptance product ability product achieve sustain market acceptance depend number factor include receipt scope regulatory approval availability public private insurance reimbursement product safety efficacy tolerability cost product ease administration dose product compare competitive product product achieve sustain market acceptance result operation suffer regulatory process food drug administration foreign agency reject limit commercialization product number reason include disagree result design clinical trial believe product haveunacceptable efficacy toxicity tolerability believe product manufacture commercial basis compliance applicable safety quality standard agency reject limit commercialization product financial result adversely affect clinical trial require regulatory approval product extremely expensive difficult accurately predict control timing expense quarter quarter addition regulatory agency require conduct additional unanticipated clinical trial product cost substantial governmental legislation reimbursement program regulatory legal legislative issue adversely affect pricing sale product federal legislation lower price product purchase reimburse federal agency state enact legislation low price product addition grow number federal state legislative proposal enact lower price product country outside government sponsor health care program set low drug price patient reimbursement level sale country relatively high price reduce product import country low price market particular concern european union require permit cross border sale concern legislation ease import restriction enact applied international credit risk subject credit risk account receivable relate european product sale european product sale government own support customer greece spain portugal italy subject significant payment delay government funding reimbursement practice significant change occur reimbursement practice european government government funding unavailable financial position result operation adversely affect compulsory licensing generic competition number develop country government official group suggest pharmaceutical company drug hiv infection available low cost case governmental authority indicate pharmaceutical company patent enforceable prevent generic competition major pharmaceutical company greatly reduce price hiv drug certain develop country certain country permit enforcement patent sale viread country reduce generic competition alternatively government country require grant compulsory license allow competitor manufacture sell version viread country reduce viread sale respond governmental concern reduce price viread situation result operation adversely affect collaboration depend collaboration development commercialization certain product revenue include collaboration fujisawa sale ambisome canada collaboration gsk clinical regulatory development commercialization hepsera asia latin america certain territory collaboration roche sale tamiflu worldwide seek additional collaboration collaboration fail number reason include partner devote sufficient resource development commercialization marketing product dispute arise partner exist collaboration fail financial result adversely affect foreign currency fluctuation significant percentage product sale denominate foreign currency increase value dollar foreign currency past reduce future reduce dollar return sale negatively impact financial condition prior january hedge exposure impact fluctuate foreign exchange rate forecast sale effective january begin use forward contract hedge percentage forecast international sale primarily denominate euro currency hedge portion account receivable balance denominate foreign currency minimize eliminate exposure currency fluctuation date sale record date cash collect additionally mitigate impact currency rate fluctuation cash outflow certain foreign currency denominate raw material purchase enter foreign exchange forward contract hedge foreign currencydenominate account payable uncertain financial result expect financial result continue fluctuate quarter quarter fluctuation substantial fluctuation cause factor control include risk factor list december accumulate deficit million critical accounting policy estimate gilead discussion analysis financial condition result operation base consolidated financial statement prepare accordance accounting principle generally accept united states preparation financial statement require estimate judgment affect report amount asset liability revenue expense relate disclosure asset liability ongoing basis evaluate estimate include related revenue recognition bad debt inventory accrue clinical preclinical expense contingency base estimate historical experience market specific assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate gilead believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement record estimate reduction revenue expect return expire product medicaid reimbursement customer incentive cash discount prompt payment estimate medicaid reimbursement cash discount base contractual term expectation utilization rate program estimate product return include new product base ongoing analysis industry historical return pattern expect return market drug generally low shelf life product range month viread month ambisome condition competitive market serve drug circumstance change action increase product return estimate offer additional customer incentive result incremental reduction future revenue time return estimate change incentive offer maintain allowance doubtful account estimate loss result inability customer require payment allowance base analysis factor include limited historical payment pattern customer individual customer circumstance analysis day sale outstanding customer geographic region review local economic environment potential impact government funding reimbursement practice financial condition customer economic environment operate deteriorate result inability payment additional allowance require write inventory base quality control review individual raw material batch generally maintain inventory reserve base estimate obsolescence risk competition primarily shelf life product long current assumption future demand competition change actual market condition favorable project management additional inventory reserve require record accrual estimate clinical preclinical study cost cost significant component research development expense management accrue cost clinical study perform contract research organization base estimate generally work upfront cost remain activity occur straightline basis life individual contract study estimate match actual service perform organization determine patient enrollment level relate activity monitor patient enrollment level relate activity extent possible management underestimate activity level associate study give point time record additional research development expense future period significant result operation revenue total revenue million million million include total revenue net product sale royalty income contract revenue include revenue research development manufacturing collaboration net product sale revenue million compare million million product sale increase compare primarily significant increase sale viread approve sale october european union february significant percentage gilead product sale continue denominate foreign currency prior hedge exposure impact fluctuate foreign exchange rate forecast sale effective january begin use forward contract hedge percentage forecast international sale reduce eliminate fluctuation sale change foreign currency exchange rate primarily denominate euro currency loss revenue hedge reduce product revenue million sale viread million total product sale compare million total product sale viread sale million sale million international sale continue market expansion viread expect viread sale approximately double range million million sale ambisome million increase ambisome sale million sale ofambisome million prior revenue primarily derive sale ambisome represent total product sale total product sale total product sale exclude impact foreign currency relative dollar ambisome sale grow year end december comparable period increase sale compare primarily volume sale increase europe offset decline sale increase sale compare primarily volume price increase europe addition exclude impact decline foreign currency relative dollar sale ambisome increase expect increase competition expect ambisome sale low range million million record royalty revenue million compare million million year period significant source royalty revenue sale ambisome fujisawa copromotion arrangement royalty revenue fujisawa million compare million million record royalty revenue million million million relate sale tamiflu tamiflu orally administer compound develop treat prevent viral influenza human gilead codevelope tamiflu roche own worldwide commercial right tamiflu require pay royalty net sale product begin recognize royalty tamiflu quarter june roche receive european regulatory approval tamiflu treatment influenza adult child prevention adolescent adult difficult estimate party product sale record royalty revenue quarter arrear total contract revenue million compare million million primary source contract revenue licensing selex process patent estate archemix collectibility concern recognize cash basis provide million contract revenue million roche milestone payment million european prophylaxis treatment approval tamiflu million milestone payment relate development tamiflu collaboration agreement contract revenue roche consist million milestone payment relate roche complete regulatory filing approval tamiflu japan december gilead entitle additional milestone payment million roche achieve certain developmental regulatory milestone april gilead gsk enter licensing agreement provide gsk right commercialize hepsera gilead antiviral treatment chronic hepatitis asia latin america certain territory agreement gilead retain right hepsera canada eastern western europe australia new zealand gsk receive exclusive right develop hepsera solely treatment hepatitis territory significant include china korea japan taiwan addition gsk pay gilead upfront licensing fee million payment additional obligation pay million achievement gsk certain regulatory development commercial milestone million million receive approval hepsera september gsk pay gilead royalty net sale hepsera gsk territory gsk responsibility development commercialization hepsera gsk territory million upfront fee million approval fee record defer revenue total million recognize contract revenue balance defer revenue december amortize contract revenue period gilead remain obligation agreement approximately year december complete sale oncology asset osi date receive million cash million osi stock agreement entitle additional payment osi million cash combination cash osi stock osi reach certain development milestone advanced oncology product candidate sell osi relate manufacturing agreement produce liposomal product include sale manufacturing facility san dimas california recognize million contract revenue manufacturing agreement october enter agreement archemix corporation relate selex technology agreement give archemix exclusive right selex process include therapeutic commercial application extent license preexist agreement archemix pay million million require license agreement ulehi pay million million payment ulehi receive warrant purchase share archemix common stock value material require license agreement ulehi transfer warrant ulehi march enter agreement eyetech pharmaceuticals inc relate gilead proprietary aptamer eye currently know macugen currently early clinical trial macugen inhibitor vascular endothelial growth factor vegf know play role development certain ophthalmic disease term agreement eyetech receive worldwide right therapeutic use macugen product successfully commercialize eyetech pay royalty worldwide sale product eyetech responsible research development cost provide clinical supply product toeyetech march receive million upfront licensing fee eyetech april recognize revenue ratably oneyear supply agreement period accordingly million license fee record contract revenue million recognize revenue entitle additional cash payment eyetech million eyetech reach certain macugen development milestone additionally receive warrant purchase share eyetech series convertible prefer stock exercisable price share price stock issue investor gross margin product gross margin compare improvement primarily drive product mix viread high margin product contribute significantly net product sale modest sale viread record foreign exchange impact gross margin price product currency country product sell significant majority manufacturing cost dollar example increase value foreign currency relative dollar positively impact gross margin manufacturing cost remain approximately revenue translate dollar increase gross margin positively impact weaken dollar gross margin negatively impact factor discuss product sale section caption revenue potential impact unpredictable uncontrollable change exchange rate relative dollar mix product sale viread hepsera ambisome expect gross margin remain relatively stable compare operating expense expense total cost expense total expense million compare million million major component expense consist personnel cost include salary benefit clinical study perform contract research organization material supply overhead allocation consist support facility relate cost activity separate main category research clinical development pharmaceutical development research cost typically consist preclinical toxicology work clinical development cost include phase clinical trial expand access program pharmaceutical development cost consist product formulation chemical analysis follow table break major component research development spend thousand research clinical development pharmaceutical development oncology divest total million decrease spending compare primarily reduction expense associate clinical program viread approve october elimination expense associate oncology program result sale oncology program osi december additionally recognize expense million million upfront license fee pay cubist pharmaceutical relate european licensing agreement daptomycin know cidecin sign january termination agreement september million record represent remain unamortized asset relate preclinical oral formulation daptomycin exclude impact triangle acquisition expect expense approximately million million approximately high expense million increase spending versus attributable recognition million million upfront payment million clinical milestone payment cubist european licensing agreement cidecin addition expense associate clinical program viread hepsera increase approximately million million respectively year recent industry report indicate biopharmaceutical company generally take year average year research develop bring market new prescription medicine average generally consistent project develop internally recent product development timeline accelerate basis drug development process include step define fda process begin file ind successful allow opportunity clinical study potential new medicine clinical development typically involve phase study phase generally account average seven year drug total development time significant cost associate clinical development phase trial tend long large study conduct drug development process currently product development phase study successful development product highly uncertain estimation completion date expense vary significantly product difficult predict successful development fda approval product undertake additional study try expand product label market potential complete discussion risk uncertainty associate complete development product risk factor affect gilead section item sell general administrative sga expense million compare million million increase expense compare primarily global sale marketing effort include expansion gilead european sale force support commercial launch viread hepsera increase sga expense versus primarily gilead increase global marketing effort expansion sale force support commercial launch viread expect sga expense exclude impact triangle acquisition approximately million million high level primarily increase marketing activity associate continued promotion viread hepsera ambisome gain sale oncology asset december complete sale oncology asset pipeline clinical stage oncology product relate intellectual property boulder colorado operation include clinical research drug development personnel infrastructure facility osi pipeline clinical candidate include liposomal lurtotecan nucleoside analogue liposomal thymidylate synthase inhibitor closing date receive million cash osi common stock value approximately million record nonoperating gain million fourth quarter result transaction addition record income taxis million connection transaction loss sale marketable security july company sell remain share osi common stock approximately million share partial consideration sale oncology asset osi december time record fair market value approximately million connection sale remain share recognize nonoperate loss approximately million year end december gain sale unconsolidated affiliate august sell percent interest proligo llc proligo degussa corporation million cash proligo joint venture gilead skw americas inc focus manufacturing oligonucleotide skw americas subsidiary degussa corporation hold remain percent proligo proceed net gilead investment proligo reflect million gain sale unconsolidated affiliate interest income interest expense record interest income million compare million million decrease compare attributable significant decline interest rate partially offset high average cash balance positive cash flow operation proceed sale oncology asset osi increase high average balance invest fund interest income depend principally prevail interest rate control level cash cash equivalent marketable security balance incur interest expense million compare million million significantincrease year interest million convertible subordinate note interest expense consist primarily interest million convertible note convert common stock august expect interest expense increase compare expense level primarily issuance million convertible senior note december income taxis provision income taxis million million million respectively income tax expense primarily associate income earn foreign subsidiary significant net operating loss reduce tax liability significant increase income tax expense result principally gain sale oncology asset osi record approximately million federal state alternative minimum taxis provision reduce change income tax law law allow net operating loss carryforward deduction offset alternative minimum taxable income result reduction income tax record previous year million record valuation allowance reduce defer tax asset likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance determine able realize defer tax asset future adjustment defer tax asset increase income period determination likewise determine able realize defer tax asset future adjustment defer tax asset charge income period determination evaluate realizibility defer tax asset quarterly basis equity loss unconsolidated affiliate record million equity loss unconsolidated affiliate proligo prior date sale percent interest record million equity loss proligo represent percent share proligo loss thirteenmonth period end december fourth quarter proligo change fiscal yearend december november cumulative effect change accounting principle year end december gilead adopt sfas accounting derivative instrument hedging activity result cumulative effect change accounting principle million year end december gilead adopt securities exchange commission staff accounting bulletin revenue recognition financial statement result cumulative effect change accounting principle million note consolidated financial statement discussion liquidity capital resource fourth quarter misclassification discover december balance sheet cash flow statement year end december million osi stock receive consideration divestiture oncology asset misclassifie balance sheet cash cash equivalent instead marketable security misclassification impact statement operation period include revenue net income december consolidated balance sheet consolidate statement cash flow report change reflect correct classification cash cash equivalent marketable security total million december million december increase million primarily million net proceed receive issuance convertible senior note december major source use cash include net cash provide operation million proceed issuance stock employee stock plan million partially offset capital expenditure million million convertible note receive triangle million loan triangle return connection complete acquisition january approximately million pay complete acquisition triangle work capital december million compare million december significant change working capital include million increase account receivable million increase inventory account receivable increase primarily increase sale viread europe million increase inventory primarily increase production viread inventory meet increase sale demand significant change current liability include million increase accrue liability million decrease accrue clinical preclinical expense million increase accrue compensation million increase account payable million increase defer revenue million increase accrue liability primarily medicaid rebate obligation associate high sale viread million decrease accrue clinical preclinical expense primarily decrease activity associate clinical trial program viread hepsera million increase accrue compensation primarily increase bonus accrual theexpansion sale force million increase account payable primarily increase raw material purchase support viread sale growth million increase defer revenue primarily relate million receive collaboration gsk enter april million effect exchange rate change cash primarily weaken dollar relative euro translation foreign subsidiary account receivable balance primarily denominate euro currency capital expenditure million million million expenditure primarily facility improvement accommodate growth laboratory manufacturing equipment capital expenditure relate research development million spend million spend expect capital spending significantly high level increase infrastructure need high spending december issue million convertible senior note december private offering note currently convertible total share gilead common stock share conversion price high gilead common stock price note issuance date note redeemable option time june specify redemption price plus accrued interest debt issuance cost million incur connection issuance note record noncurrent asset amortize interest expense straightline basis contractual term note december issue million convertible subordinated note december private offering note currently convertible total share gilead common stock share conversion price high gilead common stock price note issuance date note redeemable option time december specify redemption price plus accrued interest debt issuance cost million incur connection issuance note record noncurrent asset amortize interest expense straight line basis contractual term note august redeem convertible subordinated debenture cash price principal debenture outstanding plus accrued interest redemption price provide original debenture indenture redemption entire million principal debenture outstanding time convert newly issue share gilead common stock august defer debt issuance cost million relate debenture charge additional pay capital connection conversion debenture common stock believe exist capital resource supplement cash generate operation adequate satisfy capital need foreseeable future future capital requirement depend factor include commercial performance viread hepsera ambisome commercial performance product development receive marketing approval include emtricitabine acquisition triangle complete january success partner research development commercialization effort product partner progress research development effort scope result preclinical study clinical trial cost timing outcome regulatory review rate technological advance determination commercial potential product development administrative expense status competitive product establishment manufacturing capacity thirdparty manufacturing arrangement expansion sale marketing capability possible geographic expansion establishment additional collaborative relationship company future require additional funding form proceed equity debt financing additional collaborative agreement corporate partner fund require assure available favorable term subsidiary establish variety subsidiary country purpose conduct business location subsidiary consolidate financial statement special purpose entity unconsolidate financial statement include define variable interest entity financial accounting standard board fasb interpretation consolidation variable interest entity involve nonexchange trade commodity contract account fair value commercial commitment relate party employee loan contractual obligation form capital operating lease note payable clinical research organization contract recent accounting pronouncement june fasb issue sfas accounting cost associate exit disposal activity sfas require liability cost associate exit disposal activity recognize measure initially fair value liability incur sfas effective exit disposal activity initiate december adoption sfas expect material impact financial position result operation november eitf reach consensus issue address account arrangement involve delivery performance multiple product service andor right use asset revenue arrangement multiple deliverable divide separate unit account deliverable arrangement meet follow criterion deliver item value customer standalone basis objective reliable evidence fair value undelivere item delivery undelivered item probable arrangement consideration allocate separate unit account base relative fair value allocate deliver item limit contingent delivery additional item meeting specify performance condition final consensus applicable agreement enter fiscal period begin june early adoption permit review provision consensus determine effect company financial position result operation november fasb issue interpretation fin guarantor accounting disclosure requirement guarantee include indirect guarantee indebtedness fin elaborate exist disclosure requirement guarantee include residual value guarantee issue conjunction operate lease agreement clarify time company issue guarantee company recognize initial liability fair value obligation assume guarantee disclose information interim annual financial statement initial recognition measurement provision apply prospective basis guarantee issue modify december disclosure requirement effective financial statement interim annual period end december adoption disclosure provision fin material impact result operation financial position december fasb issue sfas accounting stockbase compensationtransition disclosure sfas amendment sfas accounting stockbase compensation issue october sfas provide alternative method transition voluntary change fair value base method accounting stockbase compensation addition statement amend disclosure requirement statement require prominent disclosure annual interim financial statement method accounting stockbase employee compensation effect method report result additional disclosure requirement sfas effective fiscal year end december elect continue follow intrinsic value method accounting prescribe accounting principle board opinion apb accounting stock issue employee account employee stock option item quantitative qualitative disclosure market riskforeign currency exchange risk operation include manufacture sale activity sale activity europe australia result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change exchange rate dollar foreign currency significant euro british pound australian dollar dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business mitigate impact change currency exchange rate cash flow foreign currency sale transaction enter foreign exchange forward contract hedge foreign currencydenominate account receivable additionally mitigate impact currency rate fluctuation cash outflow certain foreign currencydenominate raw material purchase enter foreign exchange forward contract hedge foreign currencydenominate account payable significant percentage product sale denominate foreign currency increase value dollar foreign currency past reduce future reduce dollar return sale negatively impact financial condition prior hedge exposure impact fluctuate foreign exchange rate forecast sale effective january begin use forward contract hedge percentage forecast international sale primarily denominate euro currency follow table summarize notional amount average currency exchange rate fair value open foreign exchange forward contract december contract maturity year exception hedge contract intend hedge raw material purchase quarter notional million insignificant fair value december maturity month average rate state term foreign currency dollar fair value represent estimate settlement amount december notional amount fair value dollar thousand fair value currency notional average rate december british pound euro total notional million fair value million open foreign exchange forward contract december compare total notional million fair value million open foreign exchange forward contract december interest rate risk portfolio availableforsale investment security fixedrate liability create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base duration industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return follow table summarize expect maturity average interest rate interestbeare asset fixedrate liability december dollar thousand year end december fair value december total asset availableforsale security average interest rate liability longterm obligation include current portion average interest rate convertible senior debenture interest rate convertible subordinated debenture interest rate longterm obligation consist capital lease operating lease net noncancelable sublease debt secure property plant equipment interest portion payment include international credit risk account receivable balance december million compare million december growth primarily high product sale viread europe certain country payment typically slow primarily greece spain portugal italy account receivable balance significant case slow payment practice reflect pace governmental entity reimburse customer turn increase financial risk relate certain customer sale customer country tend relatively slow pay past increase future increase average length time account receivable outstanding december past account receivable greece spain portugal italy total approximately million approximately million day past december past receivables country million approximately million day past date experience significant loss respect collection account receivable believe account receivable balance reflect consolidated balance sheet include customer country collectible continually seek improve collection process ensure fully collect amount base product sale collection timely item financial statement supplementary datum financial statement require item set forth begin report incorporate reference item change disagreement accountant account financial disclosure applicable iii item director executive officer registrant information require item concern director executive officer incorporate reference section definitive proxy statement file sec pursuant regulation connection annual meeting proxy statementunder heading nominee executive officer compliance section security exchange act item executive compensation information require item incorporate reference section proxy statement heading executive compensation compensation committee report item security ownership certain beneficial owner management information require item incorporate reference section proxy statement head security ownership certain beneficial owner management item certain relationship relate transaction information require item incorporate reference section proxy statement heading compensation committee interlock insider participation certain transaction executive compensation item control procedure day prior date report carry evaluation supervision participation principal executive officer principal financial officer effectiveness design operation disclosure control procedure base evaluation principal executive officer principal financial officer conclude disclosure control procedure effective timely alert material information require include periodic report security exchange commission note design system control base certain assumption likelihood future event certain design succeed achieve state goal potential future condition regardless remote significant change internal control factor significantly affect control subsequent date evaluation item exhibit financial statement schedule report form follow document file index list financial statement report ernst young llp independent auditor report independent accountant audit consolidated financial statement consolidate balance sheet consolidate statement operation consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement schedule include report schedule omit require require information include financial statement note thereto exhibit follow exhibit file herewith incorporate referenceexhibit exhibit footnote number description document asset purchase agreement registrant osi pharmaceuticals inc date november agreement plan merger registrant simbolo acquisition sub inc whollyowne subsidiary registrant triangle pharmaceutical inc date december amend restate certificate incorporation registrant amend bylaw registrant amend restate march reference exhibit exhibit amend restate right agreement date october registrant chasemellon shareholder services llc agreement plan merger date february registrant gazelle acquisition sub inc nexstar pharmaceuticals inc indenture date december registrant chase manhattan bank trust company national association include form note indenture date december registrant morgan trust company national association include form note registration right agreement date december registrant goldman sachs form indemnity agreement enter registrant director executive officer form employee proprietary information invention agreement enter registrant certain officer key employee registrant incentive stock option plan relate agreement registrant supplemental stock option plan relate agreement registrant employee stock purchase plan amend march registrant stock option plan amend restate april amend january amend january form nonqualified stock option issue certain executive officer director vintage park research development net lease registrant vintage park associate date march premise locate lakeside drive foster city california relate addendum exhibit amendment letter agreement date september registrant iocbrega exhibit certain confidential information omit vintage park research development net lease registrant vintage park associate date september premise locate lakeside drive foster city california related exhibit amendment agreement date october registrant iocbrega relate license agreement exhibit certain confidential information omit amendment agreement date december registrant iocbrega loan agreement date october registrant mark perry melanie pea registrant nonemployee director stock option plan amend january amend january vintage park research development lease registrant wcb sixteen limited partnership date june premise locate lakeside drive foster city california amendment vintage park research development lease registrant wcb seventeen limit partnership date june premise locate lakeside drive foster city california amendment vintage park research development lease registrant wcb seventeen limit partnership date june premise locate lakeside drive foster city california license supply agreement registrant pharmacia upjohn date august certain confidential information omit development license agreement registrant hoffmannla roche ltd hoffmannla roche inc date september certain confidential information omit amendment vintage park research development lease registrant spieker property date august premise locate lakeside drive foster city california nexstar pharmaceuticals inc incentive stock plan adopt february amend nexstar pharmaceuticals inc director option plan adopt july vestar inc stock option plan lease date march vestar inc majestic realty patrician associates inc amendment thereto amendment thereto date june amendment date january majestic realty patrician associates inc registrant lease date march vestar inc majestic realty patrician associates inc assignment royalty agreement date december effective june vestar inc city hope national medical center license agreement effective august vestar inc regents university california agreement fujisawa usa inc vestar inc date august amendment thereto date amendment agreement fujisawa usa inc vestar inc date april fujisawa usa inc vestar inc certain confidential information omit amendment agreement fujisawa usa inc registrant date march agreement fujisawa usa inc vestar inc date august lease date april vestar inc majestic realty patrician associates inc amendment lease date april majestic realty patrician associates inc vestar inc amend lease date april majestic realty patrician associates inc vestar inc license distribution agreement date september sumitomo pharmaceutical ltd nexstar pharmaceuticals inc certain confidential information omit settlement agreement date august nexstar pharmaceuticals inc fujisawa usa inc liposome company inc certain confidential information omit amendment date april sumitomo pharmaceutical ltd nexstar pharmaceuticals inc license distribution agreement date september sumitomo nexstar pharmaceuticals inc corporate plan retirement select planbasic plan document corporate plan retirement select planadoption agreement addendum gilead sciences inc defer compensation plan licensing agreement date april gilead world market limited glaxo group limited employment agreement date july gilead sciences inc sharon surreybarbari triangle pharmaceuticals inc stock incentive plan option agreement triangle pharmaceuticals inc daniel welch date august license agreement triangle pharmaceuticals inc emory university university georgia research foundation inc compound amdoxovir dapd date march license agreement triangle pharmaceuticals inc emory university coviracil ftc date april license agreement triangle pharmaceuticals inc bukwang pharm ind ltd date february exclusive license agreement triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university date settlement agreement triangle pharmaceuticals inc emory university david barry glaxo wellcome plc glaxo wellcome inc glaxo group limited wellcome foundation limited date amendment license agreement triangle pharmaceuticals inc bukwang pharm ind ltd date april amendment license agreement triangle pharmaceuticals inc emory university date amendment license agreement triangle pharmaceuticals inc emory university university georgia research foundation inc date july second amendment license agreement triangle pharmaceuticals inc emory university date july amendment license agreement triangle pharmaceuticals inc bukwang pharm ind ltd date september amendment license agreement triangle pharmaceuticals inc bukwang pharm ltd date august supply manufacturing agreement triangle pharmaceuticals inc abbott laboratories date july settlement exclusive license agreement triangle pharmaceuticals inc shire biochem inc shire pharmaceuticals group plc emory university university georgia research foundation date august second amendment license agreement triangle pharmaceuticals inc emory university university georgia research foundation inc date august sublease triangle pharmaceuticals inc eli lilly company date january sublease amendment triangle pharmaceuticals inc eli lilly company date march second amendment sublease triangle pharmaceuticals inc eli lilly company date august amendment sublease triangle pharmaceuticals inc eli lilly company date february manufacture supply agreement gilead world markets ltd ppgsipsy sas enter january subsidiary registrant consent ernst young llp independent auditor consent pricewaterhousecooper llp independent auditor power attorney reference signature certification file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form quarter end december incorporate reference file exhibit nexstar pharmaceuticals inc quarterly report form quarter end june incorporate reference file exhibit registrant current report form file october incorporate reference file exhibit registrant registration statement form amend incorporate reference file exhibit registrant quarterly report form quarter end september incorporate reference file exhibit registrant annual report fiscal year end march incorporate reference file exhibit registrant quarterly report form quarter end june incorporate reference file exhibit registrant quarterly report form quarter end september incorporate reference file exhibit registrant current report form file march incorporate reference file exhibit nexstar pharmaceuticals inc fiscal year end december incorporate reference file exhibit nexstar pharmaceuticals inc fiscal year end december incorporate reference file exhibit nexstar pharmaceuticals inc form quarterly period end september incorporate reference file exhibit nexstar pharmaceuticals inc fiscal year end december incorporate reference file march exhibit nexstar pharmaceuticals inc registration statement form file incorporate reference file exhibit nexstar pharmaceuticals inc form quarterly period end september incorporate reference file exhibit nexstar pharmaceuticals inc form quarter end june incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant registration statement form amend incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant current report form file january incorporate reference file exhibit registrant quarterly report form quarter end june incorporate reference file exhibit registrant quarterly report form quarter end september incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant current report form file december incorporate reference file exhibit registrant registration statement form file january incorporate reference file exhibit registrant registration statement form file january incorporate reference file exhibit triangle pharmaceuticals inc registration statement form amend incorporate reference file exhibit triangle pharmaceuticals inc fiscal year end december incorporate reference file exhibit triangle pharmaceuticals inc quarterly report form quarter end september incorporate reference file exhibit triangle pharmaceuticals inc quarterly report form quarter end september incorporate reference file exhibit triangle pharmaceuticals inc current report form file september incorporate reference file exhibit triangle pharmaceuticals inc quarterly report form quarter end september incorporate reference file exhibit triangle pharmaceuticals inc fiscal year end december incorporate reference certain confidential portion exhibit omit mean mark portion asterisk mark exhibit file separately secretary sec mark pursuant registrant application request confidential treatment rule securities exchange act report form registrant file report form december tender offer purchase outstanding common share triangle pharmaceuticals inc price share registrant file report form december december sale million convertible note million overallotment exercise rule offer qualified institutional buyer gilead sciences inc consolidated financial statement year end december content report ernst young llp independent auditor report independent accountant audit consolidated financial statement consolidate balance sheet consolidate statement operation consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement report ernst young llp independent auditor board director stockholder gilead sciences inc audit accompany consolidated balance sheet gilead sciences inc december relate consolidated statement operation stockholder equity cash flow year period end december audits include financial statement schedule list item annual report financial statement schedule responsibility management gilead sciences inc responsibility express opinion financial statement schedule base audits audit financial statement proligo llc limited liability company investment reflect accompany consolidated financial statement equity method accounting company equity net loss proligo llc financial statement proligo llc audit auditor report furnish opinion insofar relate amount include proligo llc base solely report auditor conduct audits accordance auditing standard generally accept united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits report auditor provide reasonable basis opinion opinion base audits report auditor consolidated financial statement refer present fairly material respect consolidate financial position gilead sciences inc december consolidate result operation cash flow year period end december conformity accounting principle generally accept united states opinion financial statement schedule refer consider relation basic financial statement take present fairly material respect information set forth discuss note consolidated financial statement effective january company change method accounting derivative instrument hedge activity effective january change method accounting non refundable upfront fee receive connection collaboration agreement ernst young llp palo alto california january report independent accountant board director member proligo llc opinion accompany consolidated balance sheet relate consolidated statement operation member equity cash flow present fairly material respect financial position proligo llc subsidiary december november result operation cash flow thirteenmonth end december year end november period august november respectively conformity accounting principle generally accept united states america financial statements responsibility company management responsibility express opinion financial statement base audit conduct audits statement accordance auditing standard generally accept united states america require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion pricewaterhousecooper llp broomfield colorado january gilead sciences inc consolidated balance sheet thousand share amount december asset current asset cash cash equivalent marketable security accounts receivable net allowance doubtful account december december note receivable triangle pharmaceutical inc inventory prepaid expense total current asset property plant equipment net noncurrent asset liabilitie stockholder equity current liability account payable accrue clinical preclinical expense accrue compensation employee benefit accrue liability defer revenue longterm obligation year total current liability longterm defer revenue accrue litigation settlement expense year longterm obligation year convertible senior debt convertible subordinated debt commitment contingency accompany note stockholder equity prefer stock par value share issuable series share authorize outstanding common stock par value share share authorize share issue outstanding december december respectively additional paidin capital accumulate comprehensive income accumulate deficit total stockholder equity accompany note gilead sciences inc consolidated statement operation thousand share amount year end december revenue product sale royalty revenue contract revenue total revenue cost expense cost good sell research development sell general administrative total cost expense income loss operation gain sale oncology asset gain sale unconsolidated affiliate loss sale marketable security interest income net interest expense income loss provision income taxis equity loss unconsolidated affiliate cumulative effect change accounting principle provision income taxis equity loss unconsolidated affiliate income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amount common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharebasic share share calculationbasic amount common sharedilute income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharedilute share share calculationdilute accompany note gilead sciences inc consolidated statement stockholder equity thousand common stock accumulate additional pay comprehensive defer total stockholder share capital income loss compensation accumulate deficit equity balance december net loss unrealize gain availablefor sale security net foreign currency translation adjustment comprehensive loss employee stock purchase plan option exercise net warrant exercise net conversion convertible subordinated debenture amortization defer compensation compensatory stock transaction balance december net income unrealize gain availablefor sale security net foreign currency translation adjustment unrealize gain cash flow hedge net comprehensive income employee stock purchase plan option exercise net tax benefit employee stock plan amortization defer compensation compensatory stock transaction balance december net income unrealize loss availablefor sale security net foreign currency translation adjustment unrealize gain cash flow hedge net comprehensive income employee stock purchase plan option exercise net tax benefit employee stock plan compensatory stock transaction balance december accompany note gilead sciences inc consolidated statement cash flow thousands year end december operating activity net income loss adjustment reconcile net income loss net cash provide operating activity depreciation amortization net effect change accounting principle gain sale oncology asset gain sale unconsolidated affiliate loss sale marketable security equity loss unconsolidated affiliate net movement provision doubtful account tax benefit employee stock plan net unrealized gain loss foreign currency transaction noncash transaction change operate asset liability account receivable inventory prepaid expense asset longterm prepay royalty account payable accrue liability defer revenue net cash provide operating activity invest activity purchase marketable security sale marketable security maturity marketable security capital expenditure issuance note triangle pharmaceuticals inc proceed sale oncology asset proceed sale unconsolidated affiliate investment unconsolidated affiliate net cash provide investing activity financing activity proceed issuance common stock repayment longterm obligation proceed issuance convertible senior note net issuance cost proceed issuance convertible subordinate note net issuance cost net cash provide financing activity effect exchange rate change cash net increase decrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year supplemental disclosure cash flow information interest pay income taxis pay noncash investing financing activity osi common stock receive sale oncology asset common stock issue conversion debenture reclassification defer debt issuance cost additional paidin capital conversion subordinate debenture accompany note gilead sciences inc note consolidated financial statement december organization summary significant accounting policy overview gilead company incorporate delaware june biopharmaceutical company focus discovery development commercialization antiviral antibacterial antifungal treat lifethreatene infectious disease multinational company revenue approve product operation country currently market viread treatment hiv infection hepsera treatment chronic hepatitis infection ambisome antifungal agent daunoxome drug approve treatment kaposi sarcoma vistide treatment cmv retinitis roche market tamiflu treatment influenza collaborative agreement seek add exist portfolio product clinical development program internal discovery program active product acquisition inlicense strategy acquisition oftriangle pharmaceuticals inc complete january internal discovery activity include identification new molecular target target screen medicinal chemistry addition currently develop product treat hiv infection expertise liposomal drug delivery technology use develop drug safe easy patient tolerate effective accompany consolidated financial statement include account gilead wholly majorityowne subsidiary significant intercompany transaction eliminate certain prior period amount include certain cash cash equivalent marketable security reclassify consistent current presentation stock split february march gilead complete twoforone stock split effect form stock dividend stockholder record february february respectively accordingly share share amount period present reflect split change accounting principle gilead adopt statement financial accounting standard sfas nos collectively refer sfas accounting derivative instrument hedge activity quarter change account change accounting principle note effective quarter gilead adopt sec staff accounting bulletin sab revenue recognition financial statement change account change accounting principle note critical accounting policy estimate preparation financial statement require estimate judgment affect report amount asset liability revenue expense relate disclosure asset liability ongoing basis management evaluate estimate include related revenue recognition bad debt inventory accrue clinical preclinical expense contingency base estimate historical experience market specific assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate revenue recognition recognize revenue product sale persuasive evidence arrangement exist delivery occur price fix determinable collectibility reasonably assure provide customer general right product return accept return product expire deem damage defective deliver provision estimate product return cash discount government discount rebate base contractual term expectation utilization rate program contract revenue research development record earn base performance requirement contract nonrefundable contract fee performance obligation exist continue involvement gilead recognize early payment receive collection assure revenue nonrefundable upfront license fee milestone payment continue involvement development collaboration obligation supply product recognize manufacturing obligation fulfil ratably development period period manufacturing obligation appropriate revenue associate substantive performance milestone recognize base achievement milestone define respective agreement revenue research development cost reimbursement contract recognize related cost incur advance payment receive excess amount earn classified defer revenue royalty revenue sale ambisome recognize month follow correspond sale occur royalty revenue sale vistide tamiflu recognize receive quarter follow quarter correspond sale occur shipping handling costsshippe handle cost incur inventory purchase product shipment record cost good sell consolidated statement operation research development expense major component expense consist personnel cost include salary benefit clinical study perform contract research organization material supply overhead allocation consist administrative facility relate cost research development activity separate main category research clinical development pharmaceutical development research cost typically consist preclinical toxicology work clinical development cost include phase clinical trial expand access program pharmaceutical development cost consist product formulation chemical analysis record accrual estimate clinical preclinical study cost cost significant component expense management accrue cost clinical study perform contract research organization base estimate typically work upfront cost remain activity generally incur straightline basis life individual contract study estimate match actual service perform organization determine patient enrollment level relate activity monitor patient enrollment level relate activity extent possible adjust estimate line actual activity incur ongoing basis advertising expense expense cost advertising include promotional expense incur advertising expense million million million stockbase compensation accordance provision sfas accounting stockbase compensation company elect continue follow accounting principle board opinion apb accounting stock issue employee interpretation fin account certain transaction involve stock compensationan interpretation apb opinion accounting employee stock option plan apb exercise price gilead employee director stock option equal exceed fair value underlie stock date grant compensation expense recognize note pro forma disclosure stockbase compensation pursuant sfas amend sfas accounting stockbase compensationtransition disclosure table present combine net income loss basic diluted net income loss common share compensation cost gilead nexstar stock option plan espp determine base estimate fair value award plan grant purchase date thousand share amount year end december net income lossa report deduct total stockbase employee compensation expense determine fair value base method award net relate tax effect pro forma net income loss thousand earning loss share basica report basicpro forma diluteda report dilutedpro forma fair value award grant stock option plan espp estimate grant purchase date blackschole option pricing model multiple option approach follow assumptionsyear end december expect life year vest date stock option espp discount rate stock option espp volatility expect dividend yield weight average estimate fair value espp share purchase share computation basic net income common share compute base weighted average number common share outstanding period dilute net income common share include effect approximately million stock option include effect million convertible note convert approximately million share million convertible note convert approximately million share effect assume conversion antidilutive diluted net income common share include effect approximately million stock option warrant include effect million convertible note convert approximately million share effect assume conversion antidilutive basic diluted loss common share compute base weighted average number common share outstanding period potential common share convertible note stock option warrant convertible debenture previously outstanding exclude computation dilute loss share effect antidilutive cash cash equivalent consider highly liquid investment insignificant interest rate risk remain maturity month purchase date cash equivalent enter overnight repurchase agreement purchase security obligation resell follow day security purchase agreement resell record face value report cash cash equivalent investment policy enter repurchase agreement repos major bank authorize dealer provide repos collateralize government security fair value fair value security sell gilead fourth quarter misclassification discover previously report december balance sheet cash flow statement december million osi stock receive consideration divestiture oncology asset misclassifie balance sheet cash cash equivalent instead marketable security december consolidated balance sheet consolidate statement cash flow report change reflect correct classification marketable security management determine appropriate classification marketable security consist solely debt security time purchase reevaluate designation balance sheet date marketable security classify availableforsale carry estimate fair value report cash equivalent marketable security december cash cash equivalent include million security designate availableforsale million december unrealize gain loss availableforsale security exclude earning report separate component stockholder equity interest income include interest dividend amortization purchase premium discount realize gain loss sale security cost security sell base specific identification method regularly review investment otherthantemporary decline fair value determine decline fair value investment accounting basis otherthantemporary reduce carry value security hold record loss decline reduction require past year concentration credit risk gilead subject credit risk portfolio cash equivalent marketable security policy limit amount invest security duration industry group investment type issuer security issue government gilead expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flowrequirement competitive aftertax rate return gilead subject credit risk account receivable relate product sale significant trade account receivable arise sale ambisome viread primarily sale european subsidiary export sale distributor europe certain country payment typically slow primarily greece spain portugal italy account receivable balance significant case slow payment practice reflect pace governmental entity reimburse customer turn increase financial risk relate certain customer sale customer country tend relatively slow pay past increase future increase average length time account receivable outstanding december past account receivable greece spain portugal italy total approximately million approximately million day past december past receivables country million approximately million day past date experience significant loss respect collection account receivable believe past account receivable reflect consolidated balance sheet include customer country collectible perform credit evaluation customer financial condition generally require collateral material utilize operation facility example depend single supplier high quality amphotericin daunorubicin hcl distearoylphosphatidylcholine high quality cholesterol manufacture liposomal product supply supplier interrupt reason unable ship viread ambisome hepsera vistide daunoxome supply product development clinical trial december million note receivable triangle pharmaceuticals inc incur conjunction acquisition complete january note include cash cash equivalent marketable security subsequently eliminate consolidation result closing acquisition january inventory inventory record low cost market cost determine firstin firstout basis management periodically review composition inventory order identify obsolete slowmoving unsaleable item item observe alternate use inventory record writedown net realizable value period unit identify impair historically inventory writedown insignificant consistent management expectation property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straightline method estimate useful life follow description estimate useful life year build leasehold improvement laboratory manufacturing equipment office computer equipment office computer equipment include capitalize computer software capitalize software purchase internally develop computer software leasehold improvement capitalize lease equipment amortize short lease term item useful life capitalize interest construction progress include property plant equipment noncurrent asset noncurrent asset december include million respectively prepay royalty pay institute organic chemistry biochemistry academy sciences czech republic rega stichte iocbrega discuss iocbrega caption note include noncurrent asset december net defer debt issuance cost million million respectively relate million convertible seniornote issue december million subordinate convertible note gilead issue december longlive asset carry value longlive asset review regular basis existence fact circumstance internally externally suggest impairment specific potential indicator impairment include significant decrease fair value asset significant change extent manner asset significant physical change asset significant adverse change legal factor business climate affect value asset adverse action assessment food drug administration regulator accumulation cost significantly excess originally expect acquire construct asset operate cash flow loss combine history operate cash flow loss projection forecast demonstrate continue loss associate incomeproduce asset indication impairment confirm compare estimate future cash flow expect result use asset eventual disposition carry asset estimate future cash flow asset group low level identifiable cash flow largely independent cash flow generate asset group sum expect future cash flow undiscounte interest change carrying asset impairment loss measure excess carrying value asset fair value recognize cash flow estimate calculation base management good estimate appropriate customary assumption projection time foreign currency translation transaction contract adjustment result translate financial statement foreign subsidiary dollar exclude determination net income accumulate separate component stockholder equity net foreign exchange transaction gain loss report sell general administrative expense consolidated statement operation realize gain loss million million million hedge certain foreign currency exposure related outstanding trade account receivable firmly commit purchase transaction forecast product sale foreign exchange forward contract general contract expose market risk gain loss contract offset gain loss transaction hedge exposure credit risk contract function change interest currency exchange rate vary time gilead limit risk counterpartie contract unable perform transact major bank limit risk loss enter contract provide net settlement maturity overall risk loss event counterparty default limit unrecognize unrealized gain outstanding contract contract positive fair value date default enter speculative foreign currency transaction write option presently hedge net investment foreign subsidiary accounting hedge account receivable record change fair value sell general administrative expense derivative instrument designate hedge fas selectively hedge anticipate currency exposure purchase forward contract hedge firmly commit purchase transaction anticipate product sale designate cash flow hedge sfas unrealized gain loss underlie forward contract record comprehensive income recognize earning forecast transaction occur december december net unrealized loss open foreign exchange forward contract million million respectively loss revenue hedge reduce product revenue million notional amount forward exchange contract outstanding million december million december contract maturity year exception hedge contract intend hedge raw material purchase quarter notional million insignificant fair value december maturity month note discussion derivative financial instrument adoption sfas fair value financial instrument company financial instrument consist principally cash cash equivalent marketable security accounts receivable certain noncurrent asset forward foreign exchange contract account payable longterm obligation convertible note cash cash equivalent marketable security forward foreign exchange contract hedge account receivable report respective fair value balance sheet forward foreign exchange contract hedge firmly commit purchase record fair value net relate deferred gain loss result report net balance zero fair value convertible senior note december million carrying value december million fair value convertible subordinate note december million fair value december million carrying value end period million fair value december december convertible note determine obtain quote market maker note management believe remain financial instrument report balance sheet amount approximate current fair value recent accounting pronouncement june fasb issue sfas accounting cost associate exit disposal activity sfas require liability cost associate exit disposal activity recognize measure initially fair value liability incur sfas effective exit disposal activity initiate december adoption sfas expect material impact financial position result operation november eitf reach consensus issue address account arrangement involve delivery performance multiple product service andor right use asset revenue arrangement multiple deliverable divide separate unit account deliverable arrangement meet follow criterion deliver item value customer standalone basis objective reliable evidence fair value undelivere item delivery undelivered item probable arrangement consideration allocate separate unit account base relative fair value allocate deliver item limit contingent delivery additional item meeting specify performance condition final consensus applicable agreement enter fiscal period begin june early adoption permit review provision consensus determine effect company financial position result operation november fasb issue interpretation fin guarantor accounting disclosure requirement guarantee include indirect guarantee indebtedness fin elaborate exist disclosure requirement guarantee include residual value guarantee issue conjunction operate lease agreement clarify time company issue guarantee company recognize initial liability fair value obligation assume guarantee disclose information interim annual financial statement initial recognition measurement provision apply prospective basis guarantee issue modify december disclosure requirement effective financial statement interim annual period end december adoption disclosure provision fin material impact result operation financial position december fasb issue sfas accounting stockbase compensationtransition disclosure sfas amendment sfas accounting stockbase compensation issue october sfas provide alternative method transition voluntary change fair value base method accounting stockbase compensation addition statement amend disclosure requirement statement require prominent disclosure annual interim financial statement method accounting stockbase employee compensation effect method report result additional disclosure requirement fas effective fiscal year end december elect continue follow intrinsic value method accounting prescribe accounting principle board opinion apb accounting stock issue employee account employee stock option cumulative effect change accounting principle december securities exchange commission issue staff accounting bulletin sab revenue recognition financial statement thing sab describe sec staff position recognition certain nonrefundable upfront fee receive connection collaboration agreement previously recognize nonrefundable technology access fee receive connection collaboration agreement revenue receive collectibility probable technology transfer effective january gilead change method accounting fee recognize related manufacturing obligation fulfil straightline basis term relate research development collaboration manufacturing supplyarrangement appropriate method good match effort provide management believe change accounting principle preferable base guidance provide sab cumulative effect change accounting principle record fourth quarter retroactively effective january defer revenue recognize contract revenue remain term research development manufacturing supply arrangement appropriate year end december net impact change accounting principle increase net loss million share loss consist million cumulative effect change january net million relate defer revenue recognize contract revenue year additional million contract revenue recognize remainder million relate deferred revenue balance december expect recognize revenue derivative financial instrument january gilead adopt sfas standard require gilead recognize derivative asset liability measure fair value company enter foreign currency forward contract hedge change fair value monetary asset liability denominate nonfunctional currency derivative designate meet definition fair value hedge change fair value derivative hedge item attributable hedge risk recognize earning company enter foreign currency forward contract generally maturitie month hedge future cash flow related purchase transaction forecast product sale foreign denominate currency derivative instrument employ eliminate minimize certain foreign currency exposure confidently identify quantify accordance sfas hedge relate anticipate foreign currency purchase raw material forecast product sale designate document inception respective hedge designate cash flow hedge evaluate effectiveness quarterly term forward contract underlie transaction match inception forward contract effectiveness calculate compare fair value contract change forward value underlie hedged item adoption sfas record fair value million relate forward contract previously reflect balance sheet recognize cumulative transition adjustment comprehensive income million effective component hedge substantially value report comprehensive income december reclassify earning month residual change fair value instrument ineffectiveness recognize immediately sell general administrative expense ineffectiveness significant gilead hold warrant purchase stock nonpublic company warrant net exercise feature sfas classify derivative instrument adoption gilead record fair value warrant million offset adjustment cumulative change accounting principle million loss hedge contract recognize income statement million increase fair value derivative recognize comprehensive income december fair value derivative include comprehensive income material sale oncology asset december gilead complete sale oncology asset pipeline clinical candidate oncology relate intellectual property boulder colorado operation include clinical research drug development operation infrastructure facility osi clinical development candidate sell osi liposomal lurtotecan nucleoside analogue liposomal thymidylate synthase inhibitor consideration gilead receive million cash share osi common stock value approximately million december number share issue gilead determine divide million average closing sale price osi common stock day precede december entitle additional payment osi million cash combination cash osi common stock osi reach certain development milestone advanced oncology product candidate sell osi milestone payment receive osi recognize contract revenue receipt base december net book value oncology asset sell million transaction cost million million relate acceleration approximately option purchase gilead common stock realize pretax gain million fourth quarter carry value transfer asset relate primarily certain property equipment osi assume gilead oncologyrelate clinical preclinical obligation lease obligation relate manufacturing agreement produce osi liposomal formulation liposomal product sell osi manufacturing facility san dimas sale marketable security july gilead sell remain share osi common stock approximately million share partialconsideration sale oncology asset osi december time record fair market value approximately million connection sale remain share recognize nonoperate loss approximately million reflect result year end december availableforsale security follow summary availableforsale security estimate fair value availableforsale security base price obtain commercial pricing service thousand gross gross amortize unrealize unrealized estimate cost gain loss fair value december treasury security obligation government agency corporate debt security assetbacke security debt security total december treasury security obligation government agency certificate deposit corporate debt security corporate equity security assetbacke security debt security total debt security consist primarily money market fund maintain marketable security nominal value record noncurrent asset december security net unrealize loss approximately million follow table present certain information relate sale availableforsale security thousand year end december proceed sale gross realize gain sale gross realize loss sale december million portfolio marketable security exclude million assetbacked security contractual maturity year million portfolio contractual maturity great year year estimate maturity assetbacked security exceed year note receivable december arrangement contemplate propose acquisition triangle gilead million loan extend triangle work capital corporate purpose triangle issue gilead unsecured convertible promissorynote completion triangle acquisition january loan eliminate consolidated result result closing acquisition january note balance sheet detail thousand december inventory raw material work process finish good total property plant equipment net building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment capitalize lease equipment construction progress accumulate depreciation amortization total accrue liability accrue medicaid rebate accrue sale marketing expense liability total collaborative arrangement contract glaxosmithkline april gilead gsk enter licensing agreement provide gsk right commercialize hepsera gilead antiviral treatment chronic hepatitis asia latin america certain territory agreement gilead retain right hepsera united states canada eastern western europe australia new zealand gsk receive exclusive right develop hepsera solely treatment hepatitis territory significant include china korea japan taiwan addition gsk pay upfront licensing fee million entitle receive additional cash payment million achievement gsk certain regulatory development commercial milestone million million receive approval hepsera september gsk pay gilead royalty net sale hepsera gsk territory gsk responsibility development commercialization hepsera gsk territory million upfront fee million approval fee record defer revenue total million recognize contract revenue balance defer revenue december amortize contract revenue period gilead remain obligation agreement approximately yearsin december gilead enter agreement glaxo wellcome gsk give gilead right novel anti tumor compound gilead develop liposome evaluate preclinical study agreement gilead exclusive worldwide right develop commercialize indication malaria gilead pay gsk upfront fee include expense december compound assign osi sale oncology asset gilead enter threepart collaboration gsk gsk receive nonexclusive right use gilead proprietary selex process target validation gilead receive exclusive right subject gsk right elect participate activity develop commercialize liposomal formulation gsk proprietary topoisomerase inhibitor lurtotecan gsk acquire share gilead common stock million private offering december collaboration license agreement modify revise term agreement gsk waive right participate development commercialization right receive royalty give gilead exclusive right compound december compound assign osi sale oncology asset cubist pharmaceutical september gilead cubist pharmaceutical jointly announce termination licensing agreement commercialization cidecin daptomycin injection oral formulation daptomycin agreement execute january grant gilead exclusive commercialization right product european country follow regulatory approval term termination agreement gilead owe future payment cubist cubist reacquire european right product termination million record research development expense represent remain unamortized asset relate preclinical oral formulation daptomycin archemix october enter agreement archemix corporation relate selex technology agreement archemix obtain exclusive right selex process include therapeutic commercial application extent license preexist agreement archemix pay million million require license agreement university license equity holdings inc ulehi pay million million payment ulehi recognize million million revenue respectively receive warrant purchase share archemix common stock value material require license agreement ulehi transfer warrant ulehi additional payment archemix agreement eyetech march gilead enter agreement eyetech pharmaceuticals inc relate proprietary aptamer eye know macugen currently early clinical trial macugen inhibitor vascular endothelial growth factor vegf know play role development certain ophthalmic disease term agreement eyetech receive worldwide right therapeutic use macugen product successfully commercialize eyetech pay royalty worldwide sale product eyetech responsible research development cost provide clinical supply product eyetech march receive million upfront licensing fee eyetech april recognize revenue ratably oneyear supply agreement period accordingly million license fee record contract revenue agreement remainder license fee recognize revenue entitle additional cash payment eyetech million eyetech reach certain macugen development milestone additionally receive warrant purchase share eyetech series convertible prefer stock exercisable price share price stock issue investor note description account treatment warrant fujisawa right market ambisome subject agreement gilead fujisawa healthcare inc successor fujisawa usa inc fujisawa term fujisawa agreement amend fujisawa gilead copromote ambisome fujisawa sole marketing right ambisome canada exclusive marketing right ambisome rest world provide pay royalty fujisawa connection sale significant asian market include japan connection sales fujisawa purchase ambisome gilead cost sale canada fujisawa purchase ambisome cost plus specify percentage fujisawa collect payment sale ambisome canada receive fujisawa gross profit sale ambisome gross profit include deduction cost good sell give current effective royalty rate approximately fujisawa net sale ambisome connection agreement fujisawa record royalty revenue million million million sumitomo september gilead sumitomo enter agreement pursuant sumitomo agree develop market ambisome japan term agreement sumitomo pay initial million licensing fee withholding taxis million october million milestone payment withholding taxis million march sumitomo require additional payment certain clinical commercial milestone meet pay royalty japanese ambisome sale agreement gilead obligate provide certain quantity ambisome sumitomo charge ambisome approve marketing japan subsequent cumulative effect change accounting principle record effective quarter result adoption sab gilead recognize initial license fee remain free supply arrangement period net impact change accounting principle sumitomo license increase net loss million cumulative effect change accounting principle charge million contract revenue million relate initial licensing fee sumitomo recognize contract revenue million recognize contract revenue remain million recognize contract revenue roche september gilead enter collaboration agreement roche develop commercialize therapy treat prevent viral influenza roche agreement roche agreement roche receive exclusive worldwide right gilead proprietary influenza neuraminidase inhibitor prior roche license fee developmental milestone payment total million gilead recognize million contract revenue milestone payment roche relate tamiflu milestone achieve year milestone include file regulatory approval japan treatment influenza japanese approval application file regulatory approval prevention influenza receipt approval recognize million milestone payment filing application market tamiflu prophylaxis european union recognize million milestone payment european approval tamiflu treatment prophylaxis december gilead entitle additional cash payment roche million roche achieve additional developmental regulatory milestone addition roche require pay gilead royalty net product sale gilead begin receive royalty roche sale tamiflu quarter record total million tamiflu royalty million royalty million royalty recognize royalty revenue roche quarter follow quarter relate tamiflu sale occur roche agreement roche reimburse relate cost program funding cost quarterly generally advance base annual budget reimbursement include contract revenue incur relate cost amount incur excess amount fund reimburse subject roche approval event revenue recognize approval obtain conversely amount fund roche exceed relate cost require repay excess funding roche record contract revenue reimbursement relate roche agreement approximately million previous year end cost relate roche agreement approximate reimbursement revenue include expense pharmacia august gilead pharmacia corporation pharmacia enter license supply agreement pharmacia agreement market vistide country outside term pharmacia agreement pharmacia pay gilead initial license fee million subsequent cumulative effect change accounting principle record effective quarter gilead recognize initial license fee straightline basis supply arrangement period sixteen year agreement date net impact change accounting principle pharmacia agreement increase net loss million cumulative effect change accounting principle relate initial license fee pharmacia million charge result operation additional contract revenue million recognize subsequent accounting change remain million relate deferred revenue expect recognize straightline basis contract revenue remain supply period term pharmacia agreement relate agreement cover expand access program vistide outside usgilead responsible maintain cidofovir patent portfolio supply pharmacia bulk cidofovir manufacture finish vistide product gilead entitle receive royalty base pharmacia sale vistide gilead receive portion royalty ship bulk drug substance vistide pharmacia remainder pharmacia sale vistide party royalty gilead receive product sell party record defer revenue thirdparty sale occur december record balance sheet approximately million defer revenue million december recognize royalty revenue sale vistide outside united states pharmacia million million million somalogic november gilead somalogic inc somalogic enter agreement gilead assign somalogic sole exclusive license certain intellectual property relate selex process diagnostic purpose include patent patent application term agreement somalogic require pay gilead total million nonrefundable installment million pay november include contract revenue year end december remain million report defer revenue december receive record contract revenue gilead ongoing research funding obligation agreement iocbrega gilead enter agreement institute organic chemistry biochemistry academy sciences czech republic rega stichte iocbrega relate certain nucleotide compound discover institution agreement gilead receive exclusive right manufacture use sell nucleotide compound gilead obligate pay iocbrega percentage net revenue receive sale product contain compound subject minimum royalty payment product cover agreement include vistide hepsera viread exclude tamiflu gilead currently make quarterly payment iocbrega base percentage vistide hepsera viread sale december agreement iocbrega amend provide reduce royalty rate future sale hepsera viread return upfront payment gilead million signing agreement payment record longterm prepay royalty classified noncurrent asset balance sheet december recognize royalty expense expect commercial life viread hepsera amortization million payment begin product launch date viread hepsera total million december southern research institute december gilead enter agreement southern research institute give gilead worldwide right develop commercialize antitumor compound gilead evaluate preclinical study term agreement gilead pay southern research institute upfront fee include research development expense december compound assign osi sale oncology asset investment sale unconsolidated affiliate july establish proligo llc delaware limited liability company proligo wholly own subsidiary transfer asset nexstar technology product division proligo proligo supply nucleic acid peptide synthesis product pharmaceutical biopharmaceutical industry sale use laboratory research reagent therapeutic diagnostic product august sell interest interest proligo skw americas inc skw payment interest receive million cash interest perseptive biosystem gmbh company hamburg germany hamburg company specialize manufacture nucleoside phosphoramidite monomer interest hamburg company fair market value approximately million record million gain connection sale january october gilead additional cash investment proligo total million maintain ownership interest proligo gilead commitment provide additional funding proligo january account investment proligo equity method accounting recognize million equity proligo net loss represent share proligo loss thirteenmonth period end december fourthquarter proligo change fiscal year end december november gilead sell interest proligo degussa corporation million cash proceed net gilead investment proligo reflect million gain sale unconsolidated affiliate prior date sale gilead record million equity loss proligo longterm obligation longterm obligation consist follow thousand december capital lease obligation monthly installment interest rate range fix rate debt monthly installment secure equipment interest rate range total longterm obligation current portion longterm obligation year maturitie longterm obligation include capital lease obligation follow thousand year end december represent interest total term debt agreement require comply certain financial operating covenant december compliance covenant convertible note december gilead issue million convertible senior note december private offer goldman sachs resold note qualified institutional investor note convertible total share gilead common stock share conversion price high gilead common stock price note issuance date note redeemable option gilead time june specify redemption price plus accrued interest debt issuance cost million incur connection issuance note record noncurrent asset amortize interest expense straightline basis contractual term note december gilead issue million convertible subordinated note december private offering morgan lehman brothers morgan stanley dean witter resold note private institutional investor note convertible total share gilead common stock share conversion price high gilead common stock price note issuance date note redeemable option gilead time december specify redemption price plus accrued interest debt issuance cost million incur connection issuance note record noncurrent asset amortize interest expense straightline basis overthe contractual term note commitment contingency lease arrangement enter longterm noncancelable operating lease equipment facility facility lease foster city san dimas california expire date lease year renewal option exception lease foster city expire contain renewal option operate lease sale marketing administrative facility europe australia term equipment lease include corporate airplane initial term year annual renewal option year lease expense net sublease income operating lease total approximately million million million addition assume facility lease durham north carolina connection acquisition triangle january lease approximately square foot administrative office laboratory space sublease approximately square foot party lease expire september currently negotiation lessor extend lease term aggregate noncancelable future minimum rental payment operate capital lease net aggregate future minimum rental receive noncancelable sublease follow thousand operating lease net noncancelable sublease year end december exclude triangle lease capital lease represent interest total capital lease obligation current portion capital lease obligation year december place million bank escrow deposit include noncurrent asset secure aggregate future payment facility lease contingent liability gilead sublease certain facility primarily california sublessee default obligation sublease primarily liable original lessor total future amount lease december million legal proceeding reach settlement elan corporation plc elan successor company liposome company company agree dismiss legal proceeding involve ambisome gilead liposomal formulation amphotericin term initial settlement agreement initial payment elan million agree additional royalty payment base ambisome sale record million accounting charge accrue litigation settlementexpense represent estimate net present value future minimum payment require june elan gilead enter agreement terminate remain ambisome payment obligation initial settlement agreement exchange payment elan million excess million settlement remain accrue litigation settlement expense balance million amortize remain life patent approximately year november ulehi notify ulehi believe gilead materially breach licensing agreement ulehi concern selex technology identify aptamer thing assign right agreement ulehi consent contest ulehi allegation meet ulehi allegation actively engage negotiation settle disagreement negotiation prove unsuccessful ulehi choose terminate ulehigilead agreement arbitration concern termination likely result unfavorable outcome arbitration rise award monetary damage adverse remedy possibly include conveyance ulehi gilead right obligation ulehi licensing agreement sublicense party legal action arise ordinary course business believe legal action material adverse impact business result operation financial position stockholder equity prefer stock gilead share authorize preferred stock issuable series board directors board authorize determine designation power preference right series reserve share prefer stock potential issuance preferred share purchase right plan prefer stock outstanding december employee stock purchase plan gilead employee stock purchase plan espp employee purchase share gilead common stock base percentage compensation purchase price share equal low percent market value date offer date purchase total share common stock reserve issuance espp december share total share reserve issue espp share december stock option plan december gilead adopt incentive stock option plan supplemental stock option plan issuance common stock employee consultant scientific advisor april board approve grant certain additional nonqualified stock option term condition substantially similar grant supplemental stock option plan option issue plan describe exercise price fair value underlie stock date grant option vest year pursuant formula determine board expire year share available grant future option plan november gilead adopt stock option plan plan issuance common stock employee consultant option issue plan shall discretion board incentive stock option nonqualifie stock option plan amend exercise price stock option equal fair value gilead common stock date grant option vest year pursuant formula determine board expire year plan amend restate april extend term plan stockholder approve amendment plan increase total number authorize share plan december share available grant future option plan november gilead adopt nonemployee director stock option plan director plan issuance common stock nonemployee directors pursuant predetermine formula exercise price option grant director plan equal fair value gilead common stock date grant option vest year date grant quarterly percent installment expire year stockholder approve amendment director plan increase total number authorize share plan december share available forgrant future option director plan stock plan assume gilead merger nexstar include stock option plan plan incentive stock plan director option plan collectively nexstar plan option pursuant plan incentive stock plan issue outstanding july convert option purchase gilead common stock result merger remain subject original term condition share available grant future option nexstar plan nexstar plan allow certain option holder execute cashless exercise option cashless exercise transaction option holder specify share exercise gilead issue specify number share number require cover exercise price base fair value stock exercise date option holder perform cashless exercise result option award consider variable recognize nominal compensation expense million million july option outstanding category follow table summarize activity gilead nexstar stock option plan year period end december option grant present table exercise price fair value underlie stock grant date share thousand year end december weight weight weight average average average exercise exercise exercise share price share price share price outstanding beginning year grant forfeit exercise outstanding end year exercisable end year weight average fair value option grant follow summary gilead option outstanding option exercisable december option thousand option outstanding weighted option exercisable average weighted remain average weighted option contractual exercise option average range exercise price outstanding life year price exercisable exercise price total company reserve aggregate share common stock future issuance equity compensation plan december pro forma disclosure elect follow accounting principle board opinion apb account employee stock option apb compensation expense recognize exercise price employee stock option equal market price underlie stock date grant information net income loss earning loss share prepare accordance fas determined account employee stock option employee stock purchase plan fair value method prescribe fas earning loss share method fas result effect net income loss earning loss share pursuant fas likely representative effect net income loss earning loss share pursuant fas future year subsequent year include additional grant year vest table present combine net income loss basic diluted net income loss common share compensation cost gilead nexstar stock option plan espp determine base estimate fair value award plan grant purchase date thousand share amount year end december net income lossa report deduct total stockbase employee compensation expense determine fair value base method award net relate tax effect pro forma net income loss earning loss share basica report basicpro forma diluteda report dilutedpro forma fair value award grant stock option plan espp estimate grant purchase date blackschole option pricing model multiple option approach follow assumption year end december expect life year vest date stock option espp discount rate stock option espp volatility expect dividend yield weight average estimate fair value espp share purchase preferred share purchase right plan november adopt preferred share purchase right plan plan provide distribution prefer stock purchase right dividend share gilead common stock purchase right currently exercisable certain condition involve acquisition propose acquisition person group common stock purchase right permit holder holder purchase gilead common stock discount market price time payment aspecifie exercise price purchase right addition event certain business combination purchase right permit purchase common stock acquirer discount market price time certain condition purchase right redeemed board price purchase right purchase right voting privilege attach automatically trade gilead common stock october board director approve amendment purchase right plan amendment provide thing increase exercise price right plan extension term plan november october acceleration stock option december complete sale oncology asset osi transaction accelerate approximately option purchase gilead common stock value million note discussion comprehensive income loss follow reclassification adjustment require avoid doublecounte net realize gain loss sale security previously include comprehensive income prior sale security thousand year end december net gain loss sale security comprehensive income net unrealize gain loss arise year reclassification adjustment net unrealized gain loss report comprehensive income loss balance accumulate comprehensive income report balance sheet consist follow component thousand december net unrealized gain availableforsale security net unrealize gain cash flow hedge net foreign currency translation loss accumulate comprehensive income disclosure segment enterprise related information gilead determine reportable segment management organize business functional line product sale consist follow thousands year end december viread ambisome follow table summarize revenue external customer collaborative partner geographic region revenue attribute country base location customer collaborative partner thousand year end december united states united kingdom france spain germany italy switzerland european country country consolidate total revenue december net book value property plant equipment million approximately asset locate december net book value property plant equipment million approximately asset locate product sale distributor account approximately total revenue product sale distributor exceed total revenue product sale distributor account approximately total revenue total revenues fujisawa include product sale royalty approximately total revenue revenue roche include royalty milestone payment reimbursement research development expense exceed total revenue account approximately total revenue income taxis gilead defer provision income taxis current provision income taxis consist follow thousands year end december current provision federal state foreign foreign pretax loss million million million difference provision taxis income compute apply federal statutory income tax rate income provision income taxis equity loss unconsolidated affiliate cumulative effect change accounting principle explain thousands year end december income loss provision income taxis equity loss unconsolidated affiliate cumulative effect change accounting principle tax federal statutory rate benefit unbenefitted loss federal alternative minimum taxis december federal net operating loss carryforward million state net operating loss carryforward million federal net operating loss carryforward expire date begin utilize state net operating loss carryforward expire date utilize addition federal state tax credit carryforward approximately million million respectively expire year utilization net operating loss credit subject annual limitation ownership change limitation provide internal revenue code similar state provision annual limitation result expiration net operating loss credit utilization significant increase income tax expense result principally gain sale oncology asset osi record approximately million federal state alternative minimum taxis provision reduce change income tax law law allow net operating loss carryforward deduction offset alternative minimum taxable income result reduction income tax record previous year million defer income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component defer tax asset liability december follow thousand december net operating loss carryforward research credit capitalize research development expense reserve accrual currently deductible net total defer tax asset valuation allowance net defer tax asset recognize valuation allowance increase million year end december decrease million year end december approximately million valuation allowance december relate tax benefit stock option deduction credit additional paidin capital realize retirement saving planas december gilead maintain retirement saving plan eligible employee defer compensation income tax purpose section internal revenue code prior january gilead maintain separate retirement saving plan plan primarily cover nexstar employee nexstar plan plan primarily cover gilead remain eligible employee gilead plan nexstar plan employee contribution exceed eligible annual compensation addition nexstar plan include company match employee contribution maximum contribution annual maximum company match december approximately million represent share gilead common stock hold nexstar plan trust plan participant effective january nexstar plan terminate combined gilead plan share gilead common stock hold nexstar plan subsequently liquidate proceed deposit investment option available gilead plan gilead plan employee contribute eligible annual compensation effective january gilead begin make match contribution gilead plan contribute employee contribution annual maximum match total matching contribution gilead plan million million combine million plan relate party transaction december chairman gilead board director senior advisor investment fund own control interest pharmaresearch corporation contract research organization perform service connection clinical study gilead payment pharmaresearch corporation million december arrangement contemplate propose acquisition triangle pharmaceuticals inc gilead million loan extend triangle work capital corporate purpose triangle issue gilead unsecured convertible promissory note completion triangle acquisition january loan eliminate consolidated result result closing acquisition january note subsequent event january complete acquisition outstanding stock triangle development stage company triangle active development antiviral drug candidate aggregate preliminary purchase price million include cash pay outstanding stock fair value option assume estimate direct transaction cost employee termination cost intend account transaction quarter expect record substantial portion aggregate purchase price inprocess research development expense quarterly result unaudite follow table thousand share amount quarter quarter quarter quarter total revenue total cost expense net income loss net income loss common sharebasic net income loss common sharedilute quarter quarter quarter quarter total revenue total cost expense income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amount common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharebasic amount common sharedilute income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharedilute year end december gilead adopt sfas report cumulative effect change accounting principle quarter dilute net income common share fourth quarter include effect stock option million convertible subordinate note december complete sale oncology asset osi record nonoperating gain million fourth quarter result transaction gilead sciences inc schedule valuation qualifying account addition balance balance begin charge charge end period expense deduction period year end december allowance doubtful account allowance sale return valuation allowance defer tax asset year end december allowance doubtful account allowance sale return valuation allowance defer tax asset year end december allowance doubtful account allowance sale return valuation allowance defer tax asset charge current tax expense charge defer tax benefit signature pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize gilead sciences inc john martin john martin president chief executive officer power attorney know person present person signature appear constitute appoint john martin mark perry true lawful attorneysinfact agent power substitution resubstitution place stead capacity sign amendment report file exhibit thereto document connection therewith securities exchange commission grant unto say attorneysinfact agent power authority perform act thing requisite necessary connection therewith fully intent purpose person ratify confirming say attorneysinfact agent substitute substitute lawfully cause virtue hereof pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate signature title date john martin president chief executive officer director march principal executive officer john martin john milligan senior vice president chief financial officer march principal financial accounting officer john milligan james denny chairman board director march james denny paul berg director march paul berg etienne davignon director march etienne davignon cordell hull director march cordell hull gordon mooredirector march gordon moore george shultz director march george shultz gayle wilson director march gayle wilson certification john martin certify review annual report gilead sciences inc base knowledge annual report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover annual report base knowledge financial statement financial information include annual report fairly present material respect financial condition result operation cash flow registrant period present annual report registrant certify officer responsible establish maintain disclosure control procedure define exchange act rule registrant design disclosure control procedure ensure material information relate registrant include consolidated subsidiary known entity particularly period annual report prepare evaluate effectiveness registrant disclosure control procedure date day prior filing date annual report evaluation date present annual report conclusion effectiveness disclosure control procedure base evaluation evaluation date registrant certify officer disclose base recent evaluation registrant auditor audit committee registrant board director person perform equivalent function significant deficiency design operation internal control adversely affect registrant ability record process summarize report financial datum identify registrant auditor material weakness internal control fraud material involve management employee significant role registrant internal control registrant certify officer indicate annual report significant change internal control factor significantly affect internal control subsequent date recent evaluation include corrective action regard significant deficiency material weaknessesdate march john martin john martin president chief executive officer certification john milligan certify review annual report gilead sciences inc base knowledge annual report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover annual report base knowledge financial statement financial information include annual report fairly present material respect financial condition result operation cash flow registrant period present annual report registrant certify officer responsible establish maintain disclosure control procedure define exchange act rule registrant design disclosure control procedure ensure material information relate registrant include consolidated subsidiary known entity particularly period annual report prepare evaluate effectiveness registrant disclosure control procedure date day prior filing date annual report evaluation date present annual report conclusion effectiveness disclosure control procedure base evaluation evaluation date registrant certify officer disclose base recent evaluation registrant auditor audit committee registrant board director person perform equivalent function significant deficiency design operation internal control adversely affect registrant ability record process summarize report financial datum identify registrant auditor material weakness internal control fraud material involve management employee significant role registrant internal control registrant certify officer indicate quarterly report significant change internal control factor significantly affect internal control subsequent date recent evaluation include corrective action regard significant deficiency material weaknesse date march john milligan john milligan senior vice president chief financial officer quicklink gilead sciences inc annual report table contentspart item business risk factor affect gilead risk relate triangle acquisition january item property item legal proceeding item submission matter vote security holder item market registrant common stock relate stockholder matter equity compensation plan information item select financial datum gilead sciences inc select consolidated financial datum thousand share datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure iii item director executive officer registrant item executive compensation item security ownership certain beneficial owner management item certain relationship relate transaction item control procedure gilead sciences inc consolidated financial statement year end december content report ernst young llp independent auditor report independent accountant gilead sciences inc consolidated balance sheet thousand share amount gilead sciences inc consolidated statement operation thousand share amount gilead sciences inc consolidated statement stockholder equity thousand gilead sciences inc consolidated statement cash flow thousand gilead sciences inc note consolidated financial statement december gilead sciences inc schedule valuation qualifying account signature certification exhibit gilead sciences inc issuer morgan trust company national association trusteeindenture date december convertible senior note december crossreference table trust indenture act section indenture section alast sentence crossreference table indenturetable content article definition provision general application section definition section compliance certificate opinion section form document deliver trustee section act holder security section notice etc trustee company section notice holder security waiver section effect heading table content section successor assign section separability clause section benefit indenture section govern law section legal holiday section conflict trust indenture act article security form section form generally section form security section form certificate authentication section form conversion notice section form assignment article iii security section title term section denomination section execution authentication delivery date section global securities nonglobal security bookentry provision section registration registration transfer exchange restriction transfer section mutilate destroy lose steal security section payment interest interest right preserve section person deem owner section cancellation section computation interest section cusip number itable content continue article satisfaction discharge section satisfaction discharge indenture section application trust money article remedy section event default section acceleration maturity rescission annulment section collection indebtedness suit enforcement trustee section trustee file proof claim section trustee enforce claim possession security section application money collect section limitation suit section unconditional right holder receive principal premium interest convert section restoration right remedy section right remedy cumulative section delay omission waiver section control holder security section waiver past default section undertaking cost section waiver stay usury extension law article trustee section certain duty responsibility section notice default section certain right trustee section responsible recital issuance security section hold security act trustee indenture section money hold trust section compensation reimbursement section corporate trustee require eligibility section resignation removal appointment successor section acceptance appointment successor iitable content continue section merger conversion consolidation succession business section authenticate agent section disqualification conflict interest section preferential collection claim company article vii consolidation merger conveyance transfer lease section company consolidate etc certain term section successor substitute article viii supplemental indenture section supplemental indenture consent holder security section supplemental indenture consent holder security section execution supplemental indentures section effect supplemental indenture section reference security supplemental indentures section notice supplemental indenture article meeting holder security section purpose meeting call section notice place meeting section person entitle vote meeting section quorum action section determination voting right conduct adjournment meeting section count vote record action meeting article covenant section payment principal premium interest section maintenance office agency section money security payment hold trust section existence iiitable content continue section intentionally leave blank section payment taxis claim section registration listing section statement officer default section delivery certain information section resale certain security section registration right section waiver certain covenant article redemption security section right redemption section applicability article section election redeem notice trustee section selection trustee security redeem section notice redemption section deposit redemption price section security payable redemption date section conversion arrangement redemption article xii conversion security section conversion privilege conversion rate section exercise conversion privilege section fraction share section adjustment conversion rate section notice adjustment conversion rate section notice certain corporate action section company reserve common stock section taxis conversion section covenant common stock section cancellation convert security section provision case consolidation merger sale asset section right issue respect common stock section responsibility trustee conversion provision ivtable content continue article xiii repurchase security option holder change control section right require repurchase section condition companys election pay repurchase price common stock section notice method exercise repurchase right etc section certain definition section consolidation merger etc article xiv holder list report trustee company nonrecourse section company furnish trustee name address holder section preservation information section report trustee section report company article immunity incorporator stockholder officer director section indenture security solely corporate obligation vindenture date december gilead sciences inc corporation duly organize exist law state delaware principal office lakeside drive foster city california call company morgan trust company national association national banking association trustee hereunder call trustee recital company company duly authorize creation issue convertible senior note december call security substantially tenor hereinafter set forth provide therefor company duly authorize execution delivery indenture thing necessary security security execute company authenticate deliver hereunder valid obligation company indenture valid agreement company accordance term thing necessary duly authorize issuance common stock company issuable conversion security duly reserve issuance number share common stock issuable conversion indenture witnesseth consideration premise purchase security holder thereof mutually covenant agree equal proportionate benefit holder security follow article definition provision general application section definition purpose indenture expressly provide context require term define article meaning assign article include plural singular accounting term define meaning assign accordance generally accept accounting principle unite states expressly provide term generally accept accounting principle respect computation require permit hereunder shall mean accounting principle generally accept date computation word hereof hereunder word similar import refer indenture particular article section subdivisionact respect holder security meaning specify section affiliate specify person mean person directly indirectly control control direct indirect common control specify person purpose definition control respect specify person mean power direct management policy person directly indirectly ownership vote security contract term control control meaning correlative forego agent member mean member participant depositary applicable procedure mean respect transfer transaction involve global security beneficial interest rule procedure dtc successor depository case extent applicable transaction effect time time authenticate agent mean person authorize pursuant section act behalf trustee authenticate security board director mean board director company duly authorize committee board board resolution mean resolution duly adopt board director copy certify secretary assistant secretary company duly adopt board director force effect date certification shall deliver trustee business day respect place payment place conversion place case mean monday tuesday wednesday thursday friday day banking institution place payment place conversion place case authorize obligate law executive order close change control meaning specify section closing price share mean respect common stock day report sale price regular way nasdaq national market common stock quote nasdaq national market report sale price regular way share case report sale take place day average report closing bid ask price regular way case principal national securities exchange common stock list admit trading iii common stock quote nasdaq national market list admit trade national securities exchange average closing bid ask price overthecounter market furnish new york stock exchange member firm select time time company purpose code meaning specify section commission mean united states securities exchange commission time time constitute create exchange act time execution indenture commission exist perform duty assign trust indenture act body perform duty time common stock mean common stock par value share company authorize date indenture originally execute stock constitute time time include change par value security subject provision section share issuable conversion security shall include share common stock share class class common stock result reclassification reclassification thereof provide time shall result class share issuable conversion security shall include share class share class issuable shall substantially proportion total number share class result reclassification bear total number share class result reclassification provide reference common stock payable connection purchase security change control accordance term section shall deem include common stock entity include parent company entity consolidate merge merge sell transfer substantially asset common stock include stock class capital stock preference respect dividend amount payable event voluntary involuntary liquidation dissolution wind issuer thereof unrestricted voting right subject redemption issuer thereof company mean person name company paragraph indenture successor person shall pursuant applicable provision indenture company shall mean successor person company notice mean specify section company request company order mean write request order sign company officer company deliver trustee constituent person mean specify section conversion agent mean person authorize company convert security accordance article xii company initially appoint trustee conversion agent pursuant section hereof conversion price meaning specify section conversion rate mean specify section corporate trust office mean office trustee particular time trust create indenture shall principally administer date indenture locate mission street floor san francisco california attention institutional trust service corporation mean corporation company association jointstock company business trust default interest mean specify section depositary mean respect security include global security clearing agency registered exchange act designate company act depositary security successor securities clearing agency register dollar mean dollar equivalent unit coin currency united states time shall legal tender payment public private debt dtc mean depository trust company new york corporation effective failure mean specify section effectiveness period mean specify section event default mean specify section exchange act mean united states securities exchange act successor statute amend time time global security mean security register security register depositary nominee thereof holder mean person security register security register indenture mean indenture originally execute time time supplement amend indenture supplemental hereto enter pursuant applicable provision hereof include purpose indenture supplemental indenture provision trust indenture act deem govern indenture supplemental indenture respectively initial purchaser mean goldman sach initial purchaser option mean specify section interest payment date mean state maturity installment interest security issue date mean december liquidate damage mean specify section makewhole payment meaning specify section maturity respect security mean date principal security payable provide state maturity declaration acceleration redemption exercise repurchase right set forth article xiii nonelecting share mean specify section notice date mean specify section notice default mean specify section officer mean chairman cochairman board directors vice chairman board director chief executive officer chief operating officer president executive vice president vice president chief financial officer company officer certificate mean certificate sign officer company deliver trustee opinion counsel mean write opinion counsel counsel company general counsel company shall reasonably acceptable trustee outstanding respect security mean date determination security theretofore authenticate deliver indenture security theretofore cancel trustee deliver trustee cancellation security money necessary pay redeem security theretofore deposit trustee pay agent company trust set aside segregate trust company company shall act pay agent holder security provide security redeem notice redemption duly give pursuant indenture provision therefor reasonably satisfactory trustee iii security pay pursuant section exchange lieu security authenticate deliver pursuant indenture security respect shall present trustee proof satisfactory security hold bona fide purchaser hand security valid obligation company security convert common stock pursuant article xii provide determine holder requisite principal outstanding security present meeting holder security quorum purpose give request demand authorization direction notice consent waiver hereunder security own company obligor security affiliate company obligor shall disregard deem outstanding determine trustee shall protect rely determination presence quorum request demand authorization direction notice consent waiver security responsible officer trustee notify writing own shall disregard security own pledge good faith regard outstanding pledgee company obligor security affiliate company obligor trustee shall protect rely officer certificate effect pay agent mean person authorize company pay principal interest security behalf company specifically set forth term shall include company shall act pay agent company initially appoint trustee pay agent pursuant section hereof person mean individual corporation limited liability company partnership joint venture trust estate unincorporated organization government agency political subdivision thereof place conversion meaning specify section place payment meaning specify section predecessor security particular security mean previous security evidencing portion debt evidence particular security purpose definition security authenticate deliver section exchange lieu mutilate destroy lose steal security shall deem evidence debt mutilate destroy lose steal security provisional redemption mean specify section purchase agreement mean purchase agreement date december company initial purchaser agreement amend time time qualified institutional buyer shall mean qualified institutional buyer define rule record date mean regular record date special record date record date period mean period close business regular record date precede interest payment date opening business interest payment date redemption date respect security redeem mean date fix redemption pursuant indenture redemption price respect security redeem mean price redeem pursuant indenture registrable security mean specify section registration default mean specify section registration right agreement mean registration right agreement date december company initial purchaser agreement amend time time accordance term regular record date interest payable respect security interest payment date mean june december business day case precede interest payment date repurchase date mean specify section repurchase price meaning specify section responsible officer respect trustee mean officer corporate trust office trustee direct responsibility administration indenture mean respect particular corporate trust matter officer matter refer knowledge familiarity particular subject restrict global security meaning specify section restrict security mean security require pursuant section bear restrict security legend term includes restrict global security restrict security legend mean collectively legend substantially form legend require form security set forth section place restrict security rule mean rule securities act successor provision amend time time rule mean rule securities act successor provision amend time time rule information mean specify section security mean ascribe paragraph caption recital company security act mean united states securities act successor statute amend time time security register security registrar respective meaning specify section shelf registration statement mean specify section significant subsidiary mean respect person subsidiary person constitute significant subsidiary term define rule regulation securities act exchange act special record date payment default interest mean date fix company pursuant section state maturity respect security installment interest thereon mean date specify security fix date principal security installment interest payable subsidiary mean corporation outstanding voting stock own directly indirectly company subsidiary company subsidiary purpose definition vote stock mean stock similar interest corporation ordinarily vote power election director person perform similar function time long senior class stock interest voting power reason contingency successor security particular security mean security issue evidencing portion debt evidence particular security purpose definition security authenticate deliver section exchange lieu mutilate destroy lose steal security shall deem evidence debt mutilate destroy lose steal security surrender certificate mean certificate substantially form set forth annex trading day mean common stock quote nasdaq national market system automate dissemination quotation security price day trade effect system common stock list admit trade national regional security exchange day national regional securities exchange open business iii common stock list national regional security exchange quote nasdaq national market system automate dissemination quotation security price day common stock trade regular way overthecounter market closing bid closing ask price common stock available trust indenture act mean trust indenture act rule regulation thereunder force date indenture execute provide event trust indenture act amend date trust indenture act mean extent require amendment trust indenture act rule regulation thereunder amend trustee mean person name trustee paragraph indenture successor trustee shall pursuant applicable provision indenture trustee shall mean successor trustee united states mean united states america include states district columbia territory possession area subject jurisdiction possession include puerto rico virgin islands guam american samoa wake island northern mariana islands unrestricted security certificate mean certificate substantially form set forth annex section compliance certificate opinion application request company trustee action provision indenture company shall furnish trustee officer certificate state condition precedent provide indenture relate propose action comply opinion counsel state opinion counsel condition precedent comply case application request furnish document specifically require provision indenture relate particular application request additional certificate opinion need furnish certificate opinion respect compliance condition covenant provide indenture include certificate provide section shall include statement individual signing certificate opinion read covenant condition definition relate thereto brief statement nature scope examination investigation statement opinion contain certificate opinion base statement opinion individual examination investigation necessary enable express informed opinion covenant condition comply statement opinion individual condition covenant comply section form document deliver trustee case matter require certify cover opinion specify person necessary matter certify cover opinion person certify cover document person certify opinion respect matter person matter person certify opinion matter document certificate opinion officer company base insofar relate legal matter certificate opinion representation counsel officer know exercise reasonable care know certificate opinion representation respect matter certificate opinion base erroneous certificate opinion counsel base insofar relate factual matter certificate opinion representation officer officer company person state information respect factual matter possession company person counsel know exercise reasonable care know certificate opinion representation respect matter erroneous person require execute application request consent certificate statement opinion instrument indenture need consolidated form instrument section act holder security request demand authorization direction notice consent waiver action provide permit indenture give take holder security embody evidence instrument substantially similar tenor sign holder person agent proxy duly appoint write holder record holder security voting favor thereof person proxy duly appoint write meeting holder security duly call held accordance provision article action shall effective instrument instrument record deliver trustee expressly require company trustee shall promptly deliver company copy instrument record deliver trustee instrument instrument record action embody evidence refer act holder security sign instrument instrument voting meet proof execution instrument write appoint agent proxy hold person security shall sufficient purpose indenture subject section conclusive favor trustee company manner provide section record meeting holder security shall prove manner provide section fact date execution person instrument writing prove affidavit witness execution certificate notary public officer authorize law acknowledgment deed certify individual signing instrument writing acknowledge execution thereof execution signer acting capacity individual capacity certificate affidavit shall constitute sufficient proof authority principal serial number security hold person date holding shall prove security register fact date execution instrument writing authority person execute prove manner trustee deem sufficient trustee instance require proof respect matter refer section company set day record date purpose determine holder entitle request demand authorization direction notice consent waiver action vote action authorize permit indenture give take holder promptly case later day set record date company shall notify trustee holder record date set company prior solicitation holder person respect action case vote prior vote record date action vote shall day later date recent list holder require provide pursuant section prior solicitation vote case regard record date holder date duly appoint agent proxy person shall entitle vote relevant action holder remain holder record date notwithstanding forego company shall set record date provision paragraph shall apply respect notice declaration direction refer paragraph receipt trustee holder notice default breach refer section default breach occur continue trustee shall give notice company declaration acceleration refer section event default occur continue trustee shall give declaration company iii direction refer section trustee shall take action specify direction respect clause iii record date shall automatically action company trustee set determine holder entitle join declaration direction record date shall close business tenth day day business day business day follow day trustee receive declaration direction respect clause trustee set day record date purpose determine holder entitle join notice default promptly receipt trustee declaration direction refer clause iii promptly set record date respect clause soon practicable trustee shall notify company holder record date fix holder record date duly appoint agent proxy person shall entitle join notice declaration direction holder remain holder record date provide notice declaration direction shall effective virtue holder requisite principal security record date duly appoint agent proxy join prior day record date notice declaration direction shall automatically action person cancel effect paragraph shall construe prevent holder duly appoint agent proxy thereof give expiration day period notice declaration direction contrary different expiration period identical notice declaration direction record date relate event new record date respect thereof shall set pursuant paragraph addition paragraph shall construe render ineffective notice declaration direction type refer paragraph give time trustee company holder duly appoint agent proxy requisite principal security date notice declaration direction give provide section request demand authorization direction notice consent election waiver act holder security shall bind future holder security holder security issue registration transfer thereof exchange therefor lieu thereof respect omit suffer trustee company reliance thereon notation action security provision section subject provision section section notice etc trustee company request demand authorization direction notice consent election waiver act holder security document provide permit indenture give furnish file trustee holder security company shall sufficient purpose hereunder give furnish file write responsible officer trustee receive corporate trust office attention institutional trust service company trustee holder security shall sufficient purpose hereunder expressly provide write mail firstclass postage prepay telecopie confirm mail firstclass postage prepay deliver hand overnight courier address company lakeside drive foster city california attention chief financial officer address previously furnish write trustee company section notice holder security waiver expressly provide indenture provide notice holder security event notice shall sufficiently give holder write mail firstclass postage prepay deliver overnight delivery service holder security affect event address holder appear security register early early date later late date prescribe give notice failure mail notice defect notice mail particular holder security shall affect sufficiency notice respect holder security case reason suspension regular mail service reason cause shall impracticable notice mail notification holder security shall approval trustee approval shall unreasonably withhold shall constitute sufficient notification holder purpose hereunder notice shall deemed give day mail mail day mail overnight courier date notice furnish telecopy hand indenture provide notice manner notice waive write person entitle receive notice event waiver shall equivalent notice waiver notice holder security shall file trustee filing shall condition precedent validity action take reliance waiver section effect heading table content article section heading table content convenience shall affect construction hereof section successor assign covenant agreement indenture company shall bind successor assign express section separability clause case provision indenture security shall invalid illegal unenforceable validity legality enforceability remain provision shall way affect impair section benefit indenture indenture security express imply shall person party hereto successor assign hereunder holder security benefit legal equitable right remedy claim indenture section govern law indenture security shall govern construe accordance law state new york united states america section legal holiday case interest payment date redemption date repurchase date state maturity security day holder security right convert security shall business day place payment place conversion case notwithstanding provision indenture security payment principal premium interest payment redemption price repurchase price payable cash share common stock combination thereof case repurchase price respect delivery conversion security need place payment place conversion case day succeed business day place payment place conversion case force effect interest payment date redemption date repurchase date state maturity day conversion provide case payment succeed business day interest shall accrue payable period interest payment date redemption date repurchase date state maturity day conversion case section conflict trust indenture act provision hereof limit qualify conflict provision trust indenture act require act govern indenture provision shall control provision indenture modifie exclude provision trust indenture act modify exclude provision shall deem apply indenture modify exclude case time indenture shall qualified trust indenture act indenture company trustee shall deem purpose hereof subject govern trust indenture act extent case indenture qualified date hereof article security form section form generally security shall substantially form set forth article appropriate insertion omission substitution variation require permit indenture letter number mark identification legend endorsement place thereon require comply rule securities exchange internal revenue code amend regulation thereunder code consistent herewith determined officer execute security evidence execution thereof security shall fully register form trustee certificate authentication shall substantially form set forth section conversion notice shall substantially form set forth section repurchase notice shall substantially form set forth section security shall print lithograph typewrite engrave produce combination method produce manner permit rule automate quotation system security exchange include steel engrave border require security exchange security list security quote list case determined officer execute security evidence execution thereof original issuance security issue contemplated purchase agreement qualified institutional buyer reliance rule shall issue form global security definitive fully register form interest coupon bear restricted security legend global security shall register dtc depositary nominee deposit trustee custodian dtc credit dtc respective account beneficial owner security represent account direct global security successor security global security collectively call restrict global security section form security form face follow legend shall appear face restrict security note common stock issuable conversion note register securities act amend securities act sell transfer absence registration applicable exemption therefrom purchaser note notify seller note rely exemption provision section security act provide rule thereunder note common stock issuable conversion note offer sell pledge transfer person transferor reasonably believe qualified institutional buyer mean rule security act acquire account account qualified institutional buyer transaction meeting requirement rule pursuant exemption registration security act provide rule thereunder available institutional investor accredit investor mean rule regulation security act pursuant exemption registration securities act available pursuant effective registration statement security act accordance applicable security law state united states jurisdiction note share common stock issuable conversion relate documentation amend supplement time time modify restriction resale transfer note share reflect change applicable law regulation interpretation thereof practice relate resale transfer restrict security generally holder note share shall deem acceptance note share agree amendment supplement follow legend shall appear face global security security global security meaning indenture hereinafter refer register depositary nominee depositary treat company trustee agent thereof owner holder security purpose certificate present authorized representative depository trust company new york corporation dtc company agent registration transfer exchange payment certificate issue register cede request authorize representative dtc payment cede entity request authorize representative dtc transfer pledge use hereof value person wrongful inasmuch register owner hereof cede interest exchange security definitive register form limit circumstance refer indenture global security transfer depositary nominee depositary nominee depositary depositary nominee depositary depositary nominee successor depositary nominee successor depositary gilead sciences inc convertible senior note december cusip gilead sciences inc corporation duly organize exist law state delaware call company term include successor person indenture refer reverse hereof value receive promise pay register assign principal sum united states dollar security global security insert principal time time increase decrease principal amount take principal amount outstanding security shall exceed initial purchaser option exercise adjustment record trustee hereinafter refer accordance indenture december pay interest thereon december recent interest payment date define interest pay duly provide semiannually arrear june december year interest payment date commence june rate annum principal hereof rate annum overdue principal premium extent permit law overdue interest interest payable punctually pay duly provide interest payment date provide indenture pay person security predecessor security register close business regular record date interest shall june december business day case precede interest payment date provide indenture interest punctually pay duly provide forthwith cease payable holder regular record date pay person security predecessor security register close business special record date payment default interest fix company notice whereof shall give holder security day prior special record date pay time lawful manner inconsistent requirement automate quotation system security exchange security quote list notice require exchange fully provide indenture payment principal shall surrender security option holder corporate trust office trustee office agency company designate purpose borough manhattan city new york lawful monie united states america time payment shall legal tender payment public private debt office agency company designate united states dollar check draw wire transfer united states dollar account wire transfer holder aggregate principal security excess holder shall furnished wire instruction write trustee later day prior relevant payment date payment interest security united states dollar check mail address person entitle thereto address shall appear security register write application holder security registrar set forth wire instruction later relevant record date transfer united states dollar account wire transfer holder aggregate principal security excess holder shall furnished wire instruction write trustee later day prior relevant payment date specifically provide indenture company shall require payment respect tax assessment governmental charge impose government political subdivision tax authority thereof reference provision security set forth reverse hereof provision shall purpose effect set forth place certificate authentication hereon execute trustee refer reverse hereof authenticate agent manual signature respective authorize signatory security shall entitle benefit indenture valid obligatory purpose witness whereof company cause security duly execute gilead sciences inc title trustee certificate authentication security refer withinmentioned indenture date morgan trust company national association trustee authorize signatory form reverse security duly authorize issue security company designate convertible senior note december call security limit aggregate principal initial purchaser option exercise issue issue indenture date december call indenture company morgan trust company national association trustee call trustee term include successor trustee indenture indenture indenture supplemental thereto reference statement respective right limitation right duty immunitie thereunder company trustee holder security term security authenticate deliver provide indenture subject certain limitation set forth security exchangeable like aggregate principal security authorize denomination request holder surrender surrender security security exchange corporate trust office trustee trustee surrender holder issue new security request denomination sink fund provide security security subject provisional redemption company provisional redemption time june prior december notice set forth section indenture redemption price equal principal security redeem plus accrue unpaid interest redemption date closing price share common stock shall exceed conversion price effect trading day consecutive trading day period end trading day prior date mailing notice redemption pursuant section indenture notice date shelf registration statement cover resale security common stock effective available use expect remain effective available use day follow redemption date registration long require redemption company shall additional payment makewhole payment respect security call redemption holder notice date equal principal security interest actually pay accrue unpaid security prior redemption date company shall makewhole payment security call redemption include security convert common stock pursuant term indenture notice date prior redemption date makewhole payment security convert common stock pursuant term indenture notice date prior redemption date shall reduce accrue unpaid interest redemption date occur business day follow record date prior succeed interest payment date case makewhole payment shall reduce interest interest payment date company makewhole payment cash subject fulfillment company condition set forth follow paragraph share common stock combination cash common stock company shall specify type consideration makewhole payment company notice purpose paragraph fair market value share common stock shall determine company shall equal average closing price share consecutive trading day end trading day prior redemption date follow shall constitute condition election company pay makewhole payment portion thereof share common stock share common stock issue payment makewhole payment portion thereof hereunder shall require registration federal security law share freely transferable subject transfer restriction security act repurchase registration require registration shall complete shall effective prior redemption date company shall state notice provisional redemption company expect registration statement shall remain effective day follow redemption date share common stock issue payment makewhole payment portion thereof hereunder shall require registration approval governmental authority state law federal law share validly issue deliver repurchase registration require approval obtain registration shall complete approval shall obtain prior redemption date share common stock issue payment makewhole payment portion thereof hereunder shall approve quotation nasdaq national market list national security exchange case prior redemption date share common stock issue payment makewhole payment portion thereof issue company authorize unissued common stock issue duly validly issue fully pay non assessable free preemptive similar right condition set forth clause satisfied accordance term thereof payment shall pay company cash security subject redemption option company time december day notice holder prior redemption date redemption price express percentage principal set forth security redeem follow period describe period redemption price begin december december begin december december redemption price equal principal case accrue interest exclude redemption date provide interest installment security state maturity prior redemption date payable holder security predecessor security record close business relevant record date refer face hereof provide indenture event redemption security company require register transfer exchange security period day immediately precede date notice give identify serial number security call redemption register transfer exchange security portion thereof call redemption case date payment principal premium interest liquidate damage security day holder security right convert security shall place payment place conversion case day banking institution place payment place conversion authorize obligate law executive order close payment principal premium interest liquidate damage delivery conversion security need date place succeed day place day banking institution authorize obligate law executive order close force effect date payment date fix redemption repurchase day conversion interest shall accrue payable period date subject compliance provision indenture holder security entitle option time close business date maturity case security portion hereof call redemption holder hereof exercise right require company repurchase security portion hereof respect security second business day immediately precede company default make payment redemption repurchase case close business second business day immediately precede redemption date repurchase date case convert security portion principal hereof integral multiple provide unconverted portion principal integral multiple excess thereof fully pay nonassessable share common stock company initial conversion rate share common stock principal security current adjust conversion rate adjustment provide indenture surrender security duly endorse assign company blank case surrender shall period close business regular record date precede interest payment date opening business interest payment date security portion thereof call redemption redemption date repurchasable repurchase date occur case period close business regular record date precede interest payment date close business business day follow interest payment date result right convert security terminate period exercise accompany payment new york clearing house fund acceptable company equal interest payable interest payment date principal security convert conversion notice hereon duly execute company corporate trust office trustee office agency company subject law regulation applicable thereto subject right company terminate appointment conversion agent define designate purpose borough manhattan city new york office agency company designate conversion agent provide security portion hereof call redemption pursuant provisional redemption redemption date repurchasable repurchase date occur case period close business regular record date precede interest payment date close business business day follow interest payment date result right convert security terminate period exercise security surrender conversion period holder security regular record date entitle receive interest accrue hereon interest payment date precede date conversion succeed interest payment date holder security convert security portion hereof period shall require pay interest surrender security conversion subject provision precede sentence case conversion close business regular record date precede interest payment date close business business day follow interest payment date right holder security predecessor security record regular record date receive relate installment interest extent circumstance provide indenture cash payment adjustment conversion interest accrue hereon interest payment date precede day conversion dividend common stock issue conversion hereof company shall deliver holder fix number share common stock cash adjustment provide indenture security convertible delivery deem satisfy company obligation pay principal security fraction share scrip represent fraction share issue conversion instead fractional interest calculate nearest share company shall pay cash adjustment provide indenture conversion rate subject adjustment provide indenture addition indenture provide case certain consolidation merger company party consolidation merger result reclassification conversion exchange cancellation common stock conveyance transfer sale lease mere grant security interest substantially property asset company indenture shall amend consent holder security security outstanding convertible period security shall convertible specified kind security cash property receivable consolidation merger conveyance transfer sale lease holder number share common stock company security convert immediately prior consolidation merger conveyance transfer sale lease assume holder common stock constituent person affiliate constituent person fail exercise right election receive share kind receive share plurality nonelecting share adjustment conversion rate adjustment require increase decrease percent rate provide adjustment carry forward take account computation subsequent adjustment security registrable security define indenture holder security security global security insert include person beneficial interest security common stock company issuable conversion hereof entitle benefit registration right agreement date december registration right agreement company initial purchaser pursuant registration right agreement company agree benefit holder time time registrable security expense day issue date file shelf registration statement shelf registration statement commission respect resale registrable security use reasonable good effort cause shelf registration statement declare effective commission day issue date security provide company write notice holder postpone shelf registration statement declare effective reasonable period exceed day company possess material nonpublic information disclosure material adverse effect company subsidiary take use reasonable good effort maintain shelf registration statement effective security act early year effective date shelf registration statement expiration period refer rule securities act respect registrable security hold nonaffiliates company iii outstanding registrable security effectiveness period company permit suspend use prospectus shelf registration statement certain period time provide registration right agreement prior day follow issue date shelf registration statement file commission prior day follow issue date shelf registration statement declare effective registration default additional interest liquidate damage accrue restricted security include day follow registration default exclude day registration default cure liquidate damage pay semi annually arrear semiannual payment interest payment date applicable respect restrict security follow date liquidate damage begin accrue accrue rate annum equal onequarter percent principal restrict security include day follow registration default rate annum equal onehalf percent thereof day follow registration default pursuant registration right agreement event shelf registration statement cease effective holder registrable security prevent restrict company effecting sale pursuant thereto effective failure effectiveness period day consecutive day period day consecutive month period liquidate damage accrue rate annum equal additional onehalf percent principal restrict security day applicable day period day applicable month period early time effective failure cure effectiveness period expire security reference context payment principal premium interest respect security mention shall deem include mention payment liquidate damage payable describe precede paragraph extent context liquidate damage payable respect security express mention payment liquidate damage applicable provision security shall construe exclude liquidate damage provision security express mention security registrable security holder security security global security insert include person beneficial interest security elect sell security pursuant shelf registration statement acceptance hereof holder security agree bind term registration right agreement relate registrable security subject election change control occur holder security holder option shall right accordance provision indenture require company repurchase security portion principal hereof integral multiple excess thereof provide portion principal security outstanding repurchase equal repurchase price equal principal thereof plus interest accrue unpaid exclude repurchase date option company repurchase price pay cash subject condition provide indenture delivery share common stock fair market value equal repurchase price cash payment combination thereof purpose paragraph fair market value share common stock shall determine company shall equal average closing price share consecutive trading day end trading day prior repurchase date security reference context principal security time reference shall deem include reference repurchase price payable respect security extent repurchase price payable time express mention repurchase price provision security shall construe exclude repurchase price payable provision security express mention follow paragraph shall appear global security event deposit withdrawal interest security include exchange transfer redemption repurchase conversion security trustee custodian depositary shall adjustment record reflect deposit withdrawal accordance applicable procedure follow paragraph shall appear security global security event redemption repurchase conversion security new security security unredeeme unrepurchased unconverted portion hereof issue holder hereof event default shall occur continue principal security accrue interest date declaration declare payable manner effect provide indenture payment principal declare payable accrue interest date declaration interest overdue principal extent permit applicable law overdue interest company obligation respect payment principal interest security shall terminate indenture permit certain exception provide amendment thereof modification right obligation company right holder security indenture time company trustee write consent holder majority principal security time outstanding adoption resolution meeting holder outstanding security quorum present holder majority aggregate principal outstanding security represent entitle vote meeting indenture contain provision permit holder specify percentage principal security time outstanding behalf holder security waive compliance company certain provision indenture certain past default indenture consequence consent waiver holder security shall conclusive bind holder future holder security security issue exchange therefor lieu hereof notation consent waiver security security provide subject provision indenture holder security shall right institute proceeding respect indenture appointment receiver trustee remedy thereunder holder shall previously give trustee write notice continue event default holder principal outstanding security shall write request trustee institute proceeding respect event default trustee offer trustee reasonable indemnity trustee shall received holder majority principal security outstanding direction inconsistent request shall fail institute proceeding days receipt notice request offer indemnity foregoing shall apply suit institute holder security enforcement payment principal hereof premium interest include liquidate damage hereon respective date express enforcement right convert security provide indenture reference indenture provision security indenture shall alter impair obligation company absolute unconditional pay principal premium interest include liquidate damage security time place rate coin currency prescribe convert security provide indenture provide indenture subject certain limitation set forth transfer security registrable security register surrender security registration transfer corporate trust office trustee office agency company designate purpose borough manhattan city new york shall initially office agency trustee office agency company designate duly endorse accompany write instrument transfer form satisfactory company security registrar duly execute holder thereof attorney duly authorize write new security authorize denomination aggregate principal issue designate transferee transferee registrar service charge shall registration transfer exchange company require payment sum sufficient recover tax governmental charge payable connection therewith prior presentation security registration transfer company trustee agent company trustee treat person security register owner thereof purpose security overdue company trustee agent shall affect notice contrary recourse payment principal premium interest security recourse obligation covenant agreement company indenture indenture supplemental thereto security creation indebtedness represent shall incorporator stockholder employee agent officer director subsidiary past present future company successor corporation directly company successor corporation virtue constitution statute rule law enforcement assessment penalty liability acceptance hereof consideration issue hereof expressly waive release indenture security shall govern construe accordance law state new york united states america term security define indenture shall meaning assign indenture abbreviation follow abbreviation inscription face security shall construe write accord applicable law regulation com tenant common unif gift min act custodian ent tenant entirety cust cust minor joint tenant right survivorship uniform gift tenant common minor act state additional abbreviation list election holder require repurchase pursuant section indenture undersign elect security repurchase company undersign direct trustee company pay cash company election common stock value set forth indenture equal principal repurchase cash payment set forth combination cash common stock plus interest accrue exclude repurchase date provide indenture date signature signature guarantee eligible guarantor institution membership approve signature guarantee program pursuant rule security exchange act signature guarantee principal repurchase integral multiple excess thereof remain principal follow repurchase notice signature forego election correspond write face security particular alteration change whatsoever section form certificate authentication trustee certificate authentication shall substantially follow form security refer withinmentioned indenture date morgan trust company national association trustee authorize signatory section form conversion notice conversion notice undersigned holder security irrevocably exercise option convert security portion principal hereof integral multiple excess thereof provide unconverted portion principal integral multiple excess thereof designate share common stock accordance term indenture refer security direct share check payment fractional share security represent unconverted principal hereof deliver register undersigned different indicate share common stock security register person undersign undersigned pay transfer taxis payable respect thereto signature guarantee eligible guarantor institution membership approve signature guarantee program pursuant rule security exchange act require pay undersigned account interest accompany security date signature share security register person holder print person address address social security identification number signature guarantee eligible guarantor institution membership approve signature guarantee program pursuant rule security exchange act signature guarantee portion security convert indicate principal convert principal denomination security represent unconverted principal issue denomination integral multiple excess thereof provide unconverted portion principal integral multiple excess thereof section form assignment value receive sell assign transfer unto insert social security identify number assignee security irrevocably constitute appoint attorney transfer say security book company power substitution premise date signature signature guarantee eligible guarantor institution membership approve signature guarantee program pursuant rule security exchange act signature guarantee article iii security section title term aggregate principal security authenticate deliver indenture limit initial purchaser option set forth section purchase agreement exercise initial purchaser option security authenticate deliver pursuant section exchange lieu security previously authenticate deliver indenture security shall know designated convertible senior note december company state maturity shall december shall bear interest principal december payable semiannually arrear june december year commencing june rate annum principal thereof rate annum overdue principal extent permit law overdue interest provide payment shall business day provide section principal premium interest security shall payable provide form security set forth section repurchase price payable cash share common stock combination thereof shall payable place identify company notice give pursuant section city pay agent locate call place payment registrable security entitle benefit registration right agreement provide section form security set forth section security entitle payment liquidate damage provide section time june december security shall subject provisional redemption company subject condition provide article form security set forth section time december security shall redeemable option company subject condition provide article form security set forth section security shall convertible provide article xii city conversion agent locate call place conversion security shall subject repurchase company option holder provide article xiii section denomination security shall issuable register form coupon denomination integral multiple excess thereof section execution authentication delivery date security shall execute behalf company officer company signature manual facsimile security bear manual facsimile signature individual time proper officer company shall bind company notwithstanding individual cease hold office prior authentication delivery security hold office date security time time time execution delivery indenture company deliver security execute company trustee order authentication company order authentication delivery security trustee accordance company order shall authenticate available delivery security indenture provide security shall date date authentication security shall entitle benefit indenture valid obligatory purpose appear security certificate authentication substantially form provide execute trustee manual signature authorize signatory certificate security shall conclusive evidence evidence security duly authenticate deliver hereunder section global securities nonglobal security bookentry provision global security global security authenticate indenture shall register depositary designate company global security nominee thereof deliver depositary nominee thereof custodian therefor global security shall constitute single security purpose indenture exchange global security definitive nonglobal security sole discretion company global security exchange security register transfer global security register person depositary global security nominee thereof depositary notify company unwilling unable long qualified continue depositary global security cease clearing agency register exchange act announce intention permanently cease business fact shall occur continue event default respect global security event successor depositary global security appoint company day company receive notice aware ineligibility company execute trustee receipt officer certificate direct authentication delivery security authenticate deliver security authorize denomination aggregate principal equal principal global security exchange global security iii global security exchange security cancel shall surrender behalf depositary nominee trustee security registrar exchange cancellation provide article iii global security exchange security cancel security exchange beneficial interest global security case provide section global security shall surrender exchange cancellation provide article iii principal thereof shall reduce increase equal portion thereof exchange cancel equal principal security exchange beneficial interest case mean appropriate adjustment record trustee security registrar trustee accordance applicable procedure shall instruct depositary authorize representative correspond adjustment record surrender adjustment global security trustee shall subject section provide article iii authenticate deliver security issuable exchange global security portion thereof order register name direct depositary authorize representative request trustee connection occurrence event specify precede paragraph company shall promptly available trustee reasonable supply security form global security trustee shall entitle rely order direction request depositary authorize representative give pursuant article iii order direction request give accordance applicable procedure security authenticate deliver registration transfer exchange lieu global security portion thereof pursuant article iii shall authenticate deliver form shall register global security security register person depositary global security nominee thereof case security shall authenticate deliver definitive fully register form interest coupon depositary nominee register owner global security shall holder global security purpose indenture security owner beneficial interest global security shall hold interest pursuant applicable procedure accordingly owner beneficial interest global security show transfer interest shall effect record maintain depositary nominee agent member owner beneficial interest global security consider owner holder thereof nonglobal security security issue event describe section lii shall definitive fully register form interest coupon shall bear restricted security legend require indenture section registration registration transfer exchange restriction transfer company shall cause keep corporate trust office trustee register register maintain office refer security register subject reasonable regulation prescribe company shall provide registration security transfer security trustee appoint security registrar purpose register security transfer exchange security provide surrender registration transfer security office agency company designate pursuant section purpose company shall execute trustee shall authenticate deliver designate transferee transferee new security authorize denomination like aggregate principal bear restrictive legend require indenture option holder subject provision section security exchange security authorize denomination like aggregate principal surrender security exchange office agency security surrender exchange subject provision section company shall execute trustee shall authenticate deliver security holder make exchange entitle receive security present surrender registration transfer exchange shall require company security registrar duly endorse accompany write instrument transfer form satisfactory company trustee security registrar duly execute holder thereof attorney duly authorize write security issue registration transfer exchange security shall valid obligation company evidence debt entitle benefit indenture security surrender registration transfer exchange service charge shall holder registration transfer exchange security provide section company require payment sum sufficient cover tax governmental charge impose connection registration transfer exchange security exchange pursuant section share common stock issue deliver holder security involve transfer stamp duty impose connection transfer exchange united states political subdivision thereof shall pay company event redemption security company security registrar require register transfer exchange security period day immediately precede date notice give identify serial number security call redemption register transfer exchange security portion thereof call redemption certain transfer exchange notwithstanding provision indenture security transfer exchange security beneficial interest global security kind specify section shall accordance section restrict global security restrict nonglobal security event nonglobal security issue pursuant section connection transfer security transfer effect accordance provision clause subject applicable procedure receipt trustee security registrar company order company direct trustee security registrar authenticate deliver security aggregate principal beneficial interest restrict global security transfer instruction contain name designate transferee transferee authorize denomination denomination security issue appropriate delivery instruction decrease beneficial interest specify agent member account restrict global security specify principal great principal restrict global security certification legal opinion information company trustee reasonably require confirm transfer pursuant exemption transaction subject registration requirement securities act trustee security registrar shall decrease principal restrict global security specify authenticate deliver security accordance instruction company provide section iii restrict nonglobal security restrict global security holder restrict security global security wish time transfer portion restrict security person wish delivery thereof form beneficial interest restrict global security transfer effect accordance provision clause subject applicable procedure receipt trustee security registrar restrict security provide section instruction company direct beneficial interest restrict global security specify principal great principal security credit specify agent member account trustee security registrar shall cancel restrict security issue new restrict security respect untransferred portion thereof provide section increase principal restrict global security specify principal provide section iii iii exchange global security nonglobal security beneficial interest global security exchange security global security provide section exchange occur connection transfer effect accordance clause provide interest beneficial interest restrict global security interest shall exchange restricted security subject case section security global security exchange beneficial interest global security exchange occur connection transfer effect accordance clause securities act legend security issue pursuant indenture successor security shall bear restricted security legend shall subject restriction transfer specify subject follow subject follow clause section security portion thereof exchange transfer global security portion thereof shall bear restricted security legend bear global security security exchange subject follow clause section new security global security issue exchange security include global security portion thereof transfer shall bear restricted security legend bear security new security exchange iii security sell dispose pursuant effective registration statement security act include shelf registration statement successor security shall bear restricted security legend company shall inform trustee write effective date registration statement register security securities act shall notify trustee write time prospectus deliver respect security sell pursuant registration statement trustee shall liable action take omit take good faith accordance aforementione registration statement time security freely transfer registration security act subject transfer restriction pursuant security act new security bear restrict security legend issue exchange lieu security global security portion thereof bear legend trustee receive unrestricted security certificate satisfactory trustee duly execute holder security bearing restrict security legend attorney duly authorize write date receipt certificate trustee shall authenticate deliver new security exchange lieu security provide article iii new security bear restricted security legend issue exchange lieu security portion thereof bear legend company judgment place legend new security necessary ensure compliance registration requirement securities act trustee direction company shall authenticate deliver new security provide article iii notwithstanding forego provision section successor security security bear restrict security legend shall bear legend company reasonable cause believe successor security restrict security mean rule case trustee direction company shall authenticate deliver new security bearing restrict security legend exchange successor security provide article iii stock certificate represent share common stock issue conversion security shall bear restricted security legend borne security extent require indenture share common stock sell pursuant registration statement declare effective security act continue effective time transfer sell pursuant rule securities act agree company write write notice thereof transfer agent common stock respect transfer share common stock issue conversion security restrict hereunder delivery certificate legal opinion instrument require security registrar case transfer security describe shall instead transfer agent common stock trustee pay agent agent shall duty monitor compliance respect federal state security tax law duty obtain documentation transfer exchange specifically require hereunder section mutilate destroy lose steal security mutilate security surrender trustee company shall execute trustee shall authenticate deliver exchange therefor new security like tenor principal bear number contemporaneously outstanding deliver company trustee evidence satisfaction destruction loss theft security security indemnity satisfactory company trustee save agent harmless absence actual notice company trustee security acquire bona fide purchaser company shall execute trustee shall authenticate deliver lieu destroy lose steal security new security like tenor principal bear number contemporaneously outstanding case mutilate destroy lose steal security payable company discretion subject conversion right instead issue new security pay security satisfaction condition set forth precede paragraph issuance new security section company require payment sum sufficient cover tax governmental charge impose relation thereto stamp duty impose connection therewith united states political subdivision thereof shall pay company expense include fee expense trustee connect therewith new security issue pursuant section lieu mutilate destroy lose steal security shall constitute original additional contractual obligation company mutilate destroy lose steal security shall time enforceable new security shall entitle benefit indenture equally proportionately security duly issue hereunder provision section exclusive shall preclude extent lawful right remedy holder respect replacement payment mutilate destroy lose steal security section payment interest interest right preserve subject paragraph section interest liquidate damage security payable punctually pay duly provide interest payment date shall pay person security predecessor security register close business regular record date interest interest liquidate damage security payable punctually pay duly provide interest payment date call defaulted interest shall forthwith cease payable holder relevant regular record date virtue holder default interest pay company election case provide clause company elect payment default interest person name security respective predecessor security register close business special record date payment default interest shall fix follow manner company shall notify trustee writing default interest propose pay security date propose payment special record date time company shall deposit trustee money equal aggregate propose pay respect default interest shall arrangement reasonably satisfactory trustee deposit prior date propose payment money deposit hold trust benefit person entitle defaulted interest clause provide special record date payment default interest shall day day prior date propose payment day receipt trustee notice propose payment trustee expense company shall cause notice propose payment default interest special record date therefor mail firstclass postage prepay holder holder address appear security register day prior special record date notice propose payment default interest special record date therefor mail defaulted interest shall pay person name security respective predecessor security register close business special record date shall long payable pursuant follow clause company payment default interest lawful manner inconsistent requirement securities exchange security list notice require exchange notice give company trustee propose payment pursuant clause manner payment shall deem practicable trustee subject foregoing follow provision section section security deliver indenture registration transfer exchange lieu security shall carry right interest accrue unpaid accrue carry security interest security convert accordance section record date period shall payable accordance provision section section person deem owner prior presentment security registration transfer company trustee pay agent agent company trustee pay agent treat person security register owner security purpose receive payment principal premium subject section interest security purpose whatsoever security overdue company trustee pay agent agent company trustee pay agent shall affect notice contrary section cancellation security surrender payment redemption repurchase registration transfer exchange conversion shall surrender person trustee deliver trustee security deliver trustee shall cancel promptly trustee agent security shall authenticate lieu exchange security cancel provide section trustee shall dispose cancel security accordance applicable law customary practice effect time time section computation interest interest security include liquidate damage shall compute basis day year day month section cusip number company issue security use cusip number generally use addition serial number trustee shall use cusip number addition serial number notice redemption repurchase convenience holder provide notice state representation correctness cusip number print security contain notice redemption repurchase reliance place serial identification number print security redemption repurchase shall affect defect omission cusip number article satisfaction discharge section satisfaction discharge indenture indenture shall company request cease effect survive right conversion registration transfer exchange replacement security expressly provide right receive liquidate damage provide registration right agreement form security set forth section company obligation trustee pursuant section trustee expense company shall execute proper instrument form substance reasonably satisfactory trustee acknowledge satisfaction discharge indenture security theretofore authenticate deliver security destroy lose steal replace pay provide section security payment money theretofore deposit trust segregate hold trust company repay company discharge trust provide section deliver trustee cancellation security theretofore deliver trustee agent cancellation security refer clause clause payable payable state maturity year call redemption year arrangement reasonably satisfactory trustee give notice redemption trustee expense company company case clause deposit cause deposited trustee trust fund immediately available holder case clause trust purpose cash sufficient pay discharge entire indebtedness security theretofore deliver trustee cancellation principal premium interest include liquidate damage date deposit case security payable state maturity redemption date case company pay cause pay sum payable hereunder company company deliver trustee officer certificate opinion counsel state condition precedent provide relate satisfaction discharge indenture comply notwithstanding satisfaction discharge indenture obligation company trustee section obligation company authenticate agent section obligation company pay liquidate damage money shall deposit trustee pursuant clause section obligation trustee section paragraph section obligation company trustee section article xii shall survive section application trust money subject provision paragraph section money deposit trustee pursuant section shall hold trust sole benefit holder monie shall apply trustee accordance provision security indenture payment directly pay agent person entitle thereto principal premium interest include liquidate damage payment money deposit trustee money deposit trustee pursuant section hold pay agent payment security subsequently convert shall return company company shall pay indemnify trustee tax fee charge impose assess money deposit trustee pursuant section income taxis franchise taxis incur payable trustee taxis fee charge incur payable trustee directly result deposit money trustee article remedy section event default event default mean follow event reason event default shall voluntary involuntary effect operation law pursuant judgment decree order court order rule regulation administrative governmental body default payment principal premium security maturity default payment interest include liquidate damage security payable continuance default period day failure company company notice accordance section default performance covenant company indenture covenant default performance specifically deal section continuance default period day give register certify mail company trustee company trustee holder principal outstanding security write notice specify default breach require remedied state notice notice default hereunder default payment state maturity acceleration thereof expiration applicable grace period bond debenture note evidence indebtedness money borrow guarantee thereof company significant subsidiary instrument aggregate principal excess indebtedness exist shall create indebtedness discharge acceleration rescind annul period day shall give register certify mail company trustee company trustee holder principal outstanding security write notice specify default require company cause indebtedness discharge cause default cure waive acceleration rescinded annulled state notice notice default hereunder entry court jurisdiction premise decree order relief respect company significant subsidiary involuntary case proceed applicable federal state bankruptcy insolvency reorganization similar law decree order adjudge company significant subsidiary bankrupt insolvent approve properly file petition seek reorganization arrangement adjustment composition respect company significant subsidiary applicable federal state law appoint custodian receiver liquidator assignee trustee sequestrator similar official company significant subsidiary substantial property order wind liquidation affair continuance decree order relief decree order unstayed effect period consecutive day commencement company significant subsidiary voluntary case proceed applicable federal state bankruptcy insolvency reorganization similar law case proceed adjudicate bankrupt insolvent consent entry decree order relief respect company significant subsidiary involuntary case proceed applicable federal state bankruptcy insolvency reorganization similar law commencement bankruptcy insolvency case proceed file petition answer consent seek reorganization similar relief applicable federal state law consent file petition appointment take possession custodian receiver liquidator assignee trustee sequestrator similar official company significant subsidiary substantial property make assignment benefit creditor admission write inability pay debt generally take corporate action company significant subsidiary furtherance action section acceleration maturity rescission annulment event default event default specify section respect company occur continue case trustee holder principal outstanding security declare principal security payable immediately notice write company trustee give holder declaration principal accrue interest thereon shall immediately payable event default specify section respect company occur principal accrue interest security shall immediately payable declaration act holder act trustee time declaration acceleration judgment decree payment money obtain trustee hereinafter article provide holder majority principal outstanding security write notice company trustee behalf holder rescind annul declaration consequence company pay deposited trustee sum sufficient pay overdue interest securities principal premium security declaration acceleration interest thereon rate borne security iii extent permit applicable law interest overdue interest rate annum sum pay advanced trustee hereunder reasonable compensation expense disbursement advance trustee agent counsel event default nonpayment principal premium interest security solely declaration acceleration cure waive provide section rescission annulment conflict judgment decree issue appropriate judicial proceeding payment trustee holder amount refer rescission annulment refer shall affect subsequent default impair right consequent thereon section collection indebtedness suit enforcement trustee company covenant default payment interest include liquidate damage security payable default continue period day default payment principal premium security maturity thereof company demand trustee pay benefit holder security payable security principal interest include liquidate damage interest overdue principal premium extent permit applicable law overdue interest include liquidate damage rate annum addition thereto shall sufficient cover reasonable cost expense collection include reasonable compensation expense disbursement advance trustee agent counsel company fail pay amount forthwith demand trustee trustee express trust institute judicial proceeding collection sum unpaid prosecute proceed judgment final decree enforce company obligor security collect money adjudge decreed payable manner provide law property company obligor security situated event default occur continue trustee discretion proceed protect enforce right right holder security appropriate judicial proceeding trustee shall deem effectual protect enforce right specific enforcement covenant agreement indenture aid exercise power grant enforce proper remedy section trustee file proof claim case pendency receivership insolvency liquidation bankruptcy reorganization arrangement adjustment composition judicial proceeding relative company obligor security property company obligor creditor trustee irrespective principal interest security shall payable express declaration irrespective trustee shall demand company payment overdue principal interest shall entitle empower intervention proceeding file prove claim principal premium interest owe unpaid respect security action include participate member voting official committee creditor appoint matter file paper document forego case necessary advisable order claim trustee include claim reasonable compensation expense disbursement advance trustee agent counsel holder security allow judicial proceeding collect receive money property payable deliverable claim distribute custodian receiver assignee trustee liquidator sequestrator similar official judicial proceeding authorize holder security payment trustee event trustee shall consent make payment directly holder security pay trustee reasonable compensation expense disbursement advance trustee agent counsel amount trustee section contain shall deem authorize trustee authorize consent accept adopt behalf holder security plan reorganization arrangement adjustment composition affect security right holder thereof authorize trustee vote respect claim holder security proceeding provide trustee behalf holder vote election trustee bankruptcy similar official section trustee enforce claim possession security right action claim indenture security prosecute enforce trustee possession security production thereof proceeding relate thereto proceeding institute trustee shall bring trustee express trust recovery judgment shall provision payment reasonable compensation expense disbursement advance trustee agent counsel ratable benefit holder security respect judgment recover section application money collect money collect trustee pursuant article shall apply follow order date date fix trustee case distribution money account principal premium interest presentation security notation thereon payment partially pay surrender thereof fully pay payment amount trustee section second payment amount unpaid principal premium interest include liquidate damage security respect benefit money collect ratably preference priority kind accord amount payable security principal premium interest include liquidate damage respectively person person extent entitle thereto fourth remain amount shall repay company section limitation suit holder security shall right institute proceeding judicial respect indenture appointment receiver trustee remedy hereunder holder previously give write notice trustee event default continue time institution holder principal outstanding security shall write request trustee institute proceeding respect event default trustee hereunder holder holder offer trustee request shall provide reasonable indemnity cost expense liability incur compliance request trustee day receipt notice request offer indemnity request receipt indemnity fail institute proceeding direction inconsistent write request give trustee day period holder majority principal outstanding security understood intend holder shall right manner virtue availing provision indenture affect disturb prejudice right holder obtain seek obtain priority preference holder enforce right indenture manner provide equal ratable benefit holder section unconditional right holder receive principal premium interest convert notwithstanding provision indenture holder security shall right absolute unconditional receive payment principal premium subject section interest include liquidate damage security respective state maturity express security case redemption repurchase redemption date repurchase date case convert security accordance article xii institute suit enforcement payment right convert right shall impair consent holder section restoration right remedy trustee holder security institute proceed enforce right remedy indenture proceed discontinue abandon reason determine adversely trustee holder case subject determination proceed company trustee holder security shall restore severally respectively position hereunder right remedy trustee holder shall continue proceed institute section right remedy cumulative provide respect replacement payment mutilate destroy lose steal security paragraph section right remedy confer reserve trustee holder security intend exclusive right remedy right remedy shall extent permit law cumulative addition right remedy give hereunder exist law equity assertion employment right remedy hereunder shall prevent concurrent assertion employment appropriate right remedy section delay omission waiver delay omission trustee holder security exercise right remedy accrue event default shall impair right remedy constitute waiver event default acquiescence right remedy give article law trustee holder security exercise time time deem expedient trustee subject limitation contain indenture holder security case section control holder security subject section holder majority principal outstanding security shall right direct time method place conduct proceed remedy available trustee exercise trust power confer trustee provide direction shall conflict rule law indenture trustee action deem proper trustee inconsistent direction trustee need action involve personal liability unjustly prejudicial holder security consent section waiver past default holder write consent majority principal outstanding securities adoption resolution meeting holder outstanding security quorum present holder majority aggregate principal outstanding security represent meeting behalf holder security waive past default hereunder consequence default payment principal premium interest include liquidate damage security respect covenant provision hereof article viii modify amend consent holder outstanding security affect waiver default shall cease exist event default arise therefrom shall deemed cure purpose indenture waiver shall extend subsequent default impair right consequent thereon section undertaking cost party indenture agree holder security acceptance thereof shall deem agree court discretion require suit enforcement right remedy indenture suit trustee action take suffer omit trustee file party litigant suit undertake pay cost suit court discretion assess reasonable cost include reasonable attorney fee expense party litigant suit regard merit good faith claim defense party litigant provision section shall apply suit institute company suit institute trustee suit institute holder group holder hold aggregate principal outstanding security suit institute holder security enforcement payment principal premium interest security respective state maturity maturity express security case redemption repurchase redemption date repurchase date case enforcement right convert security accordance article xii section waiver stay usury extension law company covenant extent lawfully time insist plead manner whatsoever claim benefit advantage stay usury extension law enact time force affect covenant performance indenture company extent lawfully expressly waive benefit advantage law covenant hinder delay impede reason law execution power grant trustee suffer permit execution power law enact article trustee section certain duty responsibility continuance event default trustee undertake perform duty duty specifically set forth indenture imply covenant obligation shall read indenture trustee absence bad faith trustee conclusively rely truth statement correctness opinion express certificate opinion furnish trustee conforming requirement indenture case certificate opinion provision hereof specifically require furnish trustee trustee shall duty examine determine conform requirement indenture verify content thereof case event default occur continue trustee shall exercise right power vest indenture use degree care skill exercise prudent man exercise use circumstance conduct affair provision indenture shall construe relieve trustee liability negligent action negligent failure act willful misconduct paragraph shall construe limit effect paragraph section trustee shall liable error judgment good faith responsible officer shall prove trustee negligent ascertain pertinent fact iii trustee shall liable respect action take omit take good faith accordance direction holder majority principal outstanding security relate time method place conduct proceed remedy available trustee exercise trust power confer trustee indenture provision indenture shall require trustee expend risk fund incur financial liability performance duty hereunder exercise right power shall reasonable ground believe repayment fund adequate indemnity risk liability reasonably assure expressly provide provision indenture relate conduct affect liability afford protection trustee shall subject provision section trustee refuse perform duty exercise right power receive indemnity satisfactory loss liability expense section notice default day occurrence default hereunder trustee receive write notice trustee shall holder security manner provide section notice default default shall cure waive provide case default payment principal premium interest security trustee shall protect withholding notice long board directors executive committee trust committee director responsible officer trustee good faith determines withholding notice interest holder provide case default character specify section notice holder security shall give day occurrence thereof applicable expiration cure period specify purpose section term default mean event notice lapse time event default section certain right trustee subject provision section trustee rely shall protect act refraining act resolution officer certificate certificate statement instrument opinion report notice request direction consent order bond debenture note coupon evidence indebtedness paper document collectively document believe genuine sign present proper party party trustee need investigate fact matter state document request direction company mention shall sufficiently evidence company request company order resolution board director shall sufficiently evidence board resolution administration indenture trustee shall deem desirable matter prove establish prior take suffering omit action hereunder trustee evidence specifically prescribe absence bad faith request rely officer certificate opinion counsel trustee consult counsel selection advice counsel opinion counsel shall complete authorization protection respect action take suffer omit hereunder good faith reliance thereon trustee shall obligation exercise right power vest indenture request direction holder security pursuant indenture holder shall offer request trustee deliver trustee reasonable security cost expense liability incur compliance request direction trustee shall bind investigation fact matter state resolution certificate statement instrument opinion report notice request direction consent order bond debenture note coupon evidence indebtedness paper document trustee inquiry investigation fact matter fit trustee shall determine inquiry investigation shall entitle examine book record premise company personally agent attorney trustee execute trust power hereunder perform duty hereunder directly agent attorney trustee shall responsible misconduct negligence agent attorney appoint care hereunder section responsible recital issuance security recital contain security trustee certificate authentication shall take statement company trustee assume responsibility correctness trustee make representation validity sufficiency indenture security common stock issuable conversion security trustee shall accountable use application company security proceed thereof section hold security act trustee indenture trustee authenticate agent pay agent conversion agent agent company trustee individual capacity owner pledgee security deal company right trustee authenticate agent pay agent conversion agent agent trustee act trustee indenture security certificate interest participation security company outstanding manner trustee hereunder section money hold trust money hold trustee trust hereunder need segregated fund extent require law trustee shall liability interest money receive hereunder agree write company section compensation reimbursement company agree pay trustee time time reasonable compensation company trustee shall time time agree write acceptance indenture service render hereunder compensation shall limited provision law regard compensation trustee express trust expressly provide reimburse trustee request reasonable expense disbursement advance incur trustee include cost expense enforce indenture defend claim asserted company holder security person liability connection exercise power duty hereunder accordance provision indenture include reasonable compensation expense disbursement agent counsel expense disbursement advance attributable negligence bad faith indemnify trustee director officer employee agent hold harmless loss liability expense incur negligence bad faith arise connection acceptance administration trust include reasonable cost expense reasonable attorney fee defend claim liability connection exercise performance power duty hereunder trustee shall lien prior security money property hold control trustee secure company payment obligation section hold trust pay principal interest include liquidate damage security trustee incur expense render service connection event default specify section section expense include reasonable charge counsel compensation service intend constitute expense administration applicable federal state bankruptcy insolvency similar law provision section shall survive termination indenture early resignation removal trustee section corporate trustee require eligibility shall time trustee hereunder shall person eligible pursuant trust indenture act act trustee parent corporation shall hold company group combine capital surplus subject supervision examination federal state authority good standing trustee affiliate trustee shall maintain established place business borough manhattan city new york corporation publish report condition annually pursuant law requirement say supervise examine authority purpose section combine capital surplus corporation shall deem combined capital surplus set forth recent report condition publish time trustee shall cease eligible accordance provision section shall resign immediately manner effect hereinafter specify article successor shall appoint pursuant section section resignation removal appointment successor resignation removal trustee appointment successor trustee pursuant article shall effective acceptance appointment successor trustee accordance applicable requirement section trustee resign time give write notice thereof company instrument acceptance successor trustee require section shall deliver trustee day give notice resignation resign trustee petition court competent jurisdiction appointment successor trustee trustee remove time act holder majority principal outstanding security deliver trustee company instrument acceptance successor trustee require section shall deliver trustee day give notice removal remove trustee petition court competent jurisdiction appointment successor trustee trustee remove time company company appoint successor trustee pursuant article provide event default continue time removal successor trustee appoint company meet eligibility requirement section iii removal resignation shall effective acceptance appointment successor trustee accordance applicable requirement section time trustee shall cease eligible section shall fail resign write request therefor company holder security bona fide holder security month trustee shall incapable act shall adjudge bankrupt insolvent receiver trustee property shall appoint public officer shall charge control trustee property affair purpose rehabilitation conservation liquidation case company board resolution remove trustee subject section holder security bona fide holder security month behalf similarly situate petition court competent jurisdiction removal trustee appointment successor trustee trustee shall resign remove incapable act vacancy shall occur office trustee cause company board resolution shall promptly appoint successor trustee shall comply applicable requirement section section successor trustee shall appoint company holder security accept appointment manner require section section holder security bona fide holder security month behalf similarly situate petition court competent jurisdiction appointment successor trustee company shall notice resignation removal trustee appointment successor trustee holder security manner provide section notice shall include successor trustee address corporate trust office section acceptance appointment successor successor trustee appoint hereunder shall execute acknowledge deliver company retire trustee instrument accept appointment resignation removal retire trustee shall effective successor trustee act deed conveyance shall vested right power trust duty retire trustee request company successor trustee retire trustee shall payment charge execute deliver instrument transferring successor trustee right power trust retire trustee shall duly assign transfer deliver successor trustee property money hold retire trustee hereunder request successor trustee company shall execute instrument fully certainly vest confirm successor trustee right power trust successor trustee shall accept appointment time acceptance successor trustee shall eligible article section merger conversion consolidation succession business corporation trustee merge convert consolidated corporation result merger conversion consolidation trustee shall party corporation succeed substantially corporate trust business trustee include trust create indenture shall successor trustee hereunder provide corporation shall eligible article execution file paper act party hereto case security shall authenticate deliver trustee office successor merger conversion consolidation authenticating trustee adopt authentication deliver security authenticate effect successor trustee authenticate security section authenticate agent trustee consent company appoint authenticate agent agent acceptable company respect security authenticating agent shall authorize act behalf trustee authenticate security issue exchange substitution pursuant indenture security authenticate authenticate agent shall entitle benefit indenture shall valid obligatory purpose authenticate trustee hereunder reference indenture authentication delivery security trustee trustee certificate authentication shall deem include authentication delivery behalf trustee authenticate agent certificate authentication execute behalf trustee authenticate agent authenticate agent shall subject acceptance company shall times corporation organize business law united states america state thereof district columbia authorize law act authenticate agent subject supervision examination government fiscal authority time authenticate agent shall cease eligible accordance provision section authenticate agent shall resign immediately manner effect specify section corporation authenticate agent merge convert consolidated corporation result merger conversion consolidation authenticate agent shall party corporation succeed corporate agency corporate trust business authenticate agent shall continue authenticate agent provide corporation shall eligible section execution file paper act trustee authenticate agent authenticating agent resign time give write notice thereof trustee company trustee time terminate agency authenticate agent give write notice thereof authenticate agent company receive notice resignation termination case time authenticate agent shall cease eligible accordance provision section trustee appoint successor authenticating agent shall subject acceptance company successor authenticate agent acceptance appointment hereunder shall vested right power duty predecessor hereunder like effect originally name authenticate agent successor authenticating agent shall appoint eligible provision section company agree pay authenticate agent time time reasonable compensation service section authenticate agent appoint respect security pursuant section security endorse thereon addition lieu trustee certification authentication alternative certificate authentication follow form security refer withinmentioned indenture morgan trust company national association trustee authenticate agent authorize signatory section disqualification conflict interest trustee shall acquire conflict interest mean trust indenture act trustee shall eliminate interest resign extent manner provide subject provision trust indenture act indenture section preferential collection claim company trustee shall creditor company obligor security trustee shall subject provision trust indenture act collection claim company obligor article vii consolidation merger conveyance transfer lease section company consolidate etc certain term company shall consolidate merge person convey transfer sell lease mere grant security interest property asset substantially entirety person company shall permit person consolidate merge company convey transfer sell lease mere grant security interest person property asset substantially entirety company person form consolidation company merge person property asset company conveyed transfer sell lease mere grant security interest shall corporation limited liability company partnership trust organize validly exist law united states america state thereof district columbia company shall expressly assume indenture supplemental hereto execute deliver trustee form reasonably satisfactory trustee punctual payment principal premium interest include liquidate damage security applicable performance observance covenant indenture company perform observed shall provide conversion right material respect accordance article xii immediately give effect transaction event default event notice lapse time event default shall occur continue company deliver trustee officer certificate opinion counsel state consolidation merger conveyance transfer lease mere grant security interest supplemental indenture require connection transaction supplemental indenture comply article condition precedent provide relate transaction comply document require section section successor substitute consolidation company merger company person conveyance transfer lease mere grant security interest substantially properties asset company accordance section successor person form consolidation company merge conveyance transfer lease mere grant security interest shall succeed substitute exercise right power company indenture effect successor person name company case lease predecessor person shall relieve obligation covenant indenture security article viii supplemental indenture section supplemental indenture consent holder security consent holder security company authorize board resolution trustee time time time enter indenture supplemental hereto follow purpose evidence succession person company assumption successor covenant obligation company securities permit article vii indenture add covenant company benefit holder security surrender right power confer company secure security provision respect conversion right holder security pursuant section provision respect repurchase right holder security pursuant section change modification indenture necessary connection registration registrable security security act contemplate section provide action pursuant clause shall adversely affect interest holder security material respect comply requirement trust indenture act rules regulations commission thereunder order effect maintain qualification indenture trust indenture act contemplate indenture evidence provide acceptance appointment hereunder successor trustee provide uncertificated security cure ambiguity correct supplement provision inconsistent provision defective provision respect matter question arise indenture company trustee deem necessary desirable provide action pursuant clause shall adversely affect interest holder security material respect company request accompany board resolution authorize execution supplemental indenture subject receipt trustee document describe section hereof trustee shall join company execution supplemental indenture authorize permit term indenture appropriate agreement stipulation contain notwithstanding provision indenture security registration right agreement obligation pay liquidate damage thereunder amend modify waive accordance provision registration right agreement section supplemental indenture consent holder security set forth section write consent holder majority principal outstanding securities act say holder deliver company trustee adoption resolution meeting holder outstanding security quorum present holder majority aggregate principal outstanding security represent meeting company authorize board resolution trustee enter indenture indenture supplemental hereto purpose add provision change manner eliminate provision indenture modify manner right holder security indenture provide supplemental indenture shall consent affirmative vote holder outstanding security affect change state maturity principal installment interest security reduce principal premium rate interest payable thereon reduce payable redemption mandatory repurchase change place currency payment principal premium interest security include payment liquidate damage effect amendment registration right agreement accordance term redemption price repurchase price respect security impair right institute suit enforcement payment respect security state maturity thereof case redemption repurchase redemption date repurchase date case reduce requirement section quorum voting reduce percentage principal outstanding security consent holder require supplemental indenture consent holder require waiver compliance certain provision indenture certain default hereunder consequence provide indenture modify provision section section increase percentage contain provide certain provision indenture modify waive consent holder outstanding security affect modify rank security manner adverse holder modify company right redeem security manner adverse holder modify provision article xii xiii manner adverse holder modify provision section manner adverse holder shall necessary act holder security section approve particular form propose supplemental indenture shall sufficient act shall approve substance thereof section execution supplemental indenture execute accept additional trust create supplemental indenture permit article modification trust create indenture trustee shall entitle receive subject section shall fully protect rely opinion counsel state execution supplemental indenture authorize permit indenture supplemental indenture duly authorize execute deliver company constitute valid legally bind obligation company enforceable company accordance term trustee shall obligate enter supplemental indenture adversely affect trustee right duty immunitie indenture section effect supplemental indenture execution supplemental indenture article indenture shall modify accordance therewith supplemental indenture shall form indenture purpose holder security theretofore authenticate deliver hereunder appertain thereto shall bind section reference security supplemental indentures security authenticate deliver execution supplemental indenture pursuant article shall require trustee bear notation form approve trustee matter provide supplemental indenture company shall determine new security modify conform opinion company trustee supplemental indenture prepare execute company authenticate deliver trustee exchange outstanding security section notice supplemental indenture promptly execution company trustee supplemental indenture pursuant provision section company shall notice holder security fact set forth general term substance supplemental indenture manner provide section failure company notice defect shall way impair affect validity supplemental indenture article meeting holder security section purpose meeting call meet holder security call time time time pursuant article request demand authorization direction notice consent waiver action provide indenture give take holder security section notice place meeting trustee company consent prior event default time meeting holder security purpose specify section hold time place borough manhattan city new york trustee shall determine notice meeting holder security set forth time place meet general term action propose take meeting shall give manner provide section day prior date fix meeting case time company pursuant board resolution event default holder principal outstanding security shall request trustee meeting holder security purpose specify section write request set forth reasonable detail action propose take meet trustee shall mail notice meeting day receipt request shall proceed cause meeting hold provide company event default holder security specify case determine time place borough manhattan city new york meeting meeting purpose give notice thereof provide paragraph section section person entitle vote meeting entitle vote meeting holder security person shall holder outstanding securities person appoint instrument write proxy holder holder outstanding security holder holder person shall entitle present speak meeting holder shall person entitle vote meeting counsel representative trustee counsel representative company counsel section quorum action person entitle vote majority principal outstanding security shall constitute quorum absence quorum minute time appoint meeting meeting shall convene request holder security dissolve case meeting adjourned period day determine chairman meet prior adjournment meeting absence quorum adjourn meeting adjourn meeting adjourned period day determine chairman meet prior adjournment adjourn meeting subject repeat application sentence notice reconvene adjourn meeting shall give provide section notice need give day prior date meeting schedule reconvene notice reconvene adjourn meeting shall state expressly percentage principal outstanding security shall constitute quorum subject foregoing reconvening meeting adjourn lack quorum person entitle vote principal outstanding security time shall constitute quorum take action set forth notice original meeting meeting adjourn meeting duly reconvene quorum present aforesaid resolution matter limited proviso section extent section require different vote shall effectively pass decide pass decide less holder majority principal outstanding securities person entitle vote majority aggregate principal outstanding security represent entitle vote meeting resolution pass decision take meeting holder security duly hold accordance section shall bind holder security present represent meeting trustee shall expense company notify holder security resolution decision pursuant section section determination voting right conduct adjournment meeting notwithstanding provision indenture trustee reasonable regulation deem advisable meeting holder security regard proof hold security appointment proxy regard appointment duty inspector vote submission examination proxy certificate evidence right vote matter concern conduct meeting shall deem appropriate permit require regulation hold security shall prove manner specify section appointment proxy shall prove manner specify section signature person execute proxy guarantee bank broker eligible institution participate recognize medallion signature guarantee program trustee shall instrument writing appoint temporary chairman trustee meeting meeting shall call company holder security provide section case company holder security call meeting case shall like manner appoint temporary chairman permanent chairman permanent secretary meeting shall elect vote person entitle vote majority principal outstanding security represent meeting meeting holder security proxy shall entitle vote principal security hold represent provide vote shall cast count meeting respect security challenge outstanding rule chairman meeting outstanding chairman meeting shall right vote holder security proxy meeting holder security duly call pursuant section quorum present adjourn time time person entitle vote majority principal outstanding security represent meeting meeting hold adjourn notice section counting vote record action meeting vote resolution submit meeting holder security shall write ballot shall subscribe signature holder security representative proxy principal amount state maturity serial number outstanding security hold represent permanent chairman meeting shall appoint inspector vote shall count vote cast meeting resolution shall file secretary meeting verify write report duplicate vote cast meeting record duplicate proceeding meet holder security shall prepare secretary meeting shall attach say record original report inspector vote vote ballot take thereat affidavit person knowledge fact set forth copy notice meeting showing say notice give provide section applicable section copy shall sign verify affidavit permanent chairman secretary meeting copy shall deliver company trustee preserve trustee attach thereto ballot vote meeting record sign verify shall conclusive evidence matter state article covenant section payment principal premium interest company covenant agree duly punctually pay principal premium interest include liquidate damage security accordance term security indenture company deposit cause deposited trustee nominee later open business date state maturity security later open business date installment interest payment payment shall immediately available fund date state maturity date case section maintenance office agency company maintain borough manhattan city new york office agency security surrender registration transfer exchange presentation payment conversion redemption repurchase notice demand company respect security indenture serve company prompt write notice trustee location change location office agency designate appoint trustee time company shall fail maintain require office agency shall fail furnish trustee address thereof presentation surrender notice demand serve corporate trust office office agency trustee borough manhattan city new york company time time time vary terminate appointment agent appoint additional agent purpose provide security deliver trustee cancellation money sufficient pay principal premium interest security available payment pay return company pursuant provision section company maintain borough manhattan city new york office agency security present surrender payment conversion shall initially corporate trust office trustee security surrender registration transfer exchange notice demand company respect security indenture serve company prompt write notice trustee notice holder accordance section appointment termination agent location change location office agency company initially designate trustee pay agent security registrar conversion agent corporate trust office trustee office agency company aforesaid purpose section money security payment hold trust company shall act pay agent date principal premium interest security segregate hold trust benefit person entitle thereto sum sufficient pay principal premium interest sum shall pay person dispose provide company promptly notify trustee write action failure act company shall pay agent later open business date principal premium interest security deposit trustee sum fund immediately payable payment date sufficient pay principal premium interest sum hold benefit person entitle principal premium interest pay agent trustee company promptly notify trustee write failure act company cause pay agent trustee execute deliver trustee instrument pay agent shall agree trustee subject provision section pay agent hold sum hold payment principal premium interest security benefit person entitle thereto sum shall pay person dispose provide trustee write notice default company obligor security make payment principal premium interest time continuance default write request trustee forthwith pay trustee sum hold pay agent company time purpose obtain satisfaction discharge indenture purpose pay company order direct pay agent pay trustee sum hold trust company pay agent sum hold trustee trust sum hold company pay agent payment pay agent trustee pay agent shall release liability respect money money deposit trustee pay agent hold company trust payment principal premium interest security remain unclaimed year principal premium interest payable shall pay company company request hold company shall discharge trust holder security shall unsecured general creditor look company payment thereof liability trustee pay agent respect trust money liability company trustee thereof shall cease section existence subject article vii company cause thing necessary preserve force effect existence right charter statutory franchise provide company shall require preserve right franchise company shall determine preservation thereof long desirable conduct business company loss thereof disadvantageous material respect holder section intentionally leave blank section payment taxis claim company shall pay shall cause subsidiary pay prior delinquency material taxis assessment governmental charge levy impose company subsidiary subject section stamp duty impose united states political subdivision thereof connection issuance transfer exchange conversion security respect indenture contested good faith appropriate proceeding failure effect payment adverse material respect holder section registration list company effect registration obtain approval governmental authority necessary united states federal state law include securities act exchange act state security blue sky law share common stock issuable conversion security issue deliver qualified list contemplated registration right agreement section limit application section section statement officer default company shall deliver trustee day end fiscal year company end date hereof officer certificate state reasonable good knowledge signer thereof company default performance observance term provision condition indenture regard period grace requirement notice provide hereunder company shall default specify default nature status thereof knowledge company deliver trustee forthwith aware default event default indenture officer certificate specify particularity default event default state action company take take propose respect thereto purpose section term default mean event notice lapse time event default notice require give section shall deliver trustee corporate trust office section delivery certain information time company subject section exchange act request holder restrict security holder share common stock issue conversion thereof company promptly furnish cause furnish rule information define holder restrict security holder share common stock issue conversion restrict security prospective purchaser security designate holder holder case extent require permit compliance holder holder rule securities act successor provision thereto connection resale security provide company shall require furnish information connection request date year later date security predecessor security acquire company date security predecessor security acquire affiliate company mean rule securities act successor provision thereto rule information shall information specify pursuant rule securities act successor provision thereto section resale certain security period begin date original issuance security end date year date shorten period rule securities act successor rule company permit subsidiary affiliate define rule securities act successor provision thereto resell security constitute restricted securities rule security security convert indenture constitute restricted security rule case reacquire trustee shall responsibility respect company performance agreement precede sentence section registration right company agree holder time time registrable security define entitled benefit registration right agreement indenture mention context payment principal premium interest respect security mention shall deem include mention payment liquidate damage provide section extent context liquidate damage payable respect thereof pursuant provision section express mention payment liquidate damage applicable provision hereof shall construe exclude liquidate damage provision hereof express mention purpose registration right agreement registrable security mean portion security issue time time indenture register form share common stock issuable conversion repurchase redemption security provide security cease registrable security long restrict security security share common stock issuable conversion security registrable security holder thereof elect sell registrable security pursuant shelf registration statement acceptance thereof holder registrable security agree bind term registration right agreement relate registrable security subject election purpose registration right agreement term holder mean person record owner registrable security include person beneficial interest registrable security book entry form liquidate damage payable registration right agreement company shall deliver trustee certificate effect state liquidate damage payable date liquidate damage payable responsible officer trustee receive corporate trust office certificate trustee assume inquiry liquidate damage payable liquidate damage pay company directly person entitle company shall deliver trustee certificate set forth particular payment section waiver certain covenant company omit particular instance comply covenant condition set forth section respect existence company subject article vii inclusive covenant condition article viii modify amend consent holder outstanding security affect time compliance holder shall write consent majority principal outstanding securities adoption resolution meeting holder outstanding security quorum present holder majority aggregate principal outstanding security represent meet waive compliance instance generally waive compliance covenant condition waiver shall extend affect covenant condition extent expressly waive waiver shall effective obligation company dutie trustee pay conversion agent respect covenant condition shall remain force effect article redemption security section right redemption security redeem accordance provision form security set forth section section applicability article redemption security election company permit require provision security indenture shall accordance provision article section election redeem notice trustee election company redeem security shall evidenced board resolution case redemption election company security company shall day prior redemption date fix company short notice shall satisfactory trustee notify trustee write redemption date section selection trustee security redeem security redeem particular security redeem shall select trustee business day receive notice describe outstanding security previously call redemption lot method trustee deem fair appropriate security select partial redemption convert termination conversion right respect portion security select convert portion security shall deem far portion select redemption security convert selection security redeem treat trustee outstanding purpose selection trustee shall promptly notify company security registrar write security select redemption case security select partial redemption principal thereof redeem purpose indenture context require provision relate redemption security shall relate case security redeem redeem portion principal security redeem section notice redemption notice redemption shall give manner provide section holder security redeem day prior redemption date notice shall irrevocable notice redemption shall state redemption date redemption price accrue interest include liquidate damage exclude redemption date outstanding security redeem aggregate principal security redeem aggregate principal security outstanding partial redemption redemption date redemption price accrue interest include liquidate damage exclude redemption date payable security redeem interest thereon shall cease accrue say date redemption provisional redemption optional redemption redemption provisional redemption makewhole payment makewhole payment pay common stock cash combination cash common stock applicable ratio cash common stock conversion rate date right convert security redeem terminate place security surrender conversion place place security surrender payment redemption price accrue interest include liquidate damage exclude redemption date case partial redemption notice shall specify serial cusip number portion thereof call redemption transfer exchange occur prior redemption date notice redemption security redeem election company shall give company company write request request shall deliver trustee simultaneously notification redemption date pursuant section trustee expense company notice redemption security redeem election company receive trustee shall give trustee pay agent expense company section deposit redemption price prior redemption date company shall deposit trustee company act pay agent segregate hold trust provide section money applicable common stock combination thereof respect makewhole payment shall immediately available fund redemption date sufficient pay redemption price redemption date shall interest payment date accrue interest include liquidate damage redemption date security redeem date security call redemption date convert prior date deposit security call redemption convert money deposit trustee segregate hold trust redemption security shall subject right holder security predecessor security receive interest provide paragraph section pay company hold company shall discharge trust section security payable redemption date notice redemption give aforesaid security redeem shall redemption date payable redemption price specify date company shall default payment redemption price include accrue interest security shall cease bear interest surrender security redemption accordance say notice security shall pay company redemption price accrue unpaid interest include liquidate damage exclude redemption date provide installment interest security state maturity prior redemption date shall payable holder security predecessor security register relevant record date accord term provision section security call redemption shall pay surrender thereof redemption principal premium extent permit applicable law accrue interest security shall pay bear interest redemption date rate annum security shall remain convertible redemption price security portion thereof case shall paid duly provide security redeem shall surrender corporate trust office office agency company designate purpose pursuant section company trustee require endorsement write instrument transfer form satisfactory company trustee duly execute holder thereof attorney duly authorize write company shall execute trustee shall authenticate available delivery holder security service charge new security security authorize denomination request holder aggregate principal equal exchange unredeemed portion principal security surrender section conversion arrangement redemption connection redemption security company arrange purchase conversion security agreement investment banker purchaser purchaser purchase security pay trustee trust holder redemption date applicable redemption price interest accrue unpaid exclude redemption date security notwithstanding contrary contain article obligation company pay redemption price interest accrue unpaid exclude redemption date shall deem satisfied discharge extent pay purchaser agreement enter copy shall file trustee prior close business business day immediately prior redemption date security call redemption duly surrender conversion holder thereof option company deem full extent permit law consistent agreement agreement purchaser acquire purchaser holder notwithstanding contrary contain article xii surrender purchasers conversion immediately prior close business redemption date right convert security shall extend time subject payment aforesaid direction company trustee shall hold dispose pay purchaser holder manner monie deposited company redemption security trustee prior write consent arrangement company purchaser purchase conversion security shall increase affect power duty responsibility obligation trustee set forth indenture company agree indemnify trustee hold harmless loss liability expense arise connection arrangement purchase conversion security company purchaser include cost expense include reasonable legal fee incur trustee defense claim liability arise connection exercise performance power duty responsibility obligation indenture article xii conversion security section conversion privilege conversion rate subject compliance provision article option holder thereof principal security convert fully pay nonassessable share calculate conversion nearest share common stock company conversion rate determine hereinafter provide effect time conversion conversion right shall commence initial issuance date security expire close business date maturity security previously redeem repurchase subject case conversion global security applicable procedure case security portion thereof call redemption election company holder thereof exercise right require company repurchase security conversion right respect security portion thereof call shall expire close business second business day immediately precede redemption date repurchase date case company default make payment redemption repurchase case case subject aforesaid applicable procedure respect global security rate share common stock shall deliver conversion call conversion rate shall initially share common stock principal security conversion rate shall adjust certain instance provide article xii section exercise conversion privilege order exercise conversion privilege holder security convert shall surrender security duly endorse blank office agency company maintain purpose pursuant section accompany duly sign conversion notice substantially form set forth section state holder elect convert security entire principal thereof convert portion thereof convert security surrender conversion record date period shall case security portion thereof call redemption pursuant provisional redemption redemption date repurchasable repurchase date occur case period close business regular record date precede interest payment date close business business day follow interest payment date result right convert security terminate period exercise accompanied payment new york clearing house fund fund acceptable company equal interest payable interest payment date principal security thereof case surrender conversion interest payable interest payment date respect security portion thereof applicable surrendered conversion record date period shall pay holder security regular record date equal interest payable security security convert close business interest payment date interest payable interest payment date respect security surrender conversion interest payment date shall pay holder security regular record date precede interest payment date notwithstanding exercise right conversion provide paragraph subject paragraph section cash payment adjustment shall conversion account interest accrue interest payment date precede conversion date respect security thereof case surrender conversion account dividend common stock issue conversion company delivery holder number share common stock cash lieu fraction thereof provide indenture security convertible deem satisfy company obligation pay principal security security shall deemed convert immediately prior close business day surrender security conversion accordance forego provision time right holder security holder shall cease person person entitle receive common stock issuable conversion shall treat purpose record holder holder common stock time promptly practicable conversion date company shall issue deliver trustee delivery holder different person indicate conversion notice certificate certificate number share common stock issuable conversion payment lieu fraction share provide section share common stock deliver conversion restrict security shall bear restrictive legend substantially form legend require set forth restrict security pursuant section shall subject restriction transfer provide legend trustee agent maintain purpose conversion shall responsibility inclusion content restrictive legend common stock provide trustee agent maintain purpose conversion shall provide company company transfer agent common stock prior concurrently request company deliver common stock write notice security deliver conversion restrict security case security convert conversion company shall execute trustee shall authenticate deliver holder thereof expense company new security security authorize denomination aggregate principal equal unconverted portion principal security security convert principal security convert integral multiple principal security remain outstanding conversion equal integral multiple excess thereof share common stock issue conversion restrict security security issue conversion restrict security register beneficial owner restrict security holder deliver conversion agent surrender certificate date date surrender restrict security sign beneficial owner compliance restriction transfer applicable restricted security trustee conversion agent registrar transfer agent shall require register beneficial owner share common stock security issue conversion restrict security accompany properly complete surrender certificate section fraction share fractional share common stock shall issue conversion security security security shall surrender conversion time holder number share shall issuable conversion thereof shall compute basis aggregate principal security specify portion thereof surrender instead fractional share common stock issuable conversion security security specify portion thereof company shall calculate pay cash adjustment respect fraction calculate nearest share equal fraction closing price share close business day conversion section adjustment conversion rate conversion rate shall subject adjustment time time follow case company shall pay dividend distribution share class capital stock payable share common stock conversion rate effect opening business day follow date fix determination shareholder entitle receive dividend distribution shall increase divide conversion rate effect immediately prior date fraction numerator shall number share common stock outstanding close business date fix determination denominator shall sum number share total number share constitute dividend distribution increase effective immediately open business day follow date fix determination date fix determination dividend distribution fact pay conversion rate shall immediately readjust effective date board director determine pay dividend distribution conversion rate effect determination date fix purpose paragraph number share common stock time outstanding shall include share hold treasury company shall include share issuable respect scrip certificate issue lieu fraction share common stock company pay dividend distribution share common stock hold treasury company case company shall issue right option warrant holder common stock entitle subscribe purchase share common stock price share current market price share determine provide paragraph section common stock date fix determination stockholder entitle receive right option warrant right option warrant term issue holder conversion security share common stock action require company person conversion rate effect opening business day follow date fix determination shall increase divide conversion rate effect immediately prior date fraction numerator shall number share common stock outstanding close business date fix determination plus number share common stock aggregate offering price total number share common stock offer subscription purchase purchase current market price denominator shall number share common stock outstanding close business date fix determination plus number share common stock offer subscription purchase increase effective immediately open business day follow date fix determination date fix determination right option warrant fact issue exercise prior expiration thereof conversion rate shall immediately readjust effective date right option warrant expire date board director determine issue right option warrant conversion rate effect unexercised right option warrant grant determination date fix case purpose paragraph number share common stock time outstanding shall include share hold treasury company shall include share issuable respect scrip certificate issue lieu fraction share common stock company issue right option warrant respect share common stock hold treasury company case outstanding share common stock shall subdivide great number share common stock conversion rate effect opening business day follow day subdivision effective shall proportionately increase conversely case outstanding share common stock shall combine small number share common stock conversion rate effect opening business day follow day combination effective shall proportionately reduce increase reduction case effective immediately open business day follow day subdivision combination effective case company shall dividend distribute holder common stock evidence indebtedness share class capital stock property include cash asset security exclude right option warrant refer paragraph section dividend distribution pay exclusively cash refer paragraph iii dividend distribution refer paragraph section consideration distribute merger consolidation section apply conversion rate shall adjust shall equal rate determine dividing conversion rate effect immediately prior close business date fix determination stockholder entitle receive distribution fraction numerator shall current market price share determine provide paragraph section common stock date fix determination fair market value determine board director determination shall conclusive describe board resolution file trustee portion asset share evidence indebtedness distribute applicable share common stock denominator shall current market price share common stock adjustment effective immediately prior open business day follow date fix determination stockholder entitle receive distribution date fix determination distribution fact conversion rate shall immediately readjust effective date board director determines distribution conversion rate effect determination date fix event fair market value determine portion evidence indebtedness share class capital stock property distribute equal great current market price share common stock date lieu forego adjustment adequate provision shall holder security shall right receive conversion evidence indebtedness share class capital stock property holder received holder convert security date case company shall dividend distribute holder common stock cash exclude cash distribute merger consolidation section apply aggregate combine aggregate allcash distribution holder common stock exclusively cash day period precede date payment distribution respect adjustment pursuant paragraph paragraph section aggregate cash plus fair market value determine board director determination shall conclusive describe board resolution noncash consideration payable respect tender offer company subsidiary portion common stock conclude day period precede date payment distribution respect adjustment pursuant paragraph section combined cash tender exceed product current market price share determine provide paragraph section common stock date determination holder share common stock entitle receive distribution time number share common stock outstanding date aggregate current market price case immediately close business date determination conversion rate shall adjust shall equal rate determine dividing conversion rate effect immediately prior close business date fix determination stockholder entitle receive distribution fraction numerator shall equal current market price share determine provide paragraph section common stock date fix determination equal quotient excess combine cash tender aggregate current market price divide number share common stock outstanding date determination denominator shall equal current market price share determine provide paragraph section common stock date fix determination case tender offer company subsidiary portion common stock shall expire tender offer amend expiration thereof shall require payment stockholder base acceptance maximum specify term tender offer purchase share define aggregate consideration fair market value determine board director determination shall conclusive describe board resolution combine aggregate cash plus fair market value determine board director determination shall conclusive describe board resolution expiration tender offer noncash consideration payable respect tender offer company subsidiary portion common stock expire day period precede expiration tender offer respect adjustment pursuant paragraph paragraph section aggregate cash distribution holder common stock day period precede expiration tender offer respect adjustment pursuant paragraph section combined tender cash exceed product current market price share common stock determine provide paragraph section time expiration time tender pursuant tender offer amend time number share common stock outstanding include tender share expiration time case immediately prior open business day date expiration time conversion rate shall adjust shall equal rate determine dividing conversion rate immediately prior close business date expiration time fraction numerator shall equal product current market price share common stock determine provide paragraph section date expiration time multiply number share common stock outstanding include tender share expiration time combine tender cash denominator shall equal product current market price share common stock determine provide paragraph section date expiration time multiply number share common stock outstanding include tender share expiration time number share validly tender withdraw expiration time share deem accept maximum refer purchase share reclassification common stock security common stock reclassification consolidation merger section apply shall deem involve distribution security common stock holder common stock effective date reclassification shall deem date fix determination stockholder entitle receive distribution date fix determination mean paragraph section subdivision combination case number share common stock outstanding immediately prior reclassification number share common stock outstanding immediately effective date reclassification shall deem day subdivision effective day combination effective case day subdivision combination effective mean paragraph section purpose computation paragraph section current market price share common stock date shall calculate company average daily closing price share consecutive trading day select company commence trading day end later early day question day date respect issuance distribution require computation purpose paragraph term date respect issuance distribution mean date common stock trade regular way applicable security market applicable security exchange right receive issuance distribution adjustment conversion rate shall require adjustment plus adjustment previously reason paragraph require increase decrease percent rate provide adjustment reason paragraph require shall carry forward take account subsequent adjustment calculation article shall near cent near onehundredth share case company increase conversion rate remain term security short term addition require paragraph section consider advisable order avoid diminish income tax holder share common stock result dividend distribution stock issuance right warrant purchase subscribe stock event treat income tax purpose company shall power resolve ambiguity correct error paragraph action shall absent manifest error final conclusive notwithstanding forego provision section adjustment conversion rate shall required issuance share common stock pursuant present future plan reinvestment dividend change par value common stock tender exchange offer character describe rule exchange act successor rule thereto extent permit applicable law company time time increase conversion rate period time period day increase irrevocable period board director shall determination increase good interest company determination shall conclusive provide increase shall take account purpose determine closing price share common stock equal exceed conversion price connection event change control pursuant section closing price share common stock exceed conversion price connection redemption security accordance provision form security set forth section hereof conversion rate increase pursuant precede sentence company shall notice increase holder manner provide section day prior date increase conversion rate take effect notice shall state increase conversion rate period effect holder security exercise right conversion date right issue company stock right agreement date october separate underlie common stock entitle receive common stock right attributable share common stock receive conversion conversion rate adjust right distribute holder common stock date separation adjustment right later redeem invalidate terminate correspond reverse adjustment conversion rate equitable basis section notice adjustment conversion rate conversion rate adjust provide company shall compute adjusted conversion rate accordance section shall prepare certificate sign principal financial officer comptroller treasurer company set forth adjust conversion rate show reasonable detail fact adjustment base certificate shall promptly file trustee conversion agent adjustment notice state conversion rate adjust set forth adjust conversion rate shall require soon practicable require notice shall provide company holder accordance section trustee conversion agent shall duty responsibility respect certificate information calculation contain exhibit holder security desiring inspection thereof office normal business hour shall deem knowledge adjustment conversion rate responsible officer trustee shall receive certificate responsible officer trustee receive certificate trustee conversion agent assume inquiry conversion rate trustee knowledge remain effect section notice certain corporate action case company shall declare dividend distribution common stock payable exclusively cash exclusively cash require adjustment pursuant section company shall authorize grant substantially holder common stock right option warrant subscribe purchase share capital stock class right reclassification common stock consolidation merger share exchange company party approval stockholder company require conveyance sale transfer lease mere grant security interest substantially asset company voluntary involuntary dissolution liquidation wind company company shall cause file office agency maintain purpose conversion security pursuant section shall cause provide holder accordance section day day case specify clause day clause prior applicable record effective date hereinafter specify notice state date record take purpose dividend distribution right option warrant record take date holder common stock record entitle dividend distribution right option warrant determine date reclassification consolidation merger conveyance transfer sale lease mere grant security interest dissolution liquidation winding expect effective date expect holder common stock record shall entitle exchange share common stock security cash property deliverable reclassification consolidation merger conveyance transfer sale lease dissolution liquidation wind failure notice notice refer follow paragraph defect shall affect legality validity proceeding describe clause section time trustee shall conversion agent copy notice shall forthwith file company trustee company shall cause file corporate trust office office agency maintain purpose conversion security pursuant section shall cause provide holder accordance section notice tender offer company subsidiary portion common stock time notice tender offer provide public generally section company reserve common stock company shall time reserve available free preemptive right authorize unissued common stock purpose effecting conversion security number share common stock issuable conversion outstanding security section taxis conversion provide sentence company pay stamp taxis duty payable respect issue delivery share common stock conversion security pursuant hereto company shall require pay tax duty payable respect income holder transfer involve issue delivery share common stock holder security security convert issue delivery shall person request issue pay company tax duty establish satisfaction company tax duty pay section covenant common stock company agree share common stock deliver conversion security delivery duly authorize validly issue fully pay nonassessable provide section company pay taxis lien charge respect issue thereof section cancellation convert security security deliver conversion shall deliver trustee agent cancel direction trustee shall dispose provide section section provision case consolidation merger sale asset case consolidation merger company person merger person company merger result reclassification conversion exchange cancellation outstanding share common stock company conveyance sale transfer lease mere grant security interest substantially asset company sale substantially asset company result reclassification conversion exchange cancellation outstanding share common stock company person form consolidation result merger acquire asset case shall execute deliver trustee supplemental indenture provide holder security outstanding shall right period security shall convertible specify section convert security kind security cash property receivable consolidation merger conveyance sale transfer lease mere grant security interest holder number share common stock company security convert immediately prior consolidation merger conveyance sale transfer lease mere grant security interest assume holder common stock company person company consolidate merge merge company conveyance sale transfer lease mere grant security interest case constituent person affiliate constituent person fail exercise right election kind security cash property receivable consolidation merger conveyance sale transfer lease mere grant security interest provide kind security cash property receivable consolidation merger conveyance sale transfer lease mere grant security interest share common stock company hold immediately prior consolidation merger conveyance sale transfer lease mere grant security interest constituent person affiliate thereof respect right election shall exercise non elect share purpose section kind security cash property receivable consolidation merger conveyance sale transfer lease mere grant security interest holder nonelecting share shall deem kind receivable share plurality nonelecting share supplemental indenture shall provide adjustment event subsequent effective date supplemental indenture shall nearly equivalent practicable adjustment provide article provision section shall similarly apply successive consolidation merger conveyance sale transfer lease mere grant security interest notice execution supplemental indenture shall give company holder security provide section promptly execution trustee conversion agent shall responsibility determine correctness provision contain supplemental indenture relate kind share stock security property cash receivable holder security conversion security consolidation merger conveyance transfer sale lease mere grant security interest adjustment accept conclusive evidence correctness provision shall protect rely officer certificate opinion counsel respect thereto company shall cause furnish trustee request section right issue respect common stock right warrant distribute company holder common stock entitling holder thereof subscribe purchase share companys capital stock initially certain circumstance right warrant occurrence specify event event trigger event deem transfer share common stock exercisable iii issue respect future issuance common stock shall deem distribute purpose section occurrence early trigger event addition event distribution right warrant trigger event respect thereto shall result adjustment conversion rate section case right warrant shall redeem repurchase exercise holder thereof conversion rate shall readjust final redemption repurchase effect distribution trigger event case cash distribution equal share redemption repurchase price receive holder common stock respect right warrant assume holder retain right warrant holder common stock date redemption repurchase case right warrant shall expire exercise holder thereof conversion price shall readjust issuance occur section responsibility trustee conversion provision trustee subject provision section conversion agent shall time duty responsibility holder security determine fact exist require adjustment conversion rate respect nature extent adjustment respect method employ supplemental indenture provide employ make supplemental indenture need enter trustee subject provision section conversion agent shall accountable respect validity value kind common stock security property cash time issue deliver conversion security representation respect thereto trustee subject provision section conversion agent shall responsible failure company calculate cash payment issue transfer deliver share common stock share certificate security property cash surrender security purpose conversion trustee subject provision section conversion agent shall responsible failure company comply covenant company contain article article xiii repurchase security option holder change control section right require repurchase event change control hereinafter define shall occur holder shall right holder option subject provision section require company repurchase exercise right company shall repurchase holder security theretofore call redemption portion principal thereof equal integral multiple excess thereof provide single security repurchase portion principal security outstanding repurchase equal integral multiple excess thereof date repurchase date day date company notice define section purchase price equal principal security repurchase plus interest accrue unpaid exclude repurchase date repurchase price provide installment interest security state maturity prior repurchase date shall payable holder security predecessor security register relevant record date accord term provision section right require repurchase security shall continue discharge company obligation respect security accordance article change control shall occur prior discharge option company repurchase price pay cash subject fulfillment company condition set forth section delivery share common stock fair market value equal repurchase price cash payment combination cash common stock indenture include section reference context principal security time reference shall deem include reference repurchase price payable respect security extent repurchase price payable time express mention repurchase price provision indenture shall construe exclude repurchase price provision indenture express mention section condition company election pay repurchase price common stock company option pay repurchase price cash common stock combination thereof extent repurchase price pay common stock company elect pay delivery share common stock pursuant section follow condition shall satisfied share common stock deliverable payment repurchase price cash payment shall fair market value repurchase date repurchase price cash payment purpose section section fair market value share common stock shall determine company shall equal average closing price share common stock consecutive trading day end trading day prior repurchase date repurchase price shall pay cash event share common stock issue repurchase security hereunder require registration federal security law share freely transferable subject transfer restriction security act repurchase registration complete effective prior repurchase date andor require registration approval governmental authority state law federal law share validly issue deliver repurchase registration complete effective approval obtain prior repurchase date payment repurchase price common stock stock shall list national security exchange approve quotation nasdaq national market case prior repurchase date share common stock issue repurchase security issue company authorize unissued common stock issue duly validly issue fully pay nonassessable free preemptive similar right condition set forth section satisfied accordance term thereof repurchase price shall pay company cash section notice method exercise repurchase right etc company shall theretofore call redemption outstanding security day occurrence change control company request expense company day occurrence trustee shall holder security manner provide section notice company notice occurrence change control repurchase right set forth arise result thereof company shall deliver copy company notice trustee company notice shall state repurchase date date repurchase right exercise iii repurchase price repurchase price shall pay company cash delivery share common stock combination thereof applicable ratio cash common stock description procedure holder follow exercise repurchase right place place security surrender payment repurchase price accrue interest include liquidate damage repurchase date repurchase date repurchase price accrue interest include liquidate damage repurchase date payable security designate holder repurchase interest thereon shall cease accrue say date conversion rate effect date right convert principal security repurchase terminate place place security surrender conversion vii place place security certificate election holder require repurchase specify section shall deliver security restrict security certificate place place surrender certificate require section shall deliver failure company forego notice defect shall limit holder right exercise repurchase right affect validity proceeding repurchase security forego provision provision article xiii inconsistent applicable law law shall govern exercise repurchase right holder shall deliver trustee day date company notice irrevocable write notice holder exercise right notice shall set forth holder principal security repurchase security repurchase serial number thereof portion principal thereof repurchase person portion thereof remain outstanding repurchase register statement election exercise repurchase right event portion repurchase price shall pay share common stock name address certificate certificate share common stock shall issue security respect repurchase right exercise write notice shall irrevocable right holder convert security respect repurchase right exercise shall continue close business second business day repurchase date event repurchase right shall exercise accordance term hereof company shall pay cause pay trustee repurchase price cash share common stock combination thereof provide payment holder repurchase date accrue unpaid interest repurchase date payable respect security repurchase right exercise provide installment interest mature prior repurchase date shall payable cash holder security predecessor security register close business relevant regular record date security portion thereof surrender repurchase shall pay repurchase date principal security portion thereof case shall pay bear interest extent permit applicable law repurchase date rate annum security shall remain convertible common stock principal security portion thereof case shall paid duly provide security repurchase shall surrender trustee company trustee require endorsement write instrument transfer form satisfactory company trustee duly execute holder thereof attorney duly authorize write company shall execute trustee shall authenticate available delivery holder security service charge new security security contain identical term condition authorize denomination aggregate principal equal exchange unrepurchased portion principal security surrender issuance share common stock respect portion repurchase price shall deemed effect immediately prior close business repurchase date person person name certificate certificate share common stock shall issuable repurchase shall deem repurchase date holder holder record share represent provide surrender repurchase date stock transfer book company shall close shall constitute person person name certificate certificate share issue record holder holder thereof purpose open business succeed day stock transfer book open payment adjustment shall dividend distribution common stock issue repurchase security declare prior repurchase date fraction share shall issue repurchase security security shall repurchase holder portion repurchase price shall payable share common stock number share shall issuable repurchase shall compute basis aggregate principal security repurchase instead fractional share common stock issuable repurchase security security company deliver applicable holder check current market value fractional share current market value fraction share determine multiply current market price share fraction rounding result nearest cent purpose section current market price share common stock closing price share common stock trading day immediately precede repurchase date issuance delivery certificate share common stock repurchase security shall charge holder security repurchase certificate tax duty respect issuance delivery certificate security represent provide company shall require pay tax duty payable respect income holder transfer involve issuance delivery certificate share common stock holder security repurchase issuance delivery shall person request issuance delivery pay company tax duty establish satisfaction company tax duty pay share common stock deliver repurchase security register beneficial owner security holder deliver trustee surrender certificate date date surrender restrict security sign beneficial owner compliance restriction transfer applicable restricted security trustee registrar transfer agent agent shall require register beneficial owner share common stock issue repurchase restrict security accompany properly complete surrender certificate security deliver repurchase shall deliver trustee cancel direction trustee shall dispose provide section section certain definition purpose article xiii term beneficial owner shall determine accordance rule effect date original execution indenture promulgate commission pursuant exchange act change control shall deem occur time original issuance security acquisition person include syndicate group deem person section exchange act beneficial ownership directly indirectly purchase merger acquisition transaction series transaction share capital stock company entitle person exercise total voting power share capital stock company entitle vote generally election director acquisition company subsidiary company employee benefit plan company consolidation company merger company person merger person company conveyance sale transfer lease mere grant security interest substantially asset company person transaction result reclassification conversion exchange cancellation outstanding share capital stock company pursuant holder total voting power share company capital stock entitle vote generally election director immediately prior transaction entitlement exercise directly indirectly total voting power share capital stock entitle vote generally election director continue survive corporation immediately transaction transaction effect solely change jurisdiction incorporation company result reclassification conversion exchange outstanding share common stock solely share common stock surviving entity iii provide change control shall deem occur closing price share common stock trading day period consecutive trading day end immediately later date change control date public announcement change control case change control clause period consecutive trading day end immediately change control case change control clause shall case trading day equal exceed conversion price security effect trading day consideration exclude cash payment fractional share cash payment pursuant dissenter appraisal right merger consolidation constitute change control clause andor clause consist share common stock depository receipt certificate represent common equity interest trade national security exchange quote nasdaq national market trade quote immediately follow merger consolidation result merger consolidation security convertible solely common stock depository receipt certificate represent common equity interest term conversion price shall equal divide conversion rate round near cent purpose section term person shall include syndicate group deemed person section exchange act effect date original execution indenture section consolidation merger etc case merger consolidation conveyance sale transfer lease mere grant security interest substantially asset company section apply common stock company change exchange result right receive share stock security property asset include cash include share common stock company common stock person issuance trade united states national securities exchange approve trading establish automate overthecounter trading market united states share constitute time change exchange effective excess aggregate fair market value share stock security property asset include cash determine company determination shall conclusive bind person form consolidation result merger combination acquire property asset include cash company case shall execute deliver trustee supplemental indenture shall comply trust indenture act force date execution supplemental indenture modify provision indenture relate right holder cause company repurchase security follow change control include limitation applicable provision article xiii definition common stock change control appropriate relate definition set forth determine good faith company determination shall conclusive bind provision apply event subsequent change control common stock issuer thereof different company common stock company lieu company common stock company article xiv holder list report trustee company nonrecourse section company furnish trustee name address holder company furnish cause furnish trustee semiannually day regular record date list form trustee reasonably require name address holder security regular record date time trustee reasonably request write day receipt company request list similar form content date day prior time list furnish provide list need furnish long trustee act security registrar section preservation information trustee shall preserve current form reasonably practicable name address holder contain recent list furnish trustee provide section name address holder receive trustee capacity security registrar trustee destroy list furnish provide section receipt new list furnish indenture qualified trust indenture act right holder communicate holder respect right indenture security correspond right duty trustee shall provide trust indenture act holder security receive holding agree company trustee company trustee agent shall hold accountable reason disclosure information name address holder pursuant trust indenture act section report trustee indenture qualified trust indenture act trustee shall transmit holder report concern trustee action indenture require pursuant trust indenture act times manner provide pursuant thereto indenture qualified trust indenture act copy report shall time transmission holder file trustee stock exchange security list commission company company notify trustee security list stock exchange section report company indenture qualified trust indenture act company shall file trustee commission transmit holder information document report summary thereof require pursuant trust indenture act times manner provide pursuant act provide information document report require file commission pursuant section security exchange act shall file trustee day require file commission article immunity incorporator stockholder officer director section indenture security solely corporate obligation recourse payment principal premium interest include liquidate damage security recourse obligation covenant agreement company indenture supplemental indenture security creation indebtedness represent shall past present future incorporator stockholder employee agent officer director subsidiary company successor corporation virtue constitution statute rule law enforcement assessment penalty expressly understand liability waive release condition consideration execution indenture issue security indenture execute number counterpart execute shall deem original counterpart shall constitute instrument witness whereof party hereto cause indenture duly execute day year write gilead sciences inc john milligan john milligan title cfo morgan trust company national association trustee james nagy james nagy title assistant vice president annex form unrestricted security certificate unrestricted security certificate removal restrict security legend pursuant section morgan trust company national association mission street floor san francisco california jpmorgan institutional trust service window new york plaza ground floor new york new york convertible senior note december gilead sciences inc security reference indenture date december indenture gilead sciences inc company morgan trust company national association trustee term define indenture rule securities act securities act define certificate relate principal security evidence follow certificate specify security cusip certificate nos person certificate execute undersigned certifie sole beneficial owner specify securities act behalf beneficial owner specify security duly authorize beneficial owner owner refer collectively owner specify security represent global security hold depositary agent member undersigned behalf owner specify security represent global security register undersigned behalf owner owner request specify security exchange security bear restrict security legend pursuant section indenture connection exchange owner certifies exchange occur period year elapse issue date owner precede month affiliate company owner acknowledge future transfer specify security comply applicable security law state united states jurisdictionsthis certificate statement contain benefit benefit company initial purchaser date print undersigned term define paragraph certificate title undersigned corporation partnership fiduciary title person sign behalf undersigned state annex form surrender certificate connection certification contemplate section relate compliance certain restriction relate transfer restrict security certification shall provide substantially form follow certificate change thereto shall approve company goldman sach certificate gilead sciences inc convertible senior note december certify date hereof respect principal abovecaptione security surrender date hereof surrender security registration transfer conversion repurchase security issuable conversion repurchase register undersigned holder transaction transfer undersigned holder define indenture certifie transfer surrender security associate transfer complie restrictive legend set forth face surrender security reason check transfer surrender securities complies rule securities act transfer surrender securities complies rule united states securities act amend securities act transfer surrender security institution accredit investor mean rule security act transaction exempt registration requirement securities act sign letter contain certain representation agreement relate restriction transfer security deliver transfer aggregate principal opinion counsel acceptable company request company transfer exempt registration transfer surrender security pursuant exemption registration securities act opinion counsel deliver company respect transfer holder date date date surrenderexhibit gilead sciences inc convertible senior note december registration right agreement december goldman sachs broad street new york new york lady gentlemen gilead sciences inc delaware corporation company propose issue sell purchaser define term set forth purchase agreement define rein convertible senior note december security inducement purchaser enter purchase agreement satisfaction condition obligation purchaser thereunder company agree purchaser benefit holder define time time registrable security define follow definition capitalize term definition shall meaning ascribe purchase agreement agreement agreement follow define term shall follow meaning act securities act mean united states securities act amend affiliate specify person mean person directly indirectly control control common control specify person purpose definition control person mean power direct indirect direct cause direction management policy person contract term control control meaning correlative forego closing date mean time delivery define purchase agreement commission mean united states securities exchange commission federal agency time administer exchange act securities act whichever relevant statute particular purpose common stock mean company common stock par value share associate prefer stock purchase right dtc mean depository trust company effective date mean assign thereto section hereof effective failure mean assign thereto section hereof effectiveness period mean assign thereto section hereof effective time mean time commission declare shelf registration statement effective shelf registration statement effective elect holder mean assign thereto section aiii hereof exchange act mean united states securities exchange act amend holder mean person record owner registrable security include person beneficial interest registrable security bookentry form indenture mean indenture date december company morgan trust company national association amend supplement time time accordance term liquidate damage mean assign thereto section hereof manage underwriter mean investment banker investment banker manager manager shall administer underwritten offering conduct pursuant section hereof nasd rule mean rule national association securities dealers inc amend time time notice questionnaire mean notice registration statement sell securityholder questionnaire substantially form appendix hereto term person mean individual partnership corporation trust unincorporated organization government agency political subdivision thereof prospectus mean prospectus include limitation preliminary prospectus final prospectus prospectus disclose information previously omit prospectus file effective registration statement reliance rule act include shelf registration statement amend supplement prospectus supplement respect term offer portion registrable security cover shelf registration statement amendment supplement prospectus include material incorporate reference prospectus document file date prospectus company exchange act incorporate reference purchase agreement mean purchase agreement date december purchaser company relate security purchaser mean goldman sach registrable security mean portion security issue time time indenture register form share common stock issuable conversion repurchase redemption security provide security cease registrable security long restrict security registration default mean assign thereto section hereof restrict security mean security share common stock issuable conversion thereof security share common stock effectively register security act sell manner contemplate shelf registration statement transfer compliance rule securities act successor provision thereto transferable pursuant paragraph rule successor provision thereto iii transfer new security share common stock subject transfer restriction security act deliver behalf company accordance section indenture rule regulation mean publish rule regulations commission promulgate securities act exchange act effect relevant time shelf registration mean registration effect pursuant section hereof shelf registration statement mean shelf registration statement file security act provide registration sale continuous delay basis holder registrable security pursuant rule securities act andor similar rule adopt commission file company pursuant provision section agreement include prospectus contain amendment supplement registration statement include post effective amendment exhibit material incorporate reference registration statement trust indenture act mean trust indenture act successor thereto rule regulation form promulgate thereunder shall amend time time term underwriter mean underwriter registrable security connection offer thereof shelf registration statement reference agreement percentage principal registrable security percentage registrable security common stock shall treat represent principal security surrender conversion exchange order receive number share common stock shelf registration company shall later calendar day follow closing date file commission shelf registration statement relate offer sale registrable security holder time time accordance method distribution elect holder set forth shelf registration statement shall use reasonable good effort cause shelf registration statement declare effective act later calendar day follow closing date provide company write notice holder postpone shelf registration statement declare effective reasonable period exceed day company possess material nonpublic information disclosure material adverse effect company subsidiary take provide holder shall entitle name sell securityholder shelf registration statement use prospectus form thereof resale registrable security holder elect holder company shall use reasonable good effort shelf registration statement continuously effective order permit prospectus form thereof usable holder earliest sale registrable security register shelf registration statement expiration period refer rule act respect registrable security hold person affiliate company year date effective date shelf registration statement declare effective period refer effectiveness period effective time shelf registration statement promptly practicable request holder registrable security elect holder action reasonably necessary enable holder use prospectus form thereof offer resale registrable security include limitation action necessary identify holder sell securityholder shelf registration statement provide subparagraph shall relieve holder obligation return complete sign notice questionnaire company accordance section aii hereof iii time security pursuant article indenture convertible security common stock cause cause successor indenture cause security include shelf registration statement later date security convertible security company shall deem reasonable good effort shelf registration statement effective period specify section company voluntarily take action result holder registrable security cover able offer sell registrable security period action require applicable law company promptly complie requirement paragraph permit pursuant section company suspend use prospectus period exceed day day period aggregate day month period board director company shall determine good faith valid business reason include avoidance company obligation hereunder include acquisition divestiture asset pende corporate development similar event good interest company suspend use prior suspending use company provide holder write notice suspension notice need specify nature event give rise suspension registration procedure connection shelf registration statement follow provision shall apply calendar day prior effective time shelf registration statement company shall mail notice questionnaire holder registrable security holder shall entitle name sell securityholder shelf registration statement effective time holder shall entitle use prospectus form thereof offer resale registrable security time holder return complete sign notice questionnaire company deadline response set forth provide holder registrable security shall calendar day date notice questionnaire mail holder return complete sign notice questionnaire company effective time shelf registration statement company shall request holder registrable security elect holder promptly send notice questionnaire holder company shall require action holder sell securityholder shelf registration statement enable holder use prospectus form thereof offer resale registrable security holder return complete sign notice questionnaire company iii term elect holder shall mean holder registrable security return complete sign notice questionnaire company accordance section aii hereof company shall furnish elect holder prior effective time copy shelf registration statement initially file commission shall furnish holder prior file thereof commission copy amendment thereto amendment supplement prospectus include shall use reasonable good effort reflect document effective time file commission case comment holder counsel holder reasonably propose subject company right section company shall promptly practicable action necessary shelf registration statement amendment thereto prospectus form thereof amendment supplement thereto report document incorporate reference case complie material respect securities act exchange act respective rule regulations thereunder shelf registration statement amendment thereto effective contain untrue statement material fact omit state material fact require state necessary statement mislead iii prospectus form shelf registration statement supplement applicable time effectiveness period include untrue statement material fact omit state material fact necessary order statement light circumstance misleading company shall promptly practicable advise elect holder shall confirm advice writing request elect holder shelf registration statement amendment thereto file commission shelf registration statement posteffective amendment thereto effective case make public announcement thereof release reuter economic service bloomberg business news request commission amendment shelf registration statement supplement prospectus include additional information iii issuance commission stop order suspend effectiveness shelf registration statement initiation proceeding purpose receipt company notification respect suspension qualification security include shelf registration statement sale jurisdiction initiation proceeding purpose happen event existence state fact require make change shelf registration statement prospectus include date shelf registration statement prospectus contain untrue statement material fact omit state material fact require state necessary statement case prospectus light circumstance misleading advice shall accompany instruction holder suspend use prospectus requisite change company shall use reasonable good effort prevent issuance issue obtain withdrawal early possible time order suspend effectiveness shelf registration statement company shall furnish elect holder charge copy shelf registration statement posteffective amendment thereto include financial statement schedule elect holder request write report document exhibit file incorporate reference shelf registration statement company shall effectiveness period deliver elect holder charge copy prospectus include preliminary prospectus include shelf registration statement supplement thereto electing holder reasonably request company consent period specify section continuance event describe section use prospectus supplement thereto elect holder connection offer sale registrable security cover prospectus supplement thereto effectiveness period prior offer registrable security pursuant shelf registration statement company shall register qualify cooperate elect holder respective counsel connection registration qualification registrable security offer sale security blue sky law jurisdiction united states elect holder reasonably request registration qualification effect comply law permit continuance offer sale jurisdiction long necessary enable elect holder underwriter complete distribution registrable security pursuant shelf registration statement iii action necessary advisable enable disposition jurisdiction registrable security provide event shall company obligate qualify foreign corporation dealer security jurisdiction require qualify section file general consent service process jurisdiction date hereof subject registrable security shall bookentry form company shall cooperate elect holder facilitate timely preparation delivery certificate represent registrable security sell pursuant shelf registration statement certificate require security exchange registrable security list shall pen lithographed engrave produce combination method steel engrave border certificate shall free restrictive legend permit denomination register name elect holder request connection sale registrable security pursuant shelf registration statement subject company exercise right section occurrence fact event contemplate paragraph company shall promptly practicable prepare posteffective amendment shelf registration statement supplement relate prospectus file require document deliver purchaser registrable security include prospectus include untrue statement material fact omit state material fact necessary statement light circumstance mislead company notifie elect holder occurrence fact event contemplate paragraph elect holder shall suspend use prospectus requisite change prospectus later effective time shelf registration statement company shall provide cusip number registrable security debt security company shall use reasonable good effort comply applicable rule regulation generally available securityholder soon practicable event later eighteen month effective date define rule securities act shelf registration statement effective date posteffective amendment shelf registration statement iii date filing company commission annual report incorporate reference shelf registration statement earn statement company subsidiary comply section security act rule regulations commission thereunder include option company rule later effective time shelf registration statement company shall cause indenture qualified trust indenture act connection qualification company shall cooperate trustee indenture holder define indenture effect change indenture require indenture qualified accordance term trust indenture act company shall execute shall use reasonable effort cause trustee execute document require effect change form document require file commission enable indenture qualified timely manner event amendment modification refer section involve appointment new trustee indenture company shall appoint new trustee thereunder pursuant applicable provision indenture event underwritten offering conduct pursuant section hereof company shall requested promptly include incorporate prospectus supplement posteffective amendment shelf registration statement information manage underwriter reasonably agree include company reasonably object shall required filing prospectus supplement posteffective amendment soon practicable notify matter include incorporate prospectus supplement posteffective amendment company shall enter customary agreement include underwriting agreement customary form event underwritten offering conduct pursuant section hereof appropriate action order expedite facilitate registration disposition registrable security connection therewith underwriting agreement enter cause contain indemnification provision procedure substantially identical substance set forth section hereof respect party indemnify pursuant section hereof company shall available inspection elect holder underwriter participate disposition pursuant shelf registration statement attorney accountant agent retain elect holder underwriter collectively inspector office normally keep reasonable business hour time time shall mutually convenient company inspector group financial record pertinent corporate document instrument company subsidiary collectively record shall reasonably necessary enable exercise applicable diligence responsibility cause officer director employee company subsidiary supply information reasonably request inspector connection shelf registration statement record company determine good faith confidential record notifie inspector confidential shall disclose inspector disclosure record necessary avoid correct material misstatement material omission shelf registration statement release record order pursuant subpoena order court competent jurisdiction disclosure information court proceeding require law information record generally available public act inspector result breach agreement provide prior notice shall provide soon practicable company potential disclosure information inspector pursuant clause sentence permit company obtain protective order waive provision paragraph inspector shall action reasonably necessary protect confidentiality information practicable extent action inconsistent impairment derogation right interest elect holder inspector provide prior disclosure inspector record company determine good faith confidential company require inspector execute confidentiality agreement inspector shall agree limitation disclosure record extent provide connection underwritten offering conduct pursuant section hereof representation warranty manage underwriter form substance scope customarily issuer underwriter primary underwritten offering equity convertible debt security cover matter include limited set forth purchase agreement iii connection underwritten offering conduct pursuant section hereof obtain opinion counsel company counsel opinion form scope substance shall reasonably satisfactory manage underwriter address underwriter cover matter customarily cover opinion request primary underwritten offering equity convertible debt securitiesin addition counsel company shall provide letter underwriter state come counsel attention time delivery effective time shelf registration statement recent posteffective amendment thereto case shelf registration statement include document incorporate reference contain untrue statement material fact omission material fact require state necessary statement misleading prospectus include document incorporate reference contain untrue statement material fact omission material fact require state necessary statement light circumstance mislead connection underwritten offering conduct pursuant section hereof obtain cold comfort letter update thereof independent public accountant company necessary independent public accountant subsidiary company business acquire company financial statement financial datum require include shelf registration statement address underwriter customary form cover matter type customarily cover cold comfort letter connection primary underwritten offering connection underwritten offering conduct pursuant section hereof deliver document certificate reasonably request manage underwriter include limitation certificate evidence compliance section hereof condition contain underwriting agreement agreement enter company company use good effort cause common stock issuable conversion security list quotation nasdaq national market system stock exchange trading system common stock primarily trade prior effective time shelf registration statement hereunder company shall use reasonable good effort step necessary effect registration offering sale registrable security cover shelf registration statement contemplate registration expense provide section company shall bear fee expense incur connection performance obligation section hereof shall bear reimburse elect holder reasonable fee disbursement single counsel select plurality elect holder aggregate registrable security cover shelf registration statement act counsel therefor connection therewith counsel holder elect holder shall pay underwriting discount commission transfer taxis relate sale disposition elect holder registrable security pursuant shelf registration statement indemnification contribution indemnification company registration registrable security pursuant section hereof company shall indemnify hold harmless electing holder underwriter sell agent security professional facilitate disposition registrable security respective officer director person control elect holder underwriter sell agent security professional meaning section security act section exchange act person refer indemnified person loss claim damage liability joint indemnified person subject security act insofar loss claim damage liability action respect thereof arise base untrue statement allege untrue statement material fact contain shelf registration statement registrable security register securities act prospectus contain furnish company indemnify person amendment supplement thereto arise base omission allege omission state material fact require state necessary statement mislead company agree reimburse indemnify person legal expense reasonably incur connection investigate defend action claim expense incur provide company shall liable indemnified person case extent loss claim damage liability arise base untrue statement allege untrue statement omission allege omission shelf registration statement prospectus amendment supplement reliance conformity write information furnish company indemnify person expressly use provide company shall liable indemnify person indemnity agreement subsection respect preliminary prospectus extent loss claim damage liability indemnify person result fact indemnify person sell registrable security person shall establish send give prior write confirmation sale copy final prospectus exclude document incorporate reference case delivery require securities act company previously furnish copy thereof sufficient quantity timely basis indemnify party loss claim damage liability indemnify person result untrue statement allege untrue statement material fact omission allege omission material fact contain preliminary prospectus identify writing include email prior time delivery final prospectus indemnify party correct final prospectus provide company shall liable indemnify person indemnity agreement subsection extent shall establish loss claim damage liability indemnify person result fact indemnify person sell registrable security indemnify person receive write notice company use prospectus suspend provide section hereof loss claim damage liability directly cause event existence state fact give rise suspension indemnification elect holder agent underwriter elect holder agree consequence inclusion elect holder registrable security shelf registration statement underwriter sell agent security professional facilitate disposition registrable security shall agree consequence facilitate disposition registrable security severally jointly indemnify hold harmless company director officer sign shelf registration statement person control company mean section securities act section exchange act loss claim damage liability company person subject security act insofar loss claim damage liability action respect thereof arise base untrue statement allege untrue statement material fact contain shelf registration statement prospectus amendment supplement arise base omission allege omission state material fact require state necessary statement misleading case extent extent untrue statement allege untrue statement omission allege omission reliance conformity write information furnish company elect holder underwriter sell agent security professional expressly use reimburse company legal expense reasonably incur company connection investigate defend action claim expense incur notice claim etc promptly receipt indemnify party subsection notice commencement action indemnify party shall claim respect thereof indemnify party section notify indemnify party writing commencement thereof omission notify indemnify party shall relieve liability indemnify party indemnification provision contemplate subsection case action shall bring indemnified party shall notify indemnify party commencement thereof indemnify party shall entitle participate extent shall wish jointly indemnify party similarly notify assume defense thereof counsel satisfactory indemnify party shall consent indemnify party counsel indemnify party notice indemnify party indemnify party election assume defense thereof indemnify party shall liable indemnify party section legal expense counsel expense case subsequently incur indemnified party connection defense thereof reasonable cost investigation indemnify party shall write consent indemnify party effect settlement compromise consent entry judgment respect pende threatened action claim respect indemnification contribution seek hereunder indemnify party actual potential party action claim settlement compromise judgment include unconditional release indemnify party liability arise action claim include statement admission fault culpability failure act behalf indemnify party contribution indemnification provide section unavailable insufficient hold harmless indemnify party subsection respect loss claim damage liability action respect thereof refer indemnify party shall contribute pay payable indemnified party result loss claim damage liability action respect thereof proportion appropriate reflect relative fault indemnify party indemnify party connection statement omission result loss claim damage liability action respect thereof relevant equitable consideration relative fault indemnify party indemnify party shall determine reference thing untrue allege untrue statement material fact omission allege omission state material fact relate information supply indemnify party indemnify party party relative intent knowledge access information opportunity correct prevent statement omission party hereto agree equitable contribution pursuant section determine pro rata allocation elect holder underwriter sell agent security professional treat entity purpose method allocation account equitable consideration refer section pay payable indemnified party result loss claim damage liability action respect thereof refer shall deem include legal fee expense reasonably incur indemnify party connection investigate defend action claim person guilty fraudulent misrepresentation meaning section securities act shall entitle contribution person guilty fraudulent misrepresentation obligation elect holder underwriter sell agent security professional section contribute shall proportion percentage principal registrable security register underwritten case joint notwithstanding provision section event elect holder require undertake liability person section amount excess dollar proceed receive holder sale holder registrable security deduct fee discount commission applicable thereto pursuant shelf registration statement registrable security register securities act underwriter sell agent security professional require undertake liability person hereunder amount excess discount commission compensation payable underwriter sell agent security professional respect registrable security underwrite distribute public obligation company section shall addition liability company indemnify person obligation indemnify person section shall addition liability indemnify person company remedy provide section exclusive shall limit right remedy available indemnify party law equity underwritten offering holder registrable security desire sell registrable security underwritten offering provide elect holder aggregate principal registrable security cover shelf registration statement shall request offer aggregate principal registrable security shall include offering provide company shall obligate cooperate underwritten offering effectiveness period receipt request company shall provide holder registrable security write notice request notice shall inform holder opportunity participate offer underwritten offer investment banker banker manager manager administer offering select underwriting arrangement respect thereto include size offer approve holder majority registrable security include offering provide investment banker manager underwriting arrangement reasonably satisfactory company holder participate underwritten offering contemplate holder agree sell holder registrable security include underwritten offering accordance approve underwriting arrangement holder complete execute reasonable questionnaire power attorney indemnity underwrite agreement lockup letter document require term approve underwriting arrangement holder elect holder holder return complete sign notice questionnaire company accordance section aii hereof reasonable time underwrite offer holder participate underwritten offering shall responsible underwriting discount commission fee subject section hereof expense counsel company shall pay expense customarily borne issuer underwritten offering include limited filing fee fee disbursement counsel independent public accountant printing expense incur connection underwritten offering notwithstanding forego provision section hereof receipt request manage underwriter representative holder majority registrable security include underwritten offering prepare file amendment supplement shelf registration statement prospectus connection underwritten offering company delay filing amendment supplement day board director company shall determine good faith company bona fide business reason delay liquidate damage pursuant section hereof company write notice holder postpone shelf registration statement declare effective reasonable period exceed day company possess material nonpublic information disclosure material adverse effect company subsidiary take notwithstanding postponement prior day follow closing date shelf registration statement file commission prior day follow closing date shelf registration statement declare effective commission registration default company shall require pay liquidate damage liquidate damage include day follow registration default shelf registration statement file file subsequently declare effective applicable rate annum equal additional onequarter percent principal registrable security include day follow registration default onehalf percent thereof day follow registration default event shelf registration statement cease effective holder registrable security prevent restrict company effecting sale pursuant thereto effective failure day consecutive day period day consecutive month period company shall pay liquidate damage rate annum equal additional onehalf percent principal registrable security day effective failure occur day period day effective failure occur month period case early time shelf registration statement effective holder registrable security able sale shelf registration statement time effectiveness period expire purpose determine effective failure day company obligate pay liquidate damage accordance forego respect prior effective failure applicable day month period case shall include event company fail file posteffective amendment shelf registration statement posteffective amendment declare effective period require section company shall pay liquidate damage rate annum equal additional onehalf percent principal registrable security include date registration default time registration default cure amount pay liquidate damage pursuant paragraph section shall pay semi annually arrear semiannual payment interest payment date define indenture applicable follow case say paragraph date registration default case say paragraph day effective failure occur day period day effective failure occur month period case liquidate damage accrue respect security rate set forth paragraph section applicable principal security respect common stock issue conversion security rate set forth paragraph section applicable applied conversion price define indenture time provide section hereof liquidate damage set forth section shall exclusive monetary remedy available holder registrable security registration default effective failure event shall company require pay liquidate damage excess applicable maximum onehalf percent set forth regardless multiple registration default exist holder shall entitle liquidate damage hereunder holder comply obligation furnish information document require agreement miscellaneous registration right company grant registration right permit person party right piggyback shelf registration statement provide manage underwriter underwritten offering conduct pursuant section hereof notifie company elect holder total security elect holder holder piggyback right intend include shelf registration statement large materially threaten success offering include price security sell subject right exist date hereof number kind security offer account holder piggyback right reduce extent necessary reduce total security include offer number kind recommend manage underwriter prior reduction registrable security include shelf registration statement specific performance party hereto acknowledge adequate remedy law company fail perform obligation hereunder purchaser holder time time irreparably harm failure accordingly agree purchaser holder addition remedy entitle law equity limit remedy available elect holder section hereof shall entitle compel specific performance obligation company registration right agreement accordance term condition registration right agreement court united states state thereof jurisdiction amendments waiver agreement include section amend waiver consent departure provision hereof give write instrument duly execute company holder majority aggregate principal registrable security outstanding holder registrable security outstanding time amendment waiver consent shall bind amendment waiver consent effect pursuant section notice write mark indicate amendment waiver consent appear registrable security deliver holder notice notice communication provide permit hereunder shall give provide indenture party interest party agreement intend holder registrable security shall entitle receive benefit agreement elect holder shall bind term provision agreement reason election respect registrable security include shelf registration statement term provision agreement shall bind shall inure benefit shall enforceable respective successor assign party hereto holder time time registrable security aforesaid extent event transferee holder registrable security shall acquire registrable security manner gift bequest purchase operation law transferee shall write action kind entitle receive benefit elect holder conclusively deem agree bind perform term provision agreement aforesaid extent counterpart agreement execute number counterpart party hereto separate counterpart execute shall deem original take shall constitute agreement heading heading agreement convenience reference shall limit affect mean hereof govern law agreement shall govern construe accordance law state new york severability event provision contain application thereof circumstance hold invalid illegal unenforceable respect reason validity legality enforceability provision respect remain provision hereof shall way impair affect intend right privilege party hereto shall enforceable full extent permit law survival respective indemnity agreement representation warranty provision set forth agreement pursuant hereto shall remain force effect regardless investigation statement result thereof behalf elect holder director officer partner holder agent underwriter director officer partner agent underwriter control person forego shall survive transfer registration registrable security holder confirm forego correctly set forth agreement company truly gilead sciences inc john milligan phd john milligan title senior vice president chief financial officer accept date hereof goldman sachs goldman sachs goldman sachs appendix gilead sciences inc instruction dtc participant urgent immediate attention request deadline response depository trust company dtc identify dtc participant beneficial interest gilead sciences inc company convertible senior note december security hold company process register security securities act resale beneficial owner thereof order security include registration statement beneficial owner complete return enclose notice registration statement sell securityholder questionnaire important beneficial owner security receive copy enclose material soon possible right security include registration statement depend return notice questionnaire forward copy enclose document beneficial owner hold interest security require copy enclose material question pertain matter contact gregg alton gilead sciences inc lakeside drive foster city california gilead sciences inc notice registration statement sell securityholder questionnaire gilead sciences inc company file united states securities exchange commission commission registration statement form shelf registration statement registration resale rule united states securities act amend securities act company convertible senior note december security share common stock par value share common stock issuable conversion thereof accordance registration right agreement date date original issuance security registration right agreement company purchaser name copy registration right agreement attach hereto capitalize term define shall meaning ascribe thereto registration right agreement order registrable security include shelf registration statement supplement amendment thereto notice registration statement sell securityholder questionnaire notice questionnaire complete execute deliver company address set forth receipt beneficial owner registrable security complete execute return notice questionnaire date name sell securityholder shelf registration statement use prospectus form thereof resale registrable security certain legal consequence arise name sell securityholder shelf registration statement relate prospectus accordingly holder beneficial owner registrable security advise consult security law counsel consequence name name sell securityholder shelf registration statement relate prospectusthe term registrable security define registration right agreement mean portion security issue time time indenture register form share common stock issuable conversion security provide security cease registrable security long restrict security term restrict security define registration right agreement mean security share common stock issuable conversion thereof security share common stock effectively register security act sell manner contemplate shelf registration statement transfer compliance rule securities act successor provision thereto transferable pursuant paragraph rule successor provision thereto iii transfer new security share common stock subject transfer restriction security act deliver behalf company accordance indenture election undersigned holder sell securityholder registrable security elect include shelf registration statement registrable security beneficially own list item undersigned signing return notice questionnaire agree bind respect registrable security term condition notice questionnaire registration right agreement include limitation section registration right agreement undersigned selling securityholder original party thereto sale registrable security pursuant shelf registration statement selling securityholder require deliver company trustee notice transfer complete sign set forth exhibit notice questionnaire selling securityholder provide follow information company represent warrant information accurate complete questionnaire legal selling securityholder legal register holder registrable security list item legal dtc participant applicable registrable security list item hold address notice sell securityholder telephone fax contact person beneficial ownership security set forth item undersigned selling securityholder beneficially security share common stock issue conversion repurchase redemption security rincipal registrable security define registration right agreement beneficially own cusip nos registrable security number share common stock issue conversion repurchase redemption registrable security principal security registrable security beneficially own cusip nos security number share common stock issue conversion security principal registrable security undersign wish include shelf registration statement cusip nos registrable security include shelf registration statement number share common stock issue conversion registrable security include shelf registration statement beneficial ownership security company set forth item undersigned selling securityholder beneficial register owner share common stock security company security share common stock list item state exception relationship company set forth sell securityholder affiliate officer director principal equity holder hold position office material relationship company predecessor affiliate past year state exception plan distribution set forth undersigned selling securityholder intend distribute registrable security list item follow registrable security sell time time directly undersigned selling securityholder alternatively underwriter brokerdealer agent registrable security sell transaction fix price prevail market price time sale vary price determine time sale negotiate price sale effect transaction involve crosse block transaction national securities exchange quotation service registrable security list quote time sale overthecounter market iii transaction exchange service overthecounter market write option connection sale registrable security sell securityholder enter hedging transaction brokerdealer turn engage short sale registrable security course hedge position assume selling securityholder sell registrable security short deliver registrable security close short position loan pledge registrable security brokerdealer turn sell security state exception note event method distribution form underwritten offer registrable security prior agreement company signing selling securityholder acknowledge understand obligation comply agree comply prospectus delivery provision securities act exchange act rule regulation thereunder particularly regulation event sell securityholder transfer portion registrable security list item date information provide company sell securityholder agree notify transferee time transfer right obligation notice questionnaire registration right agreement signing selling securityholder consent disclosure information contain answer item inclusion information shelf registration statement relate prospectus selling securityholder understand information rely company connection preparation shelf registration statement relate prospectus accordance sell securityholder obligation section registration right agreement provide information require law inclusion shelf registration statement selling securityholder agrees promptly notify company inaccuracy change information provide occur subsequent date hereof time shelf registration statement remain effect notice hereunder pursuant registration right agreement shall write handdelivery firstclass mail air courier guarantee overnight delivery follow company gilead sciences inc cooley godward llp palo alto square camino real palo alto california attention joshua gillespie esq notice questionnaire execute selling securityholder receive company term notice questionnaire representation warranty contain shall bind shall inure benefit shall enforceable respective successor heir personal representative assign company sell securityholder respect registrable security beneficially own selling securityholder list item agreement shall govern respect law state new york witness whereof undersigned authority duly give cause notice questionnaire execute deliver person duly authorize agent date selling securityholder printtype legal beneficial owner registrable security title return complete execute notice questionnaire receipt company gilead sciences inc cooley godward llp palo alto square camino real palo alto california attention joshua gillespie esq exhibit appendix notice transfer pursuant registration statement gilead sciences inc cooley godward llp palo alto square camino real palo alto california attention joshua gillespie esq morgan trust company national association mission street floor san francisco california attention institutional trust service gilead sciences inc company convertible senior note december note dear sir advise transfer aggregate principal reference note share companys common stock issue conversion repurchase redemption note pursuant effective registration statement form file file company certify prospectus delivery requirement securities act amend satisfied respect transfer describe abovename beneficial owner note common stock name sell securityholder prospectus date amendment supplement thereto aggregate principal note number share common stock transfer portion note share common stock list prospectus amend supplement opposite owner date truly authorize signatureexhibit gilead world market ltd ppg tenofovir manufacturing supply agreement party acknowledge follow supply agreement agreement enter january effective date ppgsipsy sas french company place business croix cadeau avrille cedex france ppg gilead world markets ltd company operate law cayman islands principal place business queensgate house south church street box grand cayman gwm ppg gwm refer singly party collectively party agreement ppg know manufacturer active pharmaceutical ingredient expertise cgmp manufacture gwm designee manufacture market pharmaceutical product human use include tenofovir disoproxil fumarate viread ppg gwm desire establish mutually agreeable term commercial supply tenofovir disoproxil fumarate product active pharmaceutical ingredient ppg gwm consideration ppgs agreement manufacture product supply gwm monetary amount set forth agreement promise covenant agreement valuable consideration hereinafter set forth intend legally bind party agree follow agreement acceptance ppg read understand agreement understand govern ppgs write acceptance order delivery product term condition respect order product propose ppg different addition agreement agree write gwm expressly reject gwm shall agreement order gwm read understand agreement shall purchase product manufacture ppg pay supply product accordance term provision agreement exception product delivery pursuant delivery product effective date agreement shall govern term agreement modification agreement shall prior implementation mutually agree party hereto shall accordance section general sale condition ppg general purchase condition gwm shall apply supply product ppg gwm term term agreement shall begin january shall remain effect december initial term subsequent renewal term renewal term terminate end initial term renewal term party prior write notice terminate accord section termination agreement supply term agreement ppg shall manufacture product gwm use viread term agreement ppg obligate manufacture product location quantity set forth ppg manufacture product gwm facility locate facility party agree write portion omit pursuant request confidential treatment file separately commission initial term renewal term gwm purchase ppg shall deliver quantity set forth exhibit result invoice issue calendar year describe section quantity product order addition describe section forecasting day gwm shall provide ppg project need product period commencing date forecast quantity indicate period projection affirmative obligation gwm purchase affirmative obligation ppg supply product limit quantity indicate second period projection consider forecast exception calendar year notwithstanding agreement ppgs give period shall indicate period fall acceptance ppg shall respond order receive gwm calendar day receipt response shall include ppgs inability comply confirmation delivery date quantity set forth order shipment product hereunder deliver facility gwm gwm designee quantity designate gwm purchase order gwm purchase order material transfer request subsequent write instruction give gwm accordance instruction shipping packaging include gwm purchase order facility designate shall gwm location additional term condition provide gwm purchase order shall apply term condition agreement shall apply ppg unable supply sufficient quantity product meet minimum obligation section gwm purchase order accept ppg party perceive shortfall delivery product ppg likely occur reason party shall discuss appropriate step alleviate shortfall gwm shall right quantity meet shortfall shall shortfall occur gwm cost base price agree party describe exhibit shortfall quantity limited total cost base price repeat shortfall consider material breach agreement describe section agreement release andor shipment quantity delay ppg accept order fault ppg quantity shall consider shortfall treat section delay cause gwm gwm shall remediate fault soon reasonably practicable good manufacturing practice ppg expressly warrant good cover agreement manufacture accordance current good manufacturing practice cgmp establish united states food drug administration fda european agency evaluation medicinal product emea manufacture pharmaceutical material applicable rule regulation fda emea governmental regulatory agency united states european union party shall promptly notify new instruction specification require fda federal food drug cosmetic act federal public health service act applicable rule regulations united states european union shall confer respect well mean comply requirement shall allocate cost implement change equitable basis write request gwm ppg permit representative gwm observe manufacture government inspection ppgs manufacturing process product mutually agreeable time ppg shall permit gwm inspect copy ppgs manufacturing record include batch record purpose assure product quality compliance agreedupon manufacturing procedure manufacturing process batch release testing gwm shall available ppg free charge knowhow information technical assistance need ppg allow ppg manufacture tenofovir product standard gwm precisely describe gwm write ppg start manufacture product ppg shall manufacture product conformance specification specification set forth gilead sciences tenofovir contract manufacture manual effect effective date agreement amend contract manufacture manual accord manufacturing process description set forth contract manufacture manual ppg shall test batch product conformance specification accord standard test method set forth contract manufacture manual raw material raw material manufacture product conform specification set forth contract manufacture manual raw material specification conformance verify accordance testing standard procedure specify ppg agree facilitate change raw material specification necessary appropriate light fda regulatory requirement ppg shall liable hereunder raw material meet raw material specification product fail meet specification raw material specification inadequate change manufacturing process ppg shall obtain gwm prior write approval implement plan change material equipment process procedure manufacture product constitute change cgmp impact validation status process constitute noncompliance manufacturing process set forth contract manufacture manual ppg shall disclose propose change manufacture material equipment process procedure gwm level sufficient allow gwm practice change manufacturing process gwm shall notify ppg write reasonable notice change material equipment process analytical method specification procedure manufacture product change reflected update contract manufacture manual ppg shall provide gwm authentic copy current master batch record preparation product cost implement amendment change nature procedure specification describe contract manufacture manual exist effective date agreement extra cost result implementation change shall borne party shall negotiate good faith process improvement agree communicate promptly idea substantial improvement patent unpatented develop solely jointly arise activity agreement relate processing manufacture product improvement right title improvement foreseeable use related processing manufacture product shall assign shall right utilize improvement manufacture product right title improvement patent unpatentable application relate processing manufacture product contain specific knowhow develop prior effective date shall assign shall right utilize improvement process manufacture product structurally related gilead pharmaceutical compound grant royaltyfree worldwide exclusive license limited processing manufacture product structurally related gilead pharmaceutical compound improvement application relate processing manufacture product contain specific knowhow develop prior effective date contract processing manufacture product structurally related gilead pharmaceutical compound party improvement disclose contract manufacturer right use shall restrict processing manufacture product structurally related gilead pharmaceutical compound party hereto discuss good faith appropriate remuneration implement disclosure say party quality control sample documentation manufacture product shall time strict conformance specification conformance verify accordance testing procedure specify prior delivery batch product ppg shall provide gwm quality control sample hold gwm analytical reference write confirmation batch record batch review approve ppgs quality assurance unit certificate compliance iii certificate analysis confirm batch meet specification quality control sampling specify gwm writing shall accordance current drug substance samplingtesting plan contain contract manufacture manual quantity price subject adjustment provide agreement gwm shall pay ppg price exhibit exhibit invoice price set calendar year subsequent calendar year plus forecast give gwm second accordance section adjustment base year corresponding calendar year base ppg agree process improvement discover mutually agree accordance section material effect product manufacturing cost party negotiate good faith shipping billing payment agree party write shipment shall ship incoterm pursuant write instruction provide gwm ppg shall responsible ppg package ship product accordance ppgs customary practice pharmaceutical compound specify gwm calendar day receipt shipping instruction gwm ppg shall ship invoice product destination invoice ppg gwm cover product ship gwm shall state payment ppg gwm shall payment ppg shall wire transfer bank account ppg ppg shall advise gwm time time invoice issue completion batch issuance applicable quality control sample accordance section ppgs invoice shall pay gwm later calendar day follow later receipt applicable invoice receipt certificate analysis certificate compliance invoice pay date shall assess late payment fee rate maximum rate permit applicable law respect obligation whichever credit term adjust justified termination party terminate agreement material breach party material breach encountered party repudiate breach agreement fail perform service deliver good provide agreement termination section perform give breach party write notice specify circumstance breach include provision agreement breach breach party breach occur calendar day cure breach agreement breach cure end calendar day period breach party make diligent good faith effort cure breach immediate notice breach party breach party shall default nonbreache party terminate agreement breach party make diligent good faith effort cure breach breach party shall grant additional calendar day period cure say breach termination ground material breach result gwm shall purchase raw material intermediate ppgs actual cost inventory product purchase price effect accord provision appendix hereto amend performance agreement gwm shall right obligation purchase raw material intermediate inventory product pursuant section gwm determine sole discretion event party bankrupt party immediate notice party terminate agreement liability whatsoever subject relevant legislation provision contain gwm terminate agreement time give day write notice ppg gwm sole discretion determine gwm terminate agreement result gwm terminate agreement reason contain article ppg shall reasonable measure cease ongoing production limit expense associate ongoing production gwm shall purchase raw material intermediate ppgs actual cost inventory product purchase price effect accord provision appendix hereto amend performance agreement reimburse ppg reasonable expense incur ppg respect remainder say gwm purchase order prior effective date termination set forth agreement termination agreement shall release party hereto payment liability obligation exist date termination limited warranty ppg warrant product deliver hereunder manufacture ppg accordance cgmp applicable fda emea rule regulations united states european union manufacture accordance agreedupon manufacturing procedure describe master batch record supply gwm accordance provision section modify disclose gwm accordance provision section iii conform specification set forth contract manufacture manual time product manufacture provide compliance applicable law regulation fully set forth section gwm remedy ppgs liability respect warranty set forth representation warranty ppg make express imply warranty statute arise law course deal usage trade include limitation warranty fitness particular purpose use disclaim ppg product fail conform warranty ppgs exclusive obligation gwm gwm affiliate exclusive remedy subject section shall set forth section provide immediately precede sentence event ppg liable theory recovery base negligence kind strict liability tort direct indirect special incidental consequential damage way related arise result use product section intend limitation indemnification obligation ppg pursuant section recall obligation ppg section rejection gwm reject product deliver ppg failure comply warranty section give ppg write notice party cooperate determine rejection necessary justify ppg notify gwm promptly accept gwms basis rejection party disagree product batch comply warranty submit sample product batch applicable documentation mutually acceptable independent party laboratory party laboratory shall determine product batch conform warranty determination shall final binding determinative rejection product batch justify party party tester rule shall bear cost party testing gwm give notice rejection gwm request ppg shall use good effort replace reject product party tester rule reject batch meet warranty gwm purchase batch irrespective ppg replace ppg accept gwms basis rejection party tester rule reject batch meet warranty ppg charge gwm batch shipping insurance freight cost therefor shall promptly refund amount pay gwm election gwm finally determined batch comply warranty section indemnification ppg ppg agree indemnify hold harmless defend gwm gwm director officer employee agent director officer employee agent gwm parent subsidiary relate company gwm indemnitee loss liability judgment damage cost reasonable fee expense include reasonable attorney fee collectively loss result party claim demand action suit proceed collectively party claim arise ppgs manufacture product fail comply ppgs obligation agreement transportation storage use product ppg product control iii negligent wrongful act omission ppg ppg indemnitee relate agreement include limit generality forego loss whatsoever respect party claim death injury person damage property provide gwm provide ppg prompt notice party claim exclusive ability defend reasonable cooperation gwm settle party claim extent ppg right indemnification defense respect loss party claim pursuant section indemnification gwm gwm agrees indemnify hold harmless defend ppg ppgs director officer employee agent director officer employee agent ppg parent subsidiary relate company ppg indemnitee loss result party claim arise relate manufacture product available gwm ppg possession use transformation sale product person ppg indemnitee iii negligent wrongful act omission gwm gwm indemnitee relate agreement include limit generality forego loss whatsoever respect party claim death injury person damage property provide ppg provide gwm prompt notice party claim exclusive ability defend reasonable cooperation ppg settle party claim extent gwm right indemnification defense respect loss party claim pursuant section recall adverse event recall adverse event product relate processing manufacture product ppg ppg shall provide gwm cost assistance reasonably request gwm connection recall adverse event product recall breach warranty section ppg shall responsible reasonable outofpocket expense incur connection recall seizure include loss viread notification transportation destruction expense replacement cost imply license right express imply grant agreement party use manner trade trademark intellectual property right connection performance work cover agreement independent contractor party hereto shall act independent contractor agreement shall construe party authority act bind commit party way whatsoever force majeure party shall liable failure perform delay perform obligation agreement failure delay cause lack supply material fault party act god riot fire explosion flood hostility war executive legislation administrative order condition reasonably control party provide party experiencing delay promptly notifie party delay use continue use good effort overcome cause cause shall continue period overcome party performance affect party subject force majeure liability date expiration period provide specifically exclude provision interference cause ability ppg perform obligation ppg shall inform gwm interference extent duration delay interference cause ability ppg perform obligation shall constitute shortfall section agreement nonassignability party assign transfer agreement right obligation hereunder prior write consent party gwm assignment transfer partys consent assignment transfer successor substantially business gwm relate product merger sale stock sale asset similar transaction ppg assignment transfer prior write consent provide event gwm shall option minimum write notice shall leave gwm liability assignment transfer attempt assignment transfer party violation term section shall null void legal effect case permit assignment transfer agreement agreement shall bind inure benefit successor executor heir representative administrator assign party hereto govern law agreement accordance shall govern construe interpret enforce apply law exclude choice law rule exclude united nations convention contract sale good agreement conflict applicable law provision order shall remain force party hereto shall mutually good faith modify invalid unenforceable provision maintain essentially spirit hereof original party severability event term agreement hold invalid unenforceable statute regulation ordinance executive order rule law term shall deem modify delete extent necessary comply statute regulation ordinance order rule valid enforceable portion thereof remain term agreement remain force effect invalid unenforceable provision essential importance agreement reasonably assume party entered agreement invalid term warehouse ownership product transfer gwm agreement party ppg agree hold supply product ppgs facility shipping instruction available gwm storage product shall accordance cgmp applicable fda emea rule regulations united states european union shall bear cost insurance loss product maintain ppgs facility gwm appropriate effort product ppgs facility reasonable period time notification policy term condition shall apply processing manufacture product agreement gwm substitute purpose notice notice agreement shall write shall deliver personally send day delivery internationally recognize courier service transmit facsimile transmission confirm confirmation day delivery internationally recognize courier service follow address facsimile respective party address facsimile notify pursuant section gwm copy gilead world markets ltd gilead sciences inc queensgate house lakeside drive south church street foster city box usa grand cayman attention associate director chemical manufacturing attention gregg alton director facsimile facsimile ppg copy ppgsipsy ppg industries inc croix cadeau ppg place pittsburgh usa avrille cedex france attention general manager fine chemical attention european operation manager fax fax confidentiality confidential information mean proprietary confidential information datum knowhow result trade secret technique invention idea process formula drawing diagrams disclose party party course negotiate perform agreement mark identify confidential proprietary gwm confidential information shall include confidential information gilead sciences inc define disclose ppgs predecessor interest pursuant confidential disclosure agreement effective january gilead sciences inc ppgsipsy successor interest sipsy chimie fine sca information act failure act receive party employee contractor breach hereof generally know available know receive party time receive information evidence contemporaneous write record iii furnish receive party party matter right restriction disclosure independently develop receive party reference confidential information show independent contemporaneous write record term agreement party maintain confidential information party receive agreement confidence prior write permission party shall disclose confidential information party party use confidential information purpose extent necessary permit performance agreement party shall disclose confidential information party employee agent consultant affiliate sublicensee need information performance agreement subject bind obligation hold confidence use confidential information party purpose permit agreement restrictive section party protect confidentiality party confidential information standard care use protect confidential information similar nature reasonable care party notify party promptly discovery unauthorized use disclosure confidential information party notwithstanding provision agreement party affiliate applicable disclose confidential information disclosure response valid order court governmental body united states foreign country political subdivision thereof provide receive party shall give notice party hereto shall reasonable effort obtain protective order require confidential information disclose purpose order issue require governmental law rule regulation include limitation rule regulation securities exchange commission rule national association security dealer provide receive party shall give notice party hereto order allow party opportunity seek confidential treatment confidential information iii necessary prosecute defend litigation comply applicable governmental regulation governmental patent regulatory filing enforce obligation agreement extent disclosure necessary enforcement agreement terminate expire party party election promptly return destroy confidential information receive party shall certify write party completion thereof entire agreement amendment agreement attachment exhibit supplement specifically reference agreement constitute entire final complete exclusive agreement party supersede previous agreement representation write oral respect subject matter agreement agreement modify amend waive discharge terminate orally instrument writing sign duly authorize representative party subject amendment term condition set forth constitute final complete exclusive entire agreement gwm ppg respect subject matter hereof term condition agreement confirmation document furnish gwm ppg way inconsistent term set forth expressly reject insurance party shall maintain cost insurance policy respect activity obligation agreement commercially reasonable term coverage coverage limit view scope party activity obligation agreement party request party supply certificate insurance evidencing coverage survival provision section respect sentence shall survive termination expiration agreement gilead world markets ltd mark perry mark perry date january title manage director accept acknowledge ppgsipsy rene devaumas rene devaumas date december title president ppgsipsy exhibit tenofovir purchase quantity calendar year exhibit tenofovir base price base price table invoice price set calendar year subsequent calendar year plus forecast give gwm second accordance section adjustment base year correspond calendar year base portion omit pursuant request confidential treatment file separately commission quicklink click rapidly navigate document exhibit subsidiary gilead sciences inc subsidiary country state incorporation gilead sciences limited ireland gilead irish holding limited cayman islands gilead world markets ltd cayman islands gilead international ltd cayman islands gilead international holdings ltd cayman islands gilead sciences gmbh germany gilead sciences sarl france gilead sciences srl italy gilead sciences spain gilead sciences lda portugal gilead sciences ltd united kingdom gilead sciences international ltd united kingdom gilead sciences pty limited australia gilead sciences netherlands gilead sciences hellas epe greece simbolo acquisition sub inc delaware quicklink exhibit quicklink click rapidly navigate document exhibit consent ernst young llp independent auditor consent incorporation reference registration statement form nos pertain stock option plan incentive stock option plan supplemental stock option plan employee stock purchase plan nonemployee director stock option plan gilead sciences inc nexstar pharmaceuticals inc incentive stock plan nexstar pharmaceuticals inc director option plan vestar inc stock option plan triangle pharmaceuticals inc stock incentive plan option agreement date august triangle pharmaceutical inc daniel welch registration statement form nos gilead sciences inc relate prospectuse applicable report date january respect consolidated financial statement schedule gilead sciences inc include annual report year end december ernst young llp palo alto california march quicklink exhibit consent ernst young llp independent auditor quicklink click rapidly navigate document exhibit consent independent accountant consent inclusion annual report gilead sciences inc report date january relate financial statement proligo llc thirteenmonth period end december incorporate reference annual report pricewaterhousecooper llp denver colorado march quicklink exhibit consent independent accountant quicklink click rapidly navigate document exhibit certification pursuant section public company accounting reform investor protection act usc adopt john martin chief executive officer gilead sciences inc company john milligan chief financial officer company certify good knowledge company annual report period end december certification attach exhibit annual report fully complie requirement section section securities exchange act amend information contain annual report fairly present material respect financial condition result operation company period cover annual report date march john martin john milligan john martin john milligan chief executive officer chief financial officer quicklink exhibit certificationend file edgar online inc